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This project investigates the use of a tissue engineering approach of an absorbable polymer, 
poly(propylene fumarate) (PPF) to provide long term mechanical stability while delivering a bioactive 
material, precultured human mesenchymal stem cells (hMSC) encapsulated in hydrogel, to repair bone 
defects. Annually over 2.2 million bone grafting procedures are performed worldwide; however, current 
treatment options are limited for critically sized and load bearing bone defects. Much progress has been 
made in development of bone tissue replacements within the field of bone tissue engineering. The 
combination of a polymer scaffold seeded with cells for the eventual replacement by host tissue has 
  
shown significant promise. One such polymer is PPF, a synthetic linear polyester. PPF has been shown to 
be biocompatible, biodegradable and provide sufficient mechanical strength for bone tissue engineering 
applications. Additionally PPF is able to be photocrosslinked and therefore can be fabricated into specific 
geometries using advanced three-dimensional (3-D) rapid prototyping. Current technology to culture and 
differentiate hMSCs into osteoblasts has been enhanced with the development of the tubular perfusion 
system (TPS). The TPS bioreactor has been shown to enhance osteoblastic differentiation in hMSCs when 
encapsulated in alginate beads. Although this system is effective in differentiating hMSCs it lacks the 
sufficient mechanical strength for the treatment of bone defects. Therefore this work suggests a 
combination strategy of harnessing the ability of the TPS bioreactor to enhance osteoblastic 
differentiation with the mechanical properties of poly(propylene fumarate) to develop a porous PPF 
sleeve scaffold for the treatment of bone defects. This is accomplished through four steps. The first step 
investigates the cytotoxicity of the polymer PPF. Concurrently the second step focuses on designing, 
fabricating and characterizing PPF scaffolds. The third step investigates the degradation properties of 3D 
printed porous PPF scaffolds. The fourth step characterizes alginate bead size and composition for use 
within the PPF sleeve scaffolds. The successful completion of these aims will develop a functional 
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Chapter 1: Introduction, Objectives and Background 
1.1 Introduction 
 Although there are an estimated 2.2 million bone graft cases performed annually worldwide there 
is still a lack of clinical treatment options.[2] Bone tissue engineering has emerged to develop alternative 
methods for the treatment of bone defects. Bone defects are currently repaired by using bone grafts; 
cements; metal rods, plates and screws; and some polymers. Successful resolution of bone defects 
requires the treatment to be noncytotoxic, mechanically strong, and if degradable, it must be efficacious at 
enhancing tissue ingrowth during the period of host integration. Bone tissue engineering believes that the 
optimal tissue replacement could be generated with a porous scaffold, mimicking the bone’s natural 
environment for cells seeded in the scaffold. This is believed to allow for both host tissue in-growth and 
scaffold tissue growth in situ.[3] 
Of the 2.2 million bone grafting cases allograft, autograft and xenograft are often used as repair 
products. However, each of these has their individual drawbacks such as pain, infection and disease 
transmission.[2, 4, 5] Other materials that are used for bone repair include non-skeletally sourced 
materials such as metals, ceramics and polymers. Current research has identified that use of metals for 
bone graft repairs may provide sufficient physical strength but have poor patient site integration.[6] 
Additionally metal repairs are unable to grow or be remodeled along with the natural physiological 
demands of the patient.[7] Though ceramics tend to be brittle they are biocompatible and some have been 
shown to be osteoconductive.[8] Some of the most studied ceramics are based on biodegradable 
tricalcium phosphate and hydroxyapatite.[9] However since HA lacks sufficient mechanical strength it is 
not used solely to repair load bearing bone defects. 
 Therefore much research has been performed on the suitability of polymers for bone tissue 





biomaterial research for bone tissue engineering has focused on biodegradable polymers due to their 
ability for cell seeding, dynamic scaffold design to match defect shape and size perfectly and for their 
biocompatibility.[10]  
 Development of a successful scaffold for bone tissue engineering depends on the polymer’s 
physical and biological characteristics. For successful implantation into the defect site, the polymer, plus 
any other materials used during fabrication, must be: strong, noncytotoxic, biodegradable, and easily 
sterilizable.[3, 11] For scaffold fabrication using rapid prototyping such as stereolithography, the polymer 
must be photopolymerizable with a non-cytotoxic initiator and have low viscosity at high molecular 
weights. Once these characteristics of the polymer are fulfilled, then the design of an optimized scaffold 
may begin. To fabricate scaffold designs that have precise geometries and mechanically strong we 
utilized three dimensional (3D) printing. The bioactive material in this case are human mesenchymal stem 
cells (hMSC), encapsulated in alginate. The alginate constructs are precultured in a perfusion bioreactor 
to enhance osteogenic differentiation. We hypothesize that the absorbable polymer carrier scaffold and 
the hMSC encapsulated in alginate would provide a novel tissue engineering method for the treatment of 
bone tissue defects.  
1.2 Objectives 
The overall objective of this work is to develop a combination strategy to harness the ability of the TPS 
bioreactor to enhance osteoblastic differentiation with the mechanical properties of poly(propylene 
fumarate) (PPF) for the treatment of bone defects. This goal is accomplished through the following 
objectives: 
1. The first objective was to evaluate the cellular response elicited when exposed to poly(propylene 
fumarate). Before investigating the use of PPF as a component to treat bone defects we first had to 
ensure that it is noncytotoxic when implanted in vivo. This was accomplished through evaluating 





2. The second objective was to design and investigate the use of porous PPF scaffolds. These porous 
PPF scaffolds were fabricated using three dimensional (3D) printing technology. The range of 
scaffold parameters such as pore size, wall thickness, and porosity were first investigated using a 
modular design approach. Of the wide range of designs possible, twelve designs were investigated 
further for their vascularization potential. In silico modeling was used to evaluate the impact of 
scaffold parameters on vascularization. Concurrently scaffolds were 3D printed and implanted in an 
in vivo subcutaneous rat model to provide a qualitative comparison.  
3. The third objective was to evaluate the structural and cytocompatibility properties of 3D printed 
PPF scaffolds during in vitro degradation. This was accomplished by degrading 3D printed 
scaffolds over a 32 week time period. At each timepoint changes in scaffold mechanical and 
structural properties were evaluated. Concurrently, the cytotoxicity of degradation byproducts was 
measured to predict if the PPF scaffold would elicit a cytotoxic response when implanted.  
4. The fourth objective was to characterize the size and composition of alginate beads to act as the 
bioactive component of our combination strategy. These alginate beads contain human 
mesenchymal stem cells (hMSCs) which are dynamically cultured in the TPS bioreactor to enhance 
osteoblastic differentiation. Additionally hydroxyapatite was investigated to enhance osteoblastic 
differentiation under dynamic culture conditions. The work for each of these objectives is detailed 





1.3 Background: Bone Repair Strategies and Toxicity Testing 
1.3.1 Introduction 
 Material biocompatibility is a key factor used to evaluate various types of in vivo implants. The 
long-term success of any implant depends on how biocompatible it is; those materials that provoke little 
to no immune response and minimize cytotoxicity in patients yield the best outcomes.[12] In this chapter, 
we review some of the current regulations for determining the cytotoxicity of materials, specifically those 
used for bone repair. The most popular such materials are bone grafts, metals (rods, plates and screws), 
ceramics, and polymers. 
 Current biocompatibility testing for materials used in bone repair is governed by the U.S. Food 
and Drug Administration (FDA). According to their standards, all life-supporting biomaterials are 
considered Class III Devices and must be demonstrated as safe before gaining marketing approval. While 
most bone repair materials fall into this category, tissue products (bone grafts – xenograft, allograft, and 
autograft) are regulated under the FDA’s Good Tissue Practices and are exempt from toxicity and 
biocompatibility testing. Therefore, our discussion will omit bone grafts and focus on non-tissue, acellular 
materials.   
 Bone is a versatile tissue, so finding a suitable material to repair or replace it is difficult. Our 
skeleton is made of both cortical and cancellous bone. Cortical bone bears weight. As such, it is very 
dense, with a porosity of approximately 5-10%. It can undergo compressive stresses in the range of 0.2 – 
2942MPa, and it has elastic moduli up to 17GPa.[3, 13, 14] Cancellous bone is less dense, with a porosity 
of approximately 50-90%. It can undergo compressive stresses in the range of 2 - 15MPa, and it has 
elastic moduli up to 445MPa.[3, 13] Non-tissue materials such as metals, ceramics, and polymers can 






 The skeleton’s secondary purpose is metabolic.[15] These metabolic functions, along with the 
structural functions, are accomplished through maintenance of a rigid skeletal extracellular matrix (ECM). 
This ECM is regulated in part by hormones, which allow ion release as part of the body’s metabolic 
process, but it is also regulated by bone’s three main cell types: osteoblasts, osteocytes, and osteoclasts. 
Osteoblasts are responsible for the secretion and mineralization of ECM. Osteoclasts are responsible for 
ECM resorption, allowing for the remodeling of bone. Non-tissue, acellular materials lack the abilities of 
resorption, secretion, and mineralization. 
 The problems with current bone repair materials are as follows: Research has identified that 
metals provide sufficient physical strength but have poor patient site integration.[6] Additionally, metal 
repairs are unable to grow or undergo remodeling along with the natural physiological environment of the 
patient.[7] Conversely, ceramics have shown improved site integration but tend to be brittle and lack the 
necessary mechanical strength.[6, 9] Because neither material fully meets the needs of bone repair, much 
research has been performed on the suitability of polymers for bone tissue engineering. 
Polymers can fill both requirements of strength and sufficient patient integration for eventual 
replacement. Most recent biomaterial research for bone tissue engineering has focused on biodegradable 
polymers due to the potential for cell seeding, dynamic scaffold design to match defect shape and size, 
and biocompatibility.[10] 
 The FDA requires in vitro biocompatibility testing prior to any interactions with an in vivo 
system. The first levels of in vitro tests aim to elucidate any potential material cytotoxicity. With this 
information, material and device developers can safely and effectively move onto the more sophisticated 
interactions in an in vivo system. A well-designed and implemented cytotoxicity testing plan may 
eliminate the need for wasteful in vivo studies, as it will identify any outstanding toxicity issues prior to 
implantation.[16] However, there are currently no standards for cytotoxicity testing in polymers.   
 There has been much written about the different types of materials used for bone tissue repair.[8, 





state of cytotoxicity testing for each.  
1.3.2 Metal Alloys / Compounds 
 Metals were first used as aids in bone repair in the 1890s, and there has since been much 
development in the utilization and application of metal alloys and compounds for more advanced 
treatments.[20] Original methodology included the use of rods and pins for stabilization while the body 
synthesized new bone.[21] However, metals and bone do not fully share mechanical properties, so the 
application of rods and pins can create newly developed bone that lacks the ability to handle average 
stress loads via a process called the stress shielding effect.[22] This is commonly seen in hip 
replacements.[23]  
 Stainless steel and cobalt-chromium alloys are popular choices for implants. The most commonly 
used material is 316L austenitic Stainless Steel (316L SS), which is found in a wide array of surgical tools 
and implanted devices.[24, 25] The primary components of 316L SS are iron, chromium, nickel, 
magnesium, and molybdenum; the biocompatibility of 316L SS and its components has been 
demonstrated over many years of implantation in vivo.[24] However, the presence of nickel can lead to 
allergic reactions and sensitization with extended exposure, which is why current research is evaluating 
the use of stainless steel without nickel.[26] Biocompatibility testing of nickel-free stainless steel has 
been completed and deemed the material satisfactory, a fact that is additionally supported by its 
possession of key mechanical properties; Despite these positive factors, the big concern of nickel-free 
stainless steel is that it is difficult to machine.[24]  
 Titanium and its alloys are some of the most desirable materials for skeletal applications due to its 
low elastic modulus, which can result in lower sheer stresses.[27] It is used in many formats, including 
plates, screws, and rods. Many biocompatibility studies have shown that in addition to titanium’s ability 
to provide sufficient mechanical support for new bone growth, the material is relatively inert, giving it an 





titanium naturally forms a surface oxide, leading to its successful biocompatibility.[29, 30] However this 
reduced surface interaction with the surrounding tissue can lead to issues with integration.[25] To 
increase the surface interaction, researchers have been evaluating the use of coatings like hydroxyapatite 
(HA).[30] Surface modification with chemicals and the addition of matrix proteins are some of the other 
evaluated methods of improving osseointegration.[31]  
 Alloys like titanium with 6% aluminum and 4% vanadium (Ti 6% - Al, 4% - V) were once a 
popular choice in orthopedics. However, aluminum (Al) has been linked to Alzheimer’s and vanadium 
(V) has demonstrated strong cytotoxicity; conclusions about titanium alloys that include these metals are 
debatable. There is concern about the use of this alloy in areas with high sheer stress, which causes 
particles to be released from the surface of the device and enter the patient’s blood and tissues. However, 
studies evaluating the effects of pure titanium and aluminum, as well as the effects of titanium and 
aluminum particles, have shown no cytotoxicity to various types of cells.[28, 32] 
 Recent research has focused on developing titanium and ceramic compositions as a functionally 
graded material (FGM) for implantation. Functionally graded materials utilize layering techniques to 
allow for improved cell growth while maintaining the structural integrity of the material.[31] Research 
focusing on the addition of hydroxyapatite to titanium demonstrated a non-cytotoxic reaction and an 
increased bone growth rate compared to materials without hydroxyapatite.[33] Clinical trials have 
demonstrated the benefits of HA coatings, including improved healing times, increased fixation, and 
improved bone apposition.[34] Additionally, the inclusion of 2-3% poly(L-lysine) polymers in apatite-
based coatings has drawn interest; this organoapatite yields improved tissue integration.[30, 35-37] Basic 
in vivo and in vitro testing has been performed on organoapatite, including investigation into the 
material’s impact on osteoinduction and cellular proliferation, but no biocompatibility testing has been 
published.[36, 38] This idea looks to combine the best of all three materials normally used in bone repair, 






 Ceramics are the original materials used for repairing bone voids, whether the damage is due to 
trauma or surgery.[21] They have good biocompatibility and little to no cytotoxicity because they are 
protein free; the immune response to ceramic implantation is negligent.[9] Although many ceramics are 
strong they do not provide the requisite mechanical properties due to low fracture strength and poor 
fatigue resistance (Table 1.3.1).{Li, 1995 #272} One significant characteristic of ceramics for bone tissue 
engineering, especially calcium phosphates, is that they have been shown to be osteoconductive.[17]  
Bioactive ceramics display osteoconductive properties and bond to bone even in the absence of fibrous 
interfaces; these specialized ceramics include calcium phosphates, bioactive glass, and bioactive 
compounds of glass and ceramic.[17, 34] Calcium phosphates, like biodegradable tricalcium phosphates 
and hydroxyapatite, are among the most studied ceramic materials.[9] 




























 Tricalcium phosphate is a powder of monocalcium phosphate monohydrate, alpha tricalcium 
phosphate, and calcium carbonate—these materials yield a small grain size. The mixture is then added to 
a sodium phosphate solution, which is applied to the bone defect either through injection or direct 
applications; after approximately 10 - 15 minutes, it hardens.
 





the use of tricalcium phosphate is that it has been shown to be biocompatible.  
 Hydroxyapatite (HA) cement is a preparation of calcium phosphate. While it lacks the necessary 
mechanical strength to be used on its own in load-bearing repairs, it is frequently used in the repair of 
non-stress loaded traumas, such as cranial defects, and as a component of bone void fillers.[38, 40-45] 
Because hydroxyapatite degrades very slowly, it is particularly advantageous for use with defects that 
require long-term treatments. Other advantages come from its similarities in composition and structure to 
native bone mineral.[40] It provides desirable surface roughness and the ability to adhere directly to bone, 
which is why it is commonly used in conjunction with degradable polymers.[46] Additionally, it can be 
used to modify the surface of metal alloys to allow for improved bone adhesion and integration.[26, 27, 
34] Some studies have demonstrated the ability of blood vessels to grow into HA after implantation and 
subsequent degradation.[47] Additional research has delved into combining HA, collagen, and bone 
morphogenetic proteins for improved bone repair.[48] Biocompatibility testing has been performed with 
HA to investigate the impact of particle size both in vivo and in vitro.[49, 50] Overall, hydroxyapatite was 
found to be safe for implantation.[37, 51] 
1.3.4 Polymers  
 Polymeric materials represent some of the best opportunities for bone tissue repairs. They have 
the positive characteristics of metal alloys and ceramics without some of the negative characteristics. For 
example, polymers can provide mechanical strength and may be resorbable, which allows for natural bone 
ingrowth. Additionally, they can be applied using a variety of methods, including injection and curing 
using photocrosslinking.[52-54] They may be naturally derived or synthetically made materials.
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 As 
such, polymer biocompatibility is largely varied due to degradative byproducts, surface chemistry, and the 
method of the polymer’s erosion.[55]  
 The polymers most commonly used for bone repair include polylactides, poly(methyl 





fumarate).[56] All polymers experience degradation over time, whether by exposure to heat, hydrolysis, 
oxidation, enzymatic reactions, or mechanical stresses.[9] Even so-called non-degradable polymers would 
be better termed slowly-degrading polymers; their timeline for degradation is significantly longer than 
their implanted time, but they still ultimately break down.[55] Many polymer byproducts, although 
innocuous in general, can cause side effects such as lowered pH, which can then damage the local 
environment. Table 1.3.2 lists some of the most common polymers used for bone tissue applications and 
their degradation byproducts.  
Table 1.3.2: Polymers commonly used in tissue engineering applications. 
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1.3.4.1 Polymer Degradation and Byproducts 
 Degradation rate and byproducts are two major design concerns for scaffolds used in skeletal 





of the polymer backbone.[3] The polymers outlined in Table 1 are biocompatible and produce 
degradation byproducts that are non-cytotoxic; these acidic degradation products are naturally occurring 
within the body and pose little biocompatibility risk.[58, 61] However, previous studies have shown that 
massive degradation and release of these acids may trigger an immune response.[61] Slow degradation 
combined with an increased ability for the tissue to process or remove the products can counteract this 
problem.[61] Thus, optimal polymers have few acidic degradation products and degrade slowly to avoid 
any immune response. Slow degradation also allows for implant strength until tissue regeneration and 
ingrowth is complete enough to handle weight bearing.[62]  
 Degradation can occur primarily at the surface or throughout the polymer, depending on the 
chemical composition of the polymer. Degradation times are affected by molecular weight as well as by 
the chemical structure.[3] Poly-α-hydroxy esters, PLA, and PGA allow for hydrolytic degradation through 
de-esterification.[3] Studies have observed that thick segments of polymers will degrade quicker on the 
inside of the sample than at the surface in a process known as heterogeneous degradation, which is due to 
neutralization of the carboxylic end groups at the surface of the polymer. The ability of oligomers at the 
surface to diffuse into the surroundings is also a factor; oligomers inside the polymer do not diffuse as 
easily. [3] However, with three dimensional (3D) printing, the smallest scaffolds’ strut thickness ranges 
from 50µm-250µm, which is much smaller than the samples used during heterogeneous degradation 
studies.[63, 64]  
 Most polymers currently evaluated for 3D printed scaffolds degrade via bulk degradation (Table 
1). Bulk degradation can cause issues, including scaffold failure.[3] However, in skeletal tissue 
engineering, bulk degradation is not seen as a significant issue because of the long degradation times and 
the rate of bone growth within the scaffold. Bone tissue has shown to grow into the space provided by 





1.3.4.1.1 Poly(Methyl Methacrylate) (PMMA) 
 Poly (methyl methacrylate) (PMMA) has been commonly used as a main component of bone 
cements for more than 30 years.[66] Its ability to be polymerized in situ and delivered via injection makes 
it an ideal candidate for use multiple applications including spinal fusion surgeries, craniofacial repair and 
as a fixation method to anchor prosthesis to the native bone in arthroplasties.[66-68] As PMMA is used 
frequently as a long term repair of a defect or as a fixation method, degradation has not been extensively 
studied. Many studies have evaluated one of the main defects of PMMA, the lack of mechanical strength, 
subsequent crack formation and eventual loosening of the cemented prosthesis.[69] Much work has been 
focused on developing PMMA-based composite materials to improve the mechanical strength as PMMA 
alone has a compressive strength below that of bone.[60, 68] The addition of materials bioactive 
ceramics, biodegradable polymers, and polysaccharides allows for the reduction in exothermic reaction, 
cement shrinkage after polymerization, and improved osseointegration.[14, 70, 71] All of these factors 
have been shown to improve the use of PMMA in vivo.[68] However significant concerns of cytotoxicity 
have been documented both due to increased formation of fibrous tissue where the body is exposed to the 
PMMA and exposure to the toxic monomer, methylmethacrylate, during polymerization.[66, 72] Since 
the formation of PMMA in situ is exothermic, many studies have identified that the localized increase in 
temperature may be one of the contributing factors to necrosis at the site of use.[66, 73, 74] 
1.3.4.1.2 Saturated Aliphatic Polyesters (PLA, PGA) 
 Poly(lactic acid) (PLA) and its three forms (PLLA, PDLA, and PDLLA), along with 
poly(glycolic acid) (PGA) and its co-polymer poly(lactic-co-glycolic acid), degrade through hydrolysis 
and produce lactic and glycolic acid as products.[3] Physical characteristics and degradation rates vary 
over the range of molecular weights for these polymers; generally, PLA degrades slower than PGA (Table 
1).  





enhance osteoblast proliferation.[75] Additionally, pre-osteoblasts were able to be seeded and proliferate 
on PDLLA-NVP scaffolds.[57] Although PDLLA has a high glass transition temperature, it may be 
combined with a diluent for use with SLA.[75] This work illustrates the idea that saturated aliphatic 
polyesters, like PLA and PGA, may be feasible for skeletal tissue engineering if they are made into 
strong, slowly degrading scaffolds seeded with osteoblasts.  
1.3.4.1.3 Poly(Propylene Fumarate) PPF 
Poly(propylene fumarate) (PPF) is an absorbable aliphatic polyester polymer that has been well 
characterized for use in bone tissue engineering scaffolds.[52, 76-79] Prior work has shown that the use of 
diethyl fumarate (DEF), one reagent used to make PPF, within poly(propylene fumarate) scaffolds 
increases crosslinking density and stiffness; adding the precursor DEF also lowers the viscosity enough 
for use in rapid prototyping.[52] Other studies have demonstrated that PPF degradability depends on 
molecular weight and crosslinking density.[80, 81]  
PPF scaffolds were originally photocrosslinked using only BAPO, however this formulation was 
found to be unsuccessful for use in 3D printing. The polymer resin of PPF, DEF, and BAPO required the 
use of a dye to sequester light, thus reducing any crosslinking outside of the desired area. Previous work 
suggested the addition of titanium dioxide (TiO2) to control the depth of polymerization and therefore the 
accuracy of the scaffold layer thickness[1]; plate and post scaffolds have been successfully fabricated 
with PPF, DEF, BAPO, and TiO2 using cDLP technology in the 
envisionTEC Perfactory
®
 additive manufacturing device (Figure 3.1). 
Although this work has been promising, current research has demonstrated 
even higher accuracy during scaffold fabrication by adding additional dyes 
such as 2-hydroxy-4-methoxybenzophenone (HMB) along with TiO2. 
 Previous studies have evaluated the use of PPF with SLA to produce scaffolds with controlled 
pore size and wall thickness.[64, 82-84] Many studies have looked at using propylene fumarate as a 
Figure 1.3.1: Photograph of 






copolymer because it is a linear unsaturated molecule, which would allow for the addition of copolymers 
along the polymer backbone.[85-87] These properties suggest the use of PPF in SLA fabricated scaffolds 
for its osteoblastic properties and slow degradation time, combined with quickly degrading co-polymers 
used for the delivery of additional growth factors or genes.   
1.3.4.1.4 Biocompatibility Impact of Other Materials Used for Crosslinking 
 Polymer biocompatibility is not solely dependent on the parameters of the polymer itself; it is 
also dependent on the materials used to prepare crosslinked polymers: the initiator, photoinitiator, and 
dye. Many photoinitiator and dye combinations currently used in the creation of 3D printed scaffolds are 
known to be toxic.[1] However, research has focused on the development of biocompatible photoinitiator 
and dye packages, such as oxybenzone and titanium dioxide (TiO2).[1] Oxybenzone (2-hydroxy-4-
methoxybenzophenone), or HMB, is used commercially as an ultraviolet absorber in sunscreen.[88] Many 
studies have evaluated the toxicity and metabolic pathways of HMB, and it is considered safe for topical 
application[88-91]; these studies have also determined that HMB is not genotoxic in vivo.[89] TiO2 is 
commonly used as a food and drug coloring agent, as well as an active ingredient in sunscreen.[1] The 
rutile form, with crystals 250 – 305nm in size, is used as an ultraviolet attenuator.[1] The toxicity of TiO2 
as a topical agent in sunscreens has been well characterized; it has been deemed nontoxic.[92] Many 
studies have investigated the toxicity of TiO2 for non-topical applications and have found it to have low 
toxicity levels even at intravenous doses of 5mg/kg of patient weight.[92, 93] However, at much greater 
doses (e.g. 2592mg/kg), acute toxicity was seen in mice that had intraperitoneal injections of nanoparticle 
TiO2.[73] 
1.3.5 Toxicity Evaluation Methods 
 To evaluate a material’s suitability for patient implantation, biocompatibility must be evaluated. 





in vitro and in animals; second is animal in vivo testing with the material used as designed; and finally, 
human clinical trials.[16] Currently, ISO Standard 10993 represents the framework of tests recommended 
by the FDA for assuring the safety of a material prior to approval.[94]   
1.3.5.1 ISO Standard 10993  
The FDA’s guidance document is titled “Use of International Standard ISO 10993, ‘Biological 
Evaluation of Medical Devices’ – Part 1: Evaluation and Testing.” This standard provides guidelines for 
all levels of evaluation, from the basic level of cytotoxicity to systemic toxicity from implantation.  
  Specifically, ISO Standard 10993-5 addresses “Tests for In Vitro Cytotoxicity.” The goal of the 
standard is to “determine the biological response of mammalian cells in vitro using appropriate biological 
parameters.”[95]  Overall, it provides general guidelines to ensure appropriateness of test conditions and 
evaluation. These guidelines aim to remove any unnecessary variables from testing, and they include 
recommendations for cell lines, sterilizing and aseptic techniques, solvent choices, statistical replications, 
and appropriate positive, negative, and blank controls. The standard also details a three-pronged approach 
for the evaluation of potential cytotoxicity of medical devices: extract testing, direct contact testing, and 
indirect contact testing.  
 Extract testing evaluates the cytotoxicity of leachable components from the medical device. The 
testing occurs after the medical device is incubated for at least 24 hours in a non-cytotoxic solvent, e.g. 
cell culture media with or without serum. The incubation temperature can range from physiological to 
autoclave sterilizing conditions to best mimic the environment that the medical device will encounter 
prior to exposure to the patient. Specifically, the standard states, “extraction conditions should attempt to 
simulate or exaggerate the conditions of clinical use so as to determine the potential toxicological hazard, 
without causing significant changes in the test material such as fusion, melting or alteration of the 
chemical structure.”[95] The extract and media solution is then used to replace the media used to culture 





is evaluated and compared to negative, positive, and blank media controls per the guidelines set in the 
standard.  
 Indirect contact testing is used to qualitatively evaluate cytotoxicity by exposing cells to the 
material after diffusing through an agar layer or through a filter. This method is helpful, like extract 
testing, for evaluating materials which may have a greater cytotoxic load. Diffusion allows for a gradual 
exposure to the material compared to direct contact testing, which does not allow for graded evaluation of 
the material’s impact. The method uses cells that are grown to subconfluency, which are then covered by 
a layer of agar mixed with growth media, which is allowed to solidify. Then the engineered material is 
placed on top of the agar and allowed to incubate for 24 to 72 hours, at which point the sample is removed 
and the cells are evaluated for signs of toxicity. Alternatively, cells can be grown to subconfluency on a 
filter, which is then transferred, cell side down, on to a layer of solidified agar. The material is then placed 
on the acellular side of the filter and incubated for 2 h ± 10 minutes. Cells are evaluated for signs of 
toxicity per table 1.  
Direct contact testing, as implied by its name, evaluates the cytotoxicity of the material when 
cells are in direct contact. The cell lines used for the test may be grown to subconfluency on top of the 
material, or the material may be placed on top of the cells after they’ve grown. The media is replaced and 
the culture is incubated for at least 24 hours. Cytotoxic effects are determined per the guidelines set in the 
standard. 
ISO Standard 10993 also covers other areas of biocompatibility testing. Systemic toxicity and 
pyrogenicity testing is governed under ISO Standard 10993-11, “Test for Systemic Toxicity.” ISO 10993-
6 provides the testing framework for implanted materials through the “Tests for Local Effects after 
Transplantation.”[95] 
Previous studies have tested the byproducts of polymer degradation[96] but there has been little 
focus on developing a method to test the toxicity of the polymer at different points during degradation. As 





cytotoxicity of the leachable components during the first 24-48 hours of implantation. However, this 
testing scheme is most valuable for durable polymers; those that do not experience significant degradation 
during implantation. For polymers that are implanted with the express purpose of degradation then it 
would be best to develop a testing scheme that evaluates both the leachable components and degradation 
byproducts during the lifespan of the degrading polymer. Additionally tests to evaluate biodegradability 
have been well documented and implemented but very few studies look at the biocompatibility of the 
degraded polymer.[97] 
1.3.6 Conclusion and Future Directions 
 With the increased use of biodegradable polymers in tissue engineering and medical device 
applications there is a need for standards to evaluate the cellular response to the degradation byproducts. 
Currently in vitro testing of biodegradable polymers is evaluated after 24 hours. New standards could be 
developed to investigate the impact of degradation products during long term implantations. Ideally these 
standards would initially investigate the impact of degradation in vitro as to improve the polymers during 
the initial stages of research. These new standards could expand the use of extract testing to look at the 
release of potentially cytotoxic byproducts during long term degradation. Evaluation of the systemic 
impact of degradation by products would be beneficial to better predict the response in vivo. Additionally 
if cytotoxicity testing can better predict in vivo cellular response then testing could be performed at the 
initial round of biomaterial development so that time, materials and other resources are not wasted on 









Current trends in tissue engineering focus on the impact of exogenous and endogenous signals on 
cells seeded in scaffolds. To fully understand the potential impact of these signaling molecules we must 
first review their signal expression pathways. In this chapter we focus on two of the most common cells 
used in skeletal tissue engineering osteoblasts and chondrocytes. We will discuss the basic biology of the 
skeletal system and investigate the impact of the different signaling molecules such as hormones, 
cytokines, growth factors, and the mechanotransduction signaling pathway on cell phenotype and gene 
expression.  
In tissue engineering the implementation of a successful tissue scaffold is dependent on three 
factors, an appropriate cell type, developing a scaffold to mimic the surrounding tissue, and then using 
cell signaling to drive cells to express the correct phenotype and genes. Through understanding of the 
signals that impact osteoblast and chondrocyte functions we can improve in vivo use of engineered tissue 
scaffolds.   
1.4.2 Biology of Osteoblasts 
1.4.2.1 Bone Extracellular Matrix  
The skeleton’s primary purpose is to provide structural support however its secondary purpose is 
metabolic.[15] These purposes are accomplished through maintenance of a rigid skeletal extracellular 
matrix (ECM) regulated for the release of ions through hormones. Bone is made of three cells, 
osteoblasts, osteocytes and osteoclasts, and the ECM.  
1
Adapted from: MO Wang and JP Fisher. “Signal Expression” Ch 7. In: The Biomedical 







Table 1.4.1: List of Abbreviations 
Akt v-akt murine thymoma viral oncogene homolog  
ALP alkaline phosphatase 
BAD BCL2-associated agonist of cell death 
BAX BCL2-associated X protein 
BCL-2 B-cell CLL/lymphoma 2 
BMP bone morphogenic protein 
CD44 CD44 molecule (Indian blood group) 
c-fos FBJ osteosarcoma oncogene 
ECM extracellular matrix 
ERK extracellular signal-regulated kinase 
FAC focal adhesion complex  
FADD fas-activated death domain protein 
FAK focal adhesion kinase 
Fas TNF receptor superfamily, member 6 
FGF fibroblastic growth factor 
GAGs glycosaminoglycan 
GH growth hormone 
gp130 interleukin 6 signal transducer (gp130, oncostatin M receptor) 
Grb2 growth factor receptor-binding protein 2 
Herp2 
homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain 
member 2 protein 
HesR-1 hairy and enhancer of split related-1 
HeyI hairy/enhancer-of-split related with YRPW motif 1 
IGF insulin-like growth factor 
IGF-1R insulin-like growth factor-1 receptor 
IGFBP insulin-like growth factor binding protein 
IL interleukin 
IL-1RA interleukin-1 receptor antagonist  
IL-1RAP interleukin-1 receptor associated protein  
IL-6R interleukin-6 receptor 
IL-R interleukin receptor 
IRAK interleukin-1 receptor activate kinase 
IRS insulin receptor substrate 
JNK c-Jun N-terminal kinases 
JunB jun B proto-oncogene 
Lrp-5 low density lipoprotein receptor-related protein 5 
MAPK mitogen-activated protein (MAP) kinases 





MEK map erk kinase 
MGP matrix Gla protein 
MMP matrix metalloproteinase 
NF- nuclear transcription factor - kappaB 
NO nitric oxide 
NOS2 nitric oxide synthase type II 
OCN osteonectin 
PDGFR platelet-derived growth factor receptor 
PGDF platelet-derived growth factor 
PGE2 prostaglandin E2 
PI3K phosphatidylinositol 3-kinases 
PK protein kinase  
PTH parathyroid hormone 
Raf proto-oncogene serine/threonine-protein kinase 
Ras rat sarcoma guanine triphosphatase 
Rel C-Rel proto-oncogene protein 
Runx2 runt-related transcription factor 2 
Shc src homology 2 domain containing transforming protein 1 
sIL-6R soluble interleukin-6 receptor 
Smad mothers against decapentaplegic homolog 
Smurfs smad ubiquitin regulatory factors 
Sox9 sex-determining region Y-related gene 
Src sarcoma 
STAT signal transducer and activator of transcription 
Tcf7 transcription factor 7 
TGF transforming growth factor 
TIMP tissue inhibitor of metalloproteinase 
TNF tumor necrosis factor 
TRADD tumor necrosis factor receptor-associated death domain protein 
TRAF tumor necrosis factor receptor-associated factor 
VEGF vascular endothelial growth factor 
g1 vegetalising factor-1  
Wnt wingless-type MMTV integration site family 
 
Osteoblasts are responsible for the secretion and mineralization of ECM. Osteocytes are mature 
osteoblasts encased within the ECM. Osteoclasts are responsible for ECM resorption allowing for the 





The extracellular matrix consists mainly, greater than 90%, of type 1 collagen.[98] The non-
collagenous components of the ECM include  -carboxyglutamic acid-containing proteins, glycoproteins, 
enzymes, and sialoproteins.[98] The -carboxyglutamic acid-containing proteins in the ECM are 
osteonectin (OCN) and matrix Gla protein (MGP). OCN is only found in mineralized tissues and is one of 
the most abundant non-collagen proteins in the ECM.[98] MGP is structurally similar to OCN but is 
found in many tissues throughout the body.[98] The sialoproteins osteopontin and bone sialoprotein are 
RGD-containing matrix proteins within in the SIBLING family. The enzymes in bone ECM are alkaline 
phosphatase and matrix metalloproteinases. Matrix metalloproteinases (MMP) all have the ability to 
digest ECM facilitating the movement of cells and therefore moderating the resorption and remodeling of 
bone. MMPs are used as a metric of bone homeostasis. Fibronectin, osteonectin, thrombospondin and 
proteoglycans are the glycoproteins found in the ECM.[98]  
Osteoblasts are responsible for the secretion and mineralization of the ECM. Osteoblasts 
differentiate from pluripotent mesenchymal cells through four stages. Each stage has a distinct phenotype 
with the expression of different bone matrix proteins. The first stage consists of the differentiation into an 
osteoprogenitor cell. In this stage bone morphogenic protein (BMP)-2 and wingless-type MMTV 
integration site family (Wnt) signaling is up regulated for the commitment to the osteoblastic cell line. 
The second stage is the transition from an osteoprogenitor to a pre-osteoblast cell. PTH helps to commit 
the osteoprogenitor this process; this stage is identified by the up regulation of alkaline phosphatase 
(ALP), runt-related transcription factor 2 (Runx2), and collagen Ia gene expression.[99, 100] The third 
stage, the mature osteoblast is identified by the up regulation of ALP, collagen Ia, OCN, Runx2, Osterix, 
and other genes.[101] We will focus on the signaling impact of mature osteoblasts, the main producer of 
ECM proteins and the subsequent mineralization of the ECM.[100, 101] The fourth stage occurs with the 
terminal differentiation of the mature osteoblast into an osteocyte and elevated levels of apoptosis.[100, 
101] OCN, Runx2 and low density lipoprotein receptor-related protein 5 (Lrp-5) are the main genes 





1.4.3 Biology of Chondrocytes 
1.4.3.1 Cartilage ECM 
Articular cartilage is a heterogeneous avascular, aneural and alymphatic tissue consisting of 
chondrocytes and its surrounding ECM.[102-104]  Its purpose is to act as a low-friction, material that is 
resistant to compressive loading.  The ECM is divided into four zones, superficial, middle, deep and 
calcified.[103, 105] The ECM consists mainly of collagen, proteoglycans, and noncollagenous 
proteins.[106] Unlike bone ECM, chondrocyte ECM is composed of 90% type II collagen. Other collagen 
types present are collagen types VI, IX, X, and XI.[106, 107] The remaining ECM is composed of 
proteoglycans, aggrecan, glycosaminoglycan (GAGs), hyaluronic acid, decorin, biglycan, and 
perlecan.[108] Proteoglycans are heavily glycosylated, consisting of a long linear chain of carbohydrate 
polymers that are covalently bonded to glycosaminoglycan chains.[98] GAGs are negatively charged 
allowing them to swell with water so when depressed they are able to dispel the water, compress and 
reform when the compression subsides.[109] Collagen fibers create a mesh of these molecules by binding 
decorin and biglycan to collagen fibers and then trapping proteoglycans and GAGs within the 
network.[105, 110] This collagen meshwork works to provide great tensile strength and the ability to 
remain intact under compressive forces.[105, 106, 110] 
Though chondrocytes only compose ~5% of the total volume and are sparsely distributed 
throughout the tissue they are responsible for synthesizing and maintaining cartilage homeostasis.[102, 
107, 111] Chondrocytes are spherical in morphology and contained within a pericellular matrix, made of 
type VI collagen and biglycan.[106, 108] Type VI collagen fibers interact with hyaluronic acid, biglycan, 
and decorin to provide the framework for ECM attachment and the transmission of mechanical stimuli to 
the cell.[106, 108]  
Chondrocytes also differentiate from pluripotent mesenchymal cells to either hypertrophic 





cartilage refers to the cartilage that is found during chondrogenesis in endochondral ossification and 
growth plate development.[112, 113] We will focus on the terminal differentiation into chondrocytes 
located in permanent articular cartilage. The differentiation of the mesenchymal cell into a chondrocyte is 
marked by the up regulation of sex-determining region Y-related gene (Sox9) and the secretion of ECM 
components type IIb collagen and aggrecan and is up-regulated by the addition of transforming growth 
factor (TGF)-1 and BMP-7.[112-114]  
1.4.4 Signaling Pathway Overview 
 Intracellular cell signaling occurs through the translation of extracellular mechanical or chemical 
stimuli into a cellular response.  The signaling pathways from these translations occur through the same 
general process. An extracellular signal, such as a cytokine, growth factor or hormone, is transmitted 
through the cellular membrane into the cytoplasm. Once inside the cell it may either continue to the 
nucleus via second messengers, or interact within the intracellular region with other cell components (e.g. 
the cytoskeleton) leading to the desired cellular effect whether it is a change in gene expression, 
phenotype, or metabolism. The cell signaling pathway studies referenced in this chapter used bovine, 
murine, human and other mammalian derived cells. Since this is an overview of the major cell signaling 
pathways we have not differentiated between each mammalian cell type. 
 Autocrine signaling occurs when signaling molecules released from a cell bind to receptors 
located on the same cell. Similarly paracrine signaling refers to signaling molecules that bind to receptors 
located on neighboring cells. Endocrine signal occurs when systemically circulating signaling molecules 
(e.g. hormones) bind to receptors located in cells external to their place of production.  
Cytokines, growth factors and hormones are some of the extracellular signaling molecules that 
initiate signaling pathways. Cytokines (e.g. interleukins, interferons) are primarily used for maintaining 
cell homeostasis and the body’s defensive pathways. Growth factors, closely related to cytokines, are 





like growth factor (IGF). Hormones (e.g. parathyroid hormone, growth hormone) interact with cells 
through endocrine signaling.  
Signaling pathways occur through the attachment of an extracellular signal, a ligand, to a cell 
receptor protein either spanning or extending from the plasma membrane of the cell.  Receptor proteins 
are most commonly transmembrane, structurally consisting of three segments, extracellular, intracellular 
and a hydrophobic segment located within the plasma membrane. One notable exception is for hormone 
signaling which mainly occurs through intracellular receptors. Once the ligand binds to the receptor the 
intracellular protein has a conformational change initiating the signal cascade through activation of 
proteins or other second messengers (e.g. kinase, phosphatase, calcium). Since multiple signals may lead 
to the same phenotypic response or to different outcomes it can cause a whole tissue response from the 
same signaling molecules interacting with different receptors and cells.  
 Once the desired cellular effect has occurred the ligand may be released from the receptor, then 
either degrade or bind with another receptor. Receptor and ligand complexes may also be internalized 
through clathrin-mediated endocytosis. Once internalized the complexes may be recycled back to the cell 
surface via early endosomes or degraded in late stage endosomes. Alternatively complexes may be 
degraded through endocytosis and transportation to the proteasome by calveolin-positive vesicles. For 
example Transforming growth factor beta (TGF- receptors are internalized through both the clathrin-
mediated and caveolar pathways.[115, 116] Intracellularly, after second messengers complete their role in 
the signaling cascade they may be degraded through ubiquitination, observe a conformational change to 
become inactive permanently or inactive until later activation.  
Cell homeostasis is maintained through complex feedback loops and the balance of anabolic and 
catabolic growth factors and cytokines.[117] Anabolic growth factors and cytokines work to maintain 
homeostasis by increasing the expression of gene for increased cell proliferation and for the proteins that 
make up the ECM. In contrast, catabolic growth factors and cytokines work to change gene expression 





Since osteoblasts and chondrocytes share the much of the same environment, the skeletal system, 
they are exposed to some of the same signaling molecules. However the same signaling molecules may 
impact osteoblasts and chondrocytes differently. We will look in depth at some shared cytokines and 
growth factors such as TGF-1, IGF-1, BMP-2, BMP-7, tissue necrosis factor (TNF)-and interleukin 
(IL) -1.  
1.4.5 Anabolic Growth Factors/Cytokines 
1.4.5.1 Insulin-like Growth Factor 
 IGF-1 is considered to be the main anabolic factor for chondrocyte growth, proliferation, and 
survival.[104, 111, 118] It is structurally similar to insulin and consists of a single chain of 70 amino 
acids, with a molecular weight of approximately 7.5kDa.[119] IGF functions as an endocrine, autocrine 
and paracrine growth factor.[118, 120] As an endocrine growth factor it is circulated systemically after 
production in liver but it also may act through autocrine or paracrine signaling as in osteoblasts and 
chondrocytes when it is synthesized and incorporated into the ECM. [104, 121] To maintain stability in 
the ECM IGF-1 is bound to an antagonist, the IGFBP.[121]  
4.5.1.1 IGF Signaling Pathway 
 IGF-1 signaling is initiated through the ligand binding of insulin-like growth factor-1 receptor 
(IGF-1R), a transmembrane glycoprotein tetramer. IGF-1R is a tyrosine kinase receptor with its two  and 
two  subunits connect by disulfide bonds.[102, 120] For IGF-1 to bind to its receptor it must first cleave 
the antagonist insulin-like growth factor binding protein (IGFBP). There are 6 known IGFBPs that may 
bind to both IGF-1 and IGF-2.[119, 122] IGFBPs are used for IGF transport and increasing IGF stability 
and therefore their half-lives.[121] After cleavage, ligand binding occurs with the extracellular  subunit 
IGF-1R, then the  subunit, which spans the membrane, autophosphorylates its intracellular tyrosine 
phosphorylation site.[123] Once phosphorylated, the major substrates, insulin receptor substrate (IRS)-1, 





phosphorylated, and then begin the signaling pathways [119, 124, 125] (Figure 4.1). IRS-1 initiates the 
phosphatidylinositol 3-kinases /v-akt murine thymoma viral oncogene homolog (PI3K/Akt) pathway 
mediating the antiapoptotic effects of IGF1R by phosphorylating and therefore inactivating BCL2-
associated agonist of cell death (BAD).[124] Concomitantly the rat sarcoma guanine triphosphatase/ 
mitogen-activated protein kinases (Ras/MAPK) pathway is initiated by the IRS-2 pathway and by the 
phosphorylation of Shc. The Ras/MAPK pathway leads to increased cell proliferation, and possibly the 
mediation of oxidative stress cell damage and apoptosis.[102, 124]  
 
 
Figure 1.4.1: IGF-1 signaling pathway [124], To initiate the IGF-1 signaling pathway first the antagonist IGFBR must be cleaved 
from the ligand. After proteolysis, the IGF-1 ligand may bind with its receptor, IGF-1R to initiate auto phosphorylation. Once 
IGF-1R is phosphorylated it subsequently initiates a phosphorylation chain of Shc and IRS1/2 to activate the MAPK and PI3K 





1.4.5.1.2 IGF-1 in Osteoblast and Chondrocytes 
Of all the growth factors osteoblasts produce, IGF-1 and IGF-II are the most abundant.[121] 
Although osteoblasts are capable of producing all six IGFBR, primarily in osteoblasts IGF binds with 
IGFBP-3, -4, -5.[120, 122] Of which IGFBPs -4 and -5 are the most abundant within the ECM.[121] Of 
the six IGFBP -1, -2, -4, -6 are known to inhibit osteoblast function while IGFBP -3 stimulates.[121] 
IGFBP-5 is the most controversial as it both inhibits and stimulates IGF interaction with osteoblasts.[121, 
122] IGFBR concentrations may differ depending on the levels of IGF-1 through autocrine and paracrine 
signaling.[120] In order to access IGF-1 osteoblasts secrete MMP and serine proteases which cleave 
IGFBPs [120] to free IGF-1 for ligand binding. Osteoblast apoptosis is mediated through the IGF-1 
activation of the PI3K/Akt pathway.[124] Additionally osteoblast proliferation is regulated through the 
activation of the extracellular signal-regulated kinase/ mitogen-activated protein (MAP) kinases 
(ERK/MAPK) pathway. [124] In osteoblasts IGF-1 is known to be under the control of PTH, exposure to 
PTH causes osteoblasts to express IGF-1.[120] In turn, IGF-1 has shown to stimulate osteoblast 
proliferation and ECM production.[126]   
In chondrocytes IGF-1 stimulates an increase of proteoglycans, aggrecan, hyaluronan and 
collagen synthesis.[104, 118] IGF-1 initiates proteoglycan production by activating both the PI3K and 
ERK/MAPK pathways; however, only the PI3K pathway is required for the synthesis.[118, 127] Also 
through the activation of the PI3K pathway chondrocytes have been shown to express type II 
collagen.[102] IGF-1 has been shown to inhibit ECM degradation by decreasing the production of MMP-
13, one of the major factors in ECM degradation.[109, 127]  Reduction of MMP production occurs 
through the activation of the ERK/MAPK pathway.[127, 128] Also, IGF-1 in chondrocytes upregulates 
IL-1RII, a decoy receptor for the cytokine IL-1, protecting the cell from the catabolic IL-1 signaling 
pathway. [129] Interestingly, IGF-1 in chondrocytes has shown to not activate either the c-Jun N-terminal 
kinases (JNK) or p38 proteins as seen in other cell types.[128] IGF-1 also is able to inhibit apoptosis that 





imbalance in BCL2-associated X protein/ B-cell CCL/lymphoma 2 (BAX/BCL-2) concentration levels, as 
well as a decrease of Focal adhesion kinase (FAK) and integrin expression.[130] As discussed previously 
IGF-1 increases integrin expression and therefore increases the number of mechanoreceptors available 
which may increase MAPK pathway activation.[102, 124]  
1.4.5.2 Transforming Growth Factor β Superfamily 
 Among the many signaling molecules that effect osteoblasts and chondrocytes, the TGF- 
superfamily consists of one of the largest range of impact factors. The TGF-superfamily can regulate 
cell differentiation, proliferation, maintenance and apoptosis.[100, 131-133] The TGF- superfamily 
consists of a set of structurally conserved dimeric proteins held in place through hydrophobic interactions. 
TGF-TGF-2, TGF-3 isoforms, bone morphogenetic proteins (BMPs), vegetalising factor-1 (Vg1), 
and Activin are some of the proteins within the superfamily.[132, 133] 
4.5.2.1 TGF-Signaling Pathway 
The TGF-superfamily cell signaling pathways are well characterized (Figure 4.2). Cell 
signaling occurs through association with two transmembrane serine/threonine glycoprotein kinase 
receptors, type I (TR-I) and type II (TR-II).[134] Both receptors are dimers; upon ligand binding to the 
TR-II, TR-I is recruited to make a heterotrimeric complex. The dormant TR-I is activated through 
phosphorylation by the constitutively phosphorylated active TR-II. After phosphorylation TR-I most 
commonly initiates the signaling pathway by phosphorylating the mothers against decapentaplegic 
homolog (Smad) receptor protein, or less commonly via the Non-Smad pathway.[134-137] 
Smads, or mothers against decapentaplegic homologs, are made of three subclasses: receptor 
regulated (R)-, inhibitory (I)-, and common mediator (Co)- Smads. R-Smads, Smad1, Smad2, Smad3, 
Smad5, Smad8, bind with the activated TR-I. Once phosphorylated R-Smads bind with Co-Smad, 





expression through inhibiting the interaction of TR-I and R-Smads.[138, 139] 
The Smad pathway regulates the transcription of specific genes through three methods. First is 
the direct binding of an R-Smad- Smad4 complex to the DNA. The second method occurs through the 
interaction with other protein receptors to activate transcription. Additionally R-Smad-Smad4 complexes 
may effect gene transcription through binding with either genes co-activators or co-repressors.[140] 
 
Figure 1.4.2: TGF-β signaling pathway. When the ligand, TGF- β, binds to its receptor the signaling pathway is activated. Once 
ligand binding occurs the constitutively phosphorylated T β R-II receptor phosphorylates T β R-I. This initiates the 
phosphorylation of R-Smads, and the subsequent binding with Co-Smads to activate the Smad pathway. Adapted from Izzi 
and Attisano [141]. 
1.4.5.2.2 TGF-1 
 Transforming growth factor 1, TGF-1, is the most abundant member of the TGF- 





osteoblasts.[135] TGF-1 signaling pathway occurs through Smad activation as well as through non-
Smad pathways including activation of the ERK, JNK, and p38 MAPK pathways.[137, 142]  TGF- is 
found in the ECM surrounding osteoblasts as well as in chondrocytes.  
In osteoblasts TGF-1 blocks apoptosis and allows for the transdifferentiation into osteocytes. 
TGF-1 impacts osteoblasts during early differentiation by increasing the expression of Runx2, along 
with BMP, however; during late differentiation and osteoblast maturation it suppresses Runx2, collagen 
1, ALP and osteocalcin production. Additionally as the osteoblasts mature it has been demonstrated that 
all receptors are down regulated therefore it is hypothesized that mature osteoblasts are less sensitive to 
TGF-1 and its inhibition of matrix mineralization.[134] During late differentiation osteoblasts express 
collagen 3 (MMP13) which leads to the degradation of ECM, signaling the transition for osteoclast 
resorption.[135] Studies have shown that the increased collagen 3 expression caused by TGF-1 signaling 
occurs optimally through activation of both the MAPK and the Smad pathways.[135] TGF-1 also down 
regulates ALP, osteocalcin, collagen I and BMP-2 mRNA expression.[143] 
In chondrocytes the impact of TGF-1 on ECM production has conflicting reviews. [104, 144, 
145] It has been shown to both stimulate the synthesis of ECM and decrease proteoglycan 
production.[104, 142] Specifically chondrocytes in the presence of TGF- expresses increased levels of 
aggrecan.[146]  Additionally TGF-1 has been shown to prevent chondrocyte apoptosis when stimulated 
with TNF-[147]  TGF-1 plays a main roles in ECM maintenance by reducing ECM degrading 
enzymes such as collagenase and MMP inhibitors.[148, 149] Due to the success of prior individual 
studies using TGF-1 or IGF-1 to improve chondrocyte growth, proliferation and ECM production, 
current work focuses on combining these growth factors and has shown increased collagen and 
proteoglycan synthesis.[103, 104, 150] 
1.4.5.2.3 BMP  





BMPs. Since their identification in the 1960s there have been over 30 BMP family members identified 
and 20 of which have been well characterized.[151-153] Structurally BMPs are a dimeric protein with 
seven cystine amino acid residues, six of which form an intrachain disulfide bonds and the seventh is used 
to form dimers through an interchain disulfide bond.[154] 
Since BMPs are part of the TGF- superfamily they follow the same cell signaling pathway, 
through binding of serine/threonine kinase receptors which initiate the Smad and non-Smad 
pathways.[154] Whereas the TGF-s use Smad2 and Smad3 for signal transduction, the BMP family uses 
Smad1, Smad5 and Smad8 as R-Smads. As in TGF- signaling, Smad4 is the Co-Smad and Smad6/7 are 
I-Smads. BMP signaling may be inhibited five ways, the nonsignaling of pseudoreceptors, intracellularly 
through I-Smads, ubiquitination caused by smad ubiquitin regulatory factors (Smurfs), and antagonist 
binding of R-Smads, and extracellularly through antagonist binding of BMP.[138, 155] Some of the BMP 
antagonists are noggin, gremlin, sclerostin.[155, 156]  
1.4.5.2.3.1 BMP-2 and BMP-7  
The effects of BMP-2 and BMP-7 on osteoblast differentiation, growth, proliferation and 
apoptosis are well documented, and currently are used for clinical applications in the healing bone 
defects.[131, 154] Of the BMP family, BMP-2, is known as a main factor in osteoblast homeostasis and 
BMP-7, is regarded as a main factor in chondrocyte function. [102]  
 BMP-2 can be a positive or a negative factor in osteoblast homeostasis. BMP-2 has been shown 
to promote osteoblast apoptosis as well as impact Notch and Wnt signaling through the regulation of 
hairy/enhancer-of-split related with YRPW motif 1 (HeyI) also known as hairy and enhancer of split 
related-1 (HesR-1) or homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain 
member 2 protein (Herp2) and transcription factor 7 (Tcf7) transcription factors.[131, 157, 158] BMP-2 
promotion of apoptosis occurs through the BMP-1 receptor.[131] It also has been shown to promote 





dependent path increases BAX/BCL-2 and increases the amount of cytochrome c released from the 
mitochondria therefore which activates caspase-9 and the other effector caspases to initiate osteoblast 
apoptosis.[157] TGF-1 exerts a negative regulation of BMP-2 at transcription.[143]  
 For chondrocytes BMP-2 has been shown to increase the expression of some ECM proteins, such 
as aggrecan and type II collagen.[102, 159] However it was also shown to have negative impacts as well 
such as ECM degradation.[102] BMP-2 has also been shown to upregulate vascular endothelial growth 
factor (VEGF) transcription and translation in chondrocytes.[160]  
 BMP-7 is known to have a positive effect on cartilage homeostasis, maintaining levels of 
collagen II and ECM.[161, 162] Chondrocytes incubated with BMP-7 had increased levels of 
proteoglycan synthesis even in the presence of the catabolic cytokine, IL-1.[163] Additionally BMP-7 is 
known to improve chondrocyte survival as well as inhibit proinflammatory responses initiated by 
exposure to IL-1 or IL-6.[163] 
1.4.5.3 Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor and Fibroblastic 
Growth Factor 
 
Other major growth factors in osteoblast and chondrocyte functioning are VEGF, platelet-derived 
growth factor (PDGF) and fibroblastic growth factor (FGF). VEGF, made of seven members, VEGF-A – 
VEGF-F is constitutively expressed by chondrocytes and osteoblasts.[164, 165] In osteoblasts VEGF 
synthesis is believed to be upregulated by BMP-2 and by TGF-1 through the MAPK pathway.[165, 166] 
VEGF interacts with osteoblast cell receptors for the regulation of cell migration and ECM 
mineralization.[166, 167] On chondrocytes VEGF interacts with cell receptors that regulate cell 
survival.[166] VEGF levels are low in mature chondrocytes in articular cartilage but are higher in the 
growth phase, leading to the idea that increased expression of VEGF could lead to increased matrix 
synthesis.[168] Additionally VEGF is thought to regulate chondrocyte apoptosis through regulating the 





PDGF binds to the platelet-derived growth factor receptor (PDGFR) on osteoblasts to increase 
gene expression for osteoblast proliferation through tenascin-C [169]. Studies evaluating the effect of 
PDGF, or platelet derived growth factor, on chondrocytes concluded that PDGF had a stimulatory effect 
on chondrocytes. However for differentiating chondrocytes PDGF has been shown to be α antagonist, 
causing a decrease in the amount of proteoglycan produced.[111]  
FGF-2 is a highly conserved heparin-binding growth factor. In osteoblasts and chondrocytes it is 
produced and then stored in the ECM.[170, 171] FGF-2 induces increased osteoblastic proliferation and 
TGF- production.[164] FGF-2 also is known to improve cell survival in osteoblasts through PI3K/Akt 
pathway and through the inhibition of caspase-3.[171, 172] Additionally FGF-2 activates the MAPK 
pathway in osteoblasts.[171] In chondrocytes, FGF-2 is known to increase cell proliferation and 
upregulate GAG synthesis .[173] Also with mechanical loading chondrocytes use FGF-2 to activate the 
ERK1/2 pathway.[170] 
1.4.6 Catabolic Growth Factors/Cytokines 
 To maintain tissue homeostasis catabolic growth factors must provide ECM degradation at the 
same rate of the anabolic growth factor ECM expression. The main catabolic cytokines are interleukins, 
interferons, lymphokines, and prostaglandins. We will focus on IL-1, IL-6, and TNF-, proinflammatory 
cytokines associated with the degradation of both bone and cartilage ECM. [102, 109] 
1.4.6.1 IL-1 
 IL-1 is a family of more than nine polypeptides, originally discovered as IL-1, IL-1 and 
interleukin-1 receptor antagonist (IL-1Ra) and is one of the best understood proinflammatory cytokine. 
[174, 175] It is believed to be a main factor in the development of osteoarthritis is diarthrodial joints. 
[128, 129, 176] IL-1 is synthesized in its inactive form and is activated by a protease cleavage to begin 





 The expression of IL-1 is controlled by two antagonists IL-1RI and IL-1RII  (Figure 4.3). [129] 
Signaling is only initiated with the ligand binding of IL-1to IL-1RI because IL-1RII is a decoy receptor 
and will not initiate the IL-1 signaling pathway. [129, 174] Once IL-1RI binding occurs, IL-1RI recruits 
and binds with IL1RAP. [175] Interleukin-1 receptor activate kinase-1/ interleukin-1 receptor activate 
kinase-2 (IRAK1/2) and the adaptor protein MyD88 then activate tumor necrosis factor receptor-
associated factor (TRAF)-6. [174, 175] TRAF6 then initiates the ERK, MAPK, JNK, p38 and NF-B 
pathways. [175, 177, 178]   
 
Figure 1.4.3: IL-1 signaling pathway. IL-1 signaling is controlled by IL-IRI and IL-IRII. IL-1RII is a decoy receptor and signaling is 
only initiated when IL-1 binds with IL1-RI. Once bound, IL-1RAP is recruited and along with the adaptor protein, MYD88, 






 NF-B is regarded as the “master switch” of the inflammation cascade. [108] It is a member of 
the C-Rel proto-oncogene protein (Rel) family. [180] As an inactive protein it is bound to I-B, if I-B is 
phosphorylated the NF-B subunits, (commonly 50 and p65), reform into a dimer and initiate the NF-B 
signaling pathway. [180, 181] NF-B translocates to the nucleus and mediates gene transcription through 
binding to DNA at B sites. [175, 176] 
1.4.6.1.1 IL-1 in Osteoblasts and Chondrocytes 
 IL-1 has been identified as the main cytokine for the resorption of bone while inhibiting new bone 
formation since the discovery of its role in 1983. [182, 183] IL-1 inhibits ECM mineralization, 
decreases type I collagen synthesis, and decreases ALP. [184] IL-1 also increases bone resorption by 
stimulating osteoblast expression of macrophage colony-stimulating factor (M-CSF) and prostaglandin 
E2 (PGE2) while decreasing expression of OPG, all known factors in the recruitment and differentiation 
of osteoclasts. [185] IL-1 is also known to increase osteoblast apoptosis through the increased 
expression of Fas. [186] 
 The impact of IL-1 on chondrocytes in osteoarthritic cartilage has been well studied.  In response 
to IL-1 and lipopolysaccharide stimulation chondrocytes have been shown to use nitric oxide (NO) to 
inhibit proteoglycan synthesis and cell proliferation. [187] Additionally IL-1 increases NO production by 
activating nitric oxide synthase type II (NOS2). [108] Chondrocytes cultured with IL-1 had inhibited 
levels of collagen type II synthesis known to occur through the down regulation of one component of type 
II collagen. [117, 128] Not only does IL-1 reduce collagen II production but it also upregulates the 
production of MMPs and aggrecanases to degrade the ECM. [117] IL-1 moderates the impact of TGF- 
by initiating the nuclear transcription factor - kappaB (NF-B) pathway to synthesize a transcription 
factor that competes with the transcription factors for TGF- and in turn causes the down regulation of 





signaling. [117]  
1.4.6.2 IL-6 
There are 10 identified members of the IL-6 family however IL-6 has been shown to be the most 
influential on bone resorption and formation. [179] It has been shown to be anabolic by increasing ECM 
mineralization, ALP expression and inhibiting apoptosis but also has catabolic effects through the 
inhibition of osteoblast proliferation and stimulating osteoclastic resorption. [179, 188] Since osteoblasts 
express low levels of interleukin-6 receptor (IL-6R), soluble interleukin-6 receptor sIL-6R is necessary 
for IL-6 to have a significant impact at physiological levels.  
IL-6 signaling is initiated with ligand binding to IL-6R and interleukin 6 signal transducer 
(gp130). [189] IL-6 binding causes the activation of tyrosine kinases on JNK to activate the SHP2/SCH 
and signal transducer and activator of transcription (STAT) 1/3/5 pathways. STAT1/3/5 leads to the 
catabolic phenotypes through p21, RANKL, BAX/BCL2 pathways. [179, 190] The activation of 
SHP2/SHC leads to the anabolic pathways of IRS1/2, PI3K, and Ras/ proto-oncogene serine/threonine-
protein kinase (Raf). These anabolic phenotypes are seen through the expression of IL-6, tissue inhibitor 
of metalloproteinase (TIMP)-1, Mcl-1, FBJ osteosarcoma oncogene (c-fos) and jun B proto-oncogene 
(JunB). [179] Additionally culturing osteoblasts with IL-6 increased the transcription of IGF-1 and BMP-
6, both growth factors known to increase osteoblast proliferation. [190] However IL-6 also acts 
catabolically though the stimulation of osteoblasts to release paracrine factors to activate osteoclasts. 
[189] 
The effects of IL-6 on chondrocytes are also in debate. Chondrocytes cultured with IL-6 showed 
catabolic effects including reduced proteoglycan synthesis and increased MMP production. [108, 128] 
Other studies showed that IL-6 had anabolic effects with chondrocytes increasing TIMP production and 
activation of collagen synthesis. [128] This difference seems to be dependent on the availability of sIL-





stimulation occurs. [108] 
1.4.6.3 TNF- 
 TNF- is a membrane bound protein that once cleaved may act as a cytokine similar in function 
to IL-1. [128] TNF- is proteolytically cleaved by MMPs then binds with TNF-R1 or TNF-R2, both 
found on osteoblasts and chondrocytes. [128] Once bound the TNF receptor and ligand complex form a 
trimer and begins the signaling pathway. TNF receptors associate with tumor necrosis factor receptor-
associated death domain protein (TRADD) to initiate the signaling pathways through FADD and 
TRAF2/5. [102, 191] TRAF 2/5 lead to the activation of the NF-B and MAPK pathways. [102, 128, 
191] The FADD pathway initiates apoptosis through the activation of the caspase pathway. 
 TNF- inhibits osteoblastic mineralization of the ECM by decreasing gene expression of collagen 
Ia, IGF-1, ALP, and osteocalcin. [191] Additionally in osteoblasts TNF- is able to inhibit anabolic BMP 
signaling through the activation of NF-B and the degradation of Runx2 by upregulation of Smurf1/2. 
[192, 193] TNF- also inhibits ALP activity, preventing bone growth after remodeling. [192] Apoptosis 
of osteoblasts is also promoted through the NF-B pathway. [193] In osteoblasts and in chondrocytes 
TNF- increases catabolic activity by stimulating gene expression of MMPs. [161, 191]   
Increased levels of TNF- is known to be a marker of damaged cartilage. [102] TNF- regulates 
a number of chondrocyte factors including ECM degradation, apoptosis, and MMP synthesis. [194, 195] 
TNF- controls the synthesis of ECM components through multiple pathways. It inhibits the synthesis of 
collagen II through the NF-B pathway and decreases the mRNA production of aggrecan through the 
MAPK pathway. [161] TNF- also initiates ECM degradation through the upregulation of MMPs and 
aggrecanase through the MAPK pathway. [195, 196] Like IL-1, TNF-also increases the production of 





1.4.7 Hormones  
1.4.7.1 Growth Hormone and Parathyroid Hormone 
 Endocrine signaling is an important regulator of osteoblast and chondrocyte signaling. [124, 197] 
Growth hormone (GH) and parathyroid hormone (PTH) are two of the most dynamic regulators of cell 
growth, proliferation, ECM synthesis and survival. [101, 120, 124, 198] GH is a key regulator of IGF-1 
through the activation of IRS-1 by JNK within the GH pathway. GH can also activate ERK1/2 and 
MAPK signaling pathway in osteoblasts. Similarly PTH works to regulate both osteoblast proliferation 
and apoptosis. [197] PTH activates both the PKA and PKC pathways to regulate the expression of gene 
for the production of collagenase III, osteocalcin. [197] PTH inhibits osteoblast apoptosis through both 
the regulation of BCL-2/BAD ratio and the increased expression of Runx2 to maintain survival genes. 
[199] PTH has also been shown to increase the production of IL-6, which may activate osteoclast 
functions. [98]  
1.4.7.2 Adiponectin  
 Adiponectin is a hormone that is more present in women than in men, similar in structure to TNF-
.[200] Recent studies have linked increased levels of adiponectin to cartilage degeneration. [201] 
Culture of chondrocytes with adiponectin showed an increased production of IL-6, MMP-3, and MMP-9. 
It also increased the production of NOS2. [201] In osteoblasts adiponectin has an alternate effect. It has 
shown to upregulate mRNA expression of ALP along with causing an increase in matrix 
mineralization.[202] 
1.4.8 Mechanotransduction 
 In addition to initiating intracellular signal expression through the binding of signaling molecules 
to receptor, changes in the physical environment also initiate cell signaling through a process called 
mechanotransduction. Physical stimuli is transferred from the ECM to receptors on the cell surface then 





Mechanotransduction occurs through three steps: 1)ECM-coupling, where the mechanically stimulated 
ECM interacts with the transmembrane protein, 2)coupling, where the forces are transmitted from the 
transmembrane protein to biochemical signals within the cell, and 3)gene expression change, biochemical 
signals are regulated by nuclear transcription changing gene expression levels. [110] 
For both chondrocytes and osteoblasts mechanotransduction occurs through integrins, cadherins 
and Ca
+2
 channels. [203, 204] Integrins are the main mode of mechanotransduction as they connect the 
ECM to the cytoskeleton and other intracellular signaling molecules. [15, 110, 205] Integrins are a 
heterodimeric transmembrane receptors. [110] Each integrin domain consists of an extracellular  
Figure1.4.4: Integrin mechanotransduction signaling. [209] Ligand binding initiates mechanotransduction. Once ligand 
binding occurs, additional integrins, FAK, and adapter proteins are recruited to create FACs. With the subsequent activation 








segment, a transmembrane region and an intracellular region. [15, 106, 110] There are 18 known  and 8 
known  subunits in mammals. [110, 112] Principally, in the cytoplasm the  subunit is for binding 
whereas the  subunit functions in a regulatory manner. [106] Integrin ligand binding can occur with 
collagen, fibronectin, vitronectin and laminin [110] depending on the domain structure.  
Integrin signal pathways are initiated by ligand binding to either an extracellular or intracellular 
subunit domain. For this chapter we will focus on the integrin pathway for extracellular 
mechanotransduction as it is the most common transmission of physical stimuli. Once the extracellular 
domain binds with a ligand, multiple actions occur, including the clustering of multiple integrins, the 
recruitment of focal adhesion kinases and adapter proteins (Figure 1.4.4). [110]  Adapter proteins 
(paxillin, tensin, talin, -actin) bind, along with FAK to form a complex allowing the binding of the 
cytoplasmic tail to the actin cytoskeleton forming actin stress fibers. [15, 100, 110, 206] FAK is one of 
the main components of the integrin mechanotransduction pathway. [15, 106] Once associated with the 
focal adhesion complex (FAC), FAK is subsequently activated, autophosphorylates and then binds with 
sarcoma (Src) to form a Src-homology-2 binding domain. [102, 110] As an SHC-2 it is able to 
phosphorylate other proteins such as paxillin and tensin. [110, 206]  
This process is additive as the concomitant phosphorylation activates additional paxillin and 
tensin, forming more FACs. The recruitment of these enzymes, proteins and other necessary substrates to 
a concentrated area improve reaction kinetics by reducing any spatial dependence on substrates necessary 
for signal transduction. Activated FAK also initiates the PI3K, p38 and JNK pathways, as well as ERK1/2 
to concomitantly initiate the MAPK pathway. The MAPK pathway may control cell proliferation, 






Integrin binding and subsequent clustering may activate other mechanosensing cell components 
such as stretch activated ion channels and growth factor receptors and cell-surface associated 
proteoglycans. [110] This allows for other signal transduction through other mechanoreceptors such as 
lipid raft domains, caveolins, and adherens junctions. [15, 203] 
 
 Growth factors such as TGF-1 and IGF-1 have shown to increase the expression of integrins as 
well as the production of Shc, Erk1/2 and other second messengers seen in the integrin pathway therefore 
there is an interaction between growth factor and integrin signaling pathways. [106, 111, 198, 207, 208] 
This is especially seen by the activation of the MAPK pathway by both growth factors and integrins to 
regulate cell proliferation and survival. [124] 
 
1.4.8.1 Osteoblasts 
Bone is known to be sensitive to loading and shear stresses and may be anabolic depending the 
rate, degree and frequency of loading. [15, 203, 210] For osteoblasts ion channels, integrins, connexins, 
and plasmid membrane components play a role in transmitting mechanical stimuli into chemical signals.  
[15, 203] Integrins are a primary method of mechanotransduction in osteoblasts. [15] These integrins 
transmit signals mainly through the 1 subunit. [15] Specifically osteoblasts have been demonstrated to 
activate integrin v1 and integrin 1 during periods of mechanical stress. [15] FAK is phosphorylated at 
tyrosine during osteoblast mechanical stimulation which then concomitantly activates the MAPK pathway 
through interactions with c-src, Ras and growth factor receptor-binding protein 2 (Grb2). [15] Specifically 
the MAPK pathway is activated through ERK1/2 which has shown to increase the production of collagen 
III and collagen I as well as increase proliferation. [15, 211] Loading has also been shown to activate 
osteoblasts to increase matrix production, upregulate IGF-1, VEGF, TGF-1, BMP-2 and BMP-4. [203] 





phosphorylation in FAK which may regulate cell growth and survival in osteoblasts. [15] The 
upregulation of these growth factors leads to the conclusion that there is likely crosstalk between the 
anabolic growth factors and integrin signaling to upregulate bone’s response to physical stimuli. [203]  
1.4.8.2 Chondrocytes 
 Understanding mechanotransduction in chondrocytes is integral in developing an optimal tissue 
engineered cartilage replacement because of the wide range of mechanical stresses that cartilage endures. 
Without this understanding of the impact of tensile, shear or compressive forces on chondrocytes in vivo 
one cannot develop a tissue replacement robust enough to ensure cell survival and proliferation. [110] 
Mechanical cyclical stimulation from the ECM impacts chondrocyte development, morphology, 
phenotype, function and even survival. [106, 212]  
Chondrocytes receive mechanical stimuli through multiple receptors including stretch-activated 
ion channels, CD44 molecule (Indian blood group) (CD44), anchorin II, and integrins. As in 
chondrocytes the main mechanotransduction receptors are integrins. The main integrins expressed in 
chondrocytes are: v, and , with 15 as the primary integrin. [106, 208] The 15 
integrins transmit mechanical changes to the ECM through its interactions with fibronectin. [213] Integrin 
transduction of mechanical stimuli can regulate differentiation, matrix remodeling, and cell survival for 
chondrocytes. [106, 207] In chondrocyte ligand binding of collagen II to the integrin  subunit causes 
the activation of Shc and subsequently the Ras-MAPK signaling pathway. [106] The Ras-MAPK pathway 
is known to regulate chondrocyte growth, differentiation and apoptosis. [106, 175] The Ras-MAPK 
pathway may induce apoptosis through multiple pathways: activating caspase 3 and subsequent PARP 
cleavage; inhibiting map erk kinase (MEK), and by activating JNK pathway. [106]  
Chondrocytes cultured under cyclical loading show an increase in GAG production. [214] Even 
in the presence of catabolic cytokines, IL-1, mechanical loading of chondrocytes caused an upregulation 





chondrocytes increased proteoglycan synthesis but not in middle or deep zone chondrocytes. [216] Not all 
stress is anabolic to chondrocytes, chondrocytes in monolayer express higher levels of NO in response to 
increasing fluid flow shear stresses. [187]  NO may contribute to chondrocyte loss of phenotype, 
apoptosis and ECM degradation.[180, 201, 217] 
1.4.8 Dual Growth Factor Studies 
 With the success of many anabolic growth factors increasing cell proliferation and ECM 
synthesis current studies are interested in elucidating any positive impact by combining multiple growth 
factors in tissue engineering scaffolds. Exogenous delivery of multiple growth factors works to 
recapitulate the complex in vivo environment. See Table 1.4.2 for a list of different biomaterials, delivery 
of growth factors and their impact on cell proliferation and ECM synthesis. Newer studies have begun to 
elucidate the role of sequentially adding growth factors to best recapitulate the in vivo milieu. This is the 
next logical step in growth factor studies to develop/design an optimal tissue engineering scaffold. 
 However there are currently not enough studies to be able to conclusively determine which combination 
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oligo (poly (ethylene glycol) fumarate), 
gelatin 
- - 
(Holland et al., 2007, 
Holland et al., 2005) 
IGF-1, 
TGF- 
Chondrocyte poly (lactic acid-co-glycolic acid) + 
 




poly (ethylene oxide) hydrogels in poly 
(lactic acid-co-glycolic acid) (PLGA) 
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(Elisseeff et al., 2001) 
IGF-1, 
TGF-1 
Osteoblast poly(D,L-lactide) + 
 





Chondrocyte PLGA fiber mesh 
 
+ (Pei et al., 2002) 
IGF-1, 
TGF- 





PLGA microspheres in PPF rod 
surrounded by gelatin hydrogel 
++ 
 





gelatin microsphere in PPF scaffold ++ 
 
(Patel et al., 2008) 
1.4.9 Conclusion 
 Understanding the wide range of impact from cytokines, growth factors and hormones on 
osteoblasts and chondrocytes allows for their combination and use in designing an optimal tissue 
engineering scaffold for the skeletal system. Growth factors such as TGF- and IGF-1 are anabolic for 
both osteoblasts and chondrocytes; whereas cytokines such as IL-1 and TNF-are catabolic. In addition 
to the growth factors and cytokines that act as autocrine and paracrine signaling molecules one must take 
into account the impact of hormones such as PTH, GH and adiponectin when developing bone and 
cartilage replacements. With further studies as to the additive effects of dual delivery of growth factors 
one will be able to determine the optimal factors in developing a tissue engineering replacement for either 
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 Cell and tissue response are key factors in the design and application of successful biomaterials. 
One method to evaluate cell and tissue response is to measure in vitro cytotoxicity, or its quality of being 
toxic to a cell. Cell toxicity is determined by cell lysis (death) or the inhibition of cell proliferation. Prior 
to investigating a material in vivo, cytotoxicity can provide insight to any potential issues with the local 
tissue response. 
 For bone tissue regeneration key factors in designing ideal biomaterials include mechanical 
strength, biocompatibility, and consistent mechanical performance during degradation.[218] 
Poly(propylene fumarate) (PPF) is a well characterized polymer that has been demonstrated to fit these 
characteristics.[52, 219] PPF is an aliphatic polyester with a repeating unit that contains a carbon-carbon 





Figure 2.1: A Schematic of Poly(propylene fumarate). Poly(propylene fumarate) contains a repeating unit of two ester groups 
flanking a carbon-carbon double bond.  
Covalent crosslinking of PPF occurs through the unsaturated carbon bond on the fumarate functional 
group either by thermal- or photo-initiation. Hydrolytic degradation of the ester bond produces fumaric 
acid and propylene glycol as byproducts.[220] As fumaric acid is a known byproduct of the Kreb’s cycle 
and propylene glycol is commonly used as a food additive, both of these degradation products are thought 
to be nontoxic in low concentrations.[218] 
1Adapted from: MO Wang, Etheridge, JM, Thompson, JA, Vorwald, CE, Dean, D, and JP Fisher. 
“Evaluation of the In Vitro Cytotoxicity of Crosslinked Biomaterials.” Biomacromolecules. 2013, 14 (5), pp 1321–






 Previous studies have evaluated the cell and tissue response and degradability of thermally 
crosslinked PPF and have found it to be acceptable for in vivo implantation with responses ranging from a 
lack of an inflammatory response to a mild inflammatory response. [81, 221, 222] Although previous 
studies have evaluated the toxicity of thermally crosslinked PPF they were performed either using in vivo 
models or when using an in vitro model, they did not implement the previously developed standards for in 
vitro cytotoxicity. With the further development of PPF as a photocrosslinkable polymer, many studies 
have evaluated the use of PPF as a coating for cortical bone implants, a scaffold to repair critical sized 
bone defects, and as a delivery method for signaling factors. [79, 223-225] Additional studies have 
evaluated the in vitro degradation of photocrosslinked PPF. [226] In vivo studies of photocrosslinked PPF 
have identified it as having a mild tissue response initially following implantation but after 8 weeks a 
reduction in this response was observed. [78] Previous work has also identified that un-crosslinked PPF 
co-polymers (PPF/PPF-diacrylate (PPF/PPF-DA)) are highly cytotoxic (viability <3%), compared to 
crosslinked networks; whereas crosslinked PPF networks had cell viabilities >80%.[227] This study 
investigates the in vitro cytotoxicity of PPF that has been photocrosslinked using the photoinitiator 
bis(2,4,6-trimethylbenzoyl) phenylphosphine oxide (BAPO) using the ISO 10993-5 standards.  
 We hypothesized that PPF will have a low cytotoxic response as its degradation byproducts are 
nontoxic, and previous research has demonstrated biocompatibility using other crosslinking methods. To 
test this we investigated the cellular response of four cell types: fibroblasts (L929), pre-osteoblasts 
(MC3T3) and mesenchymal stem cells (human and canine) (hMSC, cMSC) to PPF. The cell types studied 
where chosen to represent the many tissues that PPF will interact with in vivo during bone regeneration.  
2.2 Experimental Section: Materials and Methods 
2.2.1 Poly(propylene fumarate) synthesis and film fabrication 





Briefly, propylene glycol and diethyl fumarate were combined in a 3:1 molar ratio. Zinc chloride and 
hydroquinone were added in a 0.01:0.002 molar ratio to act as catalyst and radical inhibitor, respectively. 
The solution was reacted under a flow of nitrogen gas producing ethanol as a byproduct and 
bis(hydroxypropyl) as the intermediate. The second step is a transesterification of the intermediate, 
performed under a vacuum, to produce PPF with propylene glycol as a byproduct. Gel permeation 
chromatography was used to calculate the number average molecular weight (Mn) and polydispersity 
index (PDI) of the purified PPF. For the 3 hour UV crosslinked PPF (180M PPF) Mn = 1100g/mol and 
PDI = 2.7; for the PPF films crosslinked using 30 minute UV exposure (30M PPF) the Mn = 1290g/mol 
and PDI = 2.01. Thin films of PPF were photocrosslinked using BAPO as an initiator according to 
previously reported methods.[229] A solution of 4g BAPO in 10 mL methylene chloride was prepared. 
The PPF mixture was spread evenly onto a glass plate and placed into the oven to spread for 2 minutes. A 
glass plate was depressed on top of the PPF mixture to create a thin film. The two plates were then placed 
in a UV cross-linking light box for 3 hours (180M) or 30 minutes (30M). The films were then washed in 
phosphate buffered saline (PBS) for 15 minutes to remove surface debris followed by a 30 minutes wash 
in acetone to remove soluble components and then washed twice, 15 minutes in PBS to remove any 
remaining acetone. One group was left un-washed to evaluate the soluble components of the 30M film 
(UN-30M).  
2.2.2 Sol Fraction and Crosslinking Density 
To assess the crosslinking density the sol fraction was measured per the previously described 
method.[52] Samples of the photocrosslinked film were weighed (Wi) prior to incubation in acetone, the 
solvent. The samples were then submerged in the solvent for 24 h. After incubation, samples were dried 






Crosslinking density (q) was then approximated using the Charlesby-Pinner equation and the relationship 
between crosslinking coefficient (), the weight average degree of polymerization (Xw) and the sol 
fraction (s). Sol fraction and crosslinking coefficient are related by the Charlesby-Pinner equation which 
assumes the following: a high degree of crosslinking without main chain scission, the initial molecular 
weight distribution is random (PDI ≈ 2), that the structure of the polymer does not affect crosslinking or 
main chain scission, and that the degree of crosslinking and main-chain scission is proportional to the 
radiation dose. From the crosslinking coefficient, the weight average degree of polymerization (Xw), 
derived from Mw, and Mo, the molecular weight of the monomer unit (156.19Da), the crosslinking density 
was approximated using the following formula.[28] [230] 
 
2.2.3 Material Preparation 
 Tests were performed using either a 12 well or 24 well tissue culture polystyrene plate (Corning, 




, respectively. High-density polyethylene (HDPE) 
(U.S. Plastic Corp, Lima, OH) and polyurethane film containing 0.1% zinc diethyldithiocarbamate (ZCF) 





, for the 12 well or 24 well tests, respectively, to ensure that at least 10% of 
the surface area of the well was covered by the material. After washing and drying, the PPF was 
apportioned using a calculation of the density of PPF ρ, (ρ = 1.3g/cm
3
), film thickness (t), and the 
required area of sample (A) using the formula 
 
This formula ensured that the surface area of each sample was at least 10% of the total well surface area. 
Each material used was sterilized at 121°C for 15 minutes prior to use in cell culture. For extract studies 
the method used is the same, but the required sample mass is halved because both sides of the sample are 





2.2.4 Cell Culture 
Four cell types were evaluated: L929 (ATCC, Manassas, VA), MC3T3 (ATCC), hMSC (Lonza, 
Walkersville, MD), and cMSC (Case Western Reserve University, Cleveland, OH). L929, mouse 
fibroblasts, are suggested for use per ISO Standard 10993-5. L929 cells were cultured per the 
manufacturer’s specifications with Minimum Essential Medium (MEM) (Life Technologies, Frederick, 
MD) and 10% horse serum (Life Technologies). MC3T3, a mouse osteoblast precursor cell, were cultured 
per the manufacturer’s specifications with alpha Minimum Essential Medium (αMEM) (Life 
Technologies) containing ribonucleosides, deoxyribonucleosides, 2 mM L-glutamine (Life Technologies), 
1 mM sodium pyruvate (Life Technologies), and 10% fetal bovine serum (FBS) (Life Technologies). The 
hMSCs were cultured as previously described and per the manufacturer’s protocol, with Dulbeccos 
Modified Eagle Medium (DMEM) (Life Technologies), supplemented with 10% fetal bovine serum (Life 
Technologies), 1.0% v/v penicillin/streptomycin (Life Technologies), 0.1mM non-essential amino acids 
(Life Technologies), and 4mM L-glutamine (Life Technologies).[231, 232] The cMSCs were cultured 
with low glucose DMEM (Life Technologies) containing 10ng/mL of fibroblast growth factor and 10% 
FBS. Cells were plated and grown to ~80% confluency prior to initiating the assays.  
2.2.5 Cytotoxicity Assays 
For all assays HDPE (U.S. Plastic Corp.) was used as a negative, or non-cytotoxic, control. Cells 
cultured under normal, or blank conditions and without any material were used as a blank control (blank). 
For the direct and indirect testing a polyurethane film containing 0.1% zinc diethyldithiocarbamate (ZCF) 
was used as a positive, or a cytotoxic, control which has been shown to provide a reproducible cytotoxic 





Following ISO standard 10993-5 three different culturing methods were implemented to evaluate 
if there is a cytotoxic response to PPF: direct contact, indirect contact and extract tests. For the direct 
contact test (Figure 2.2A) cells were plated and cultured per the methods described above. The direct 
contact test allows for the physical interaction of the cells and the material. The test was initiated by 
placing the material onto the cell monolayer. The material was incubated at 37°C and 5% CO2 for 24 h 
after which the cytotoxicity of the material was evaluated qualitatively with fluorescence microscopy and 
quantitatively through the XTT cell metabolic activity assay (Roche, Mainheim, Germany). To reduce 
disrupting the cell monolayer the materials were removed using a Pasteur pipet attached to a vacuum line 
so that the material and the media were removed simultaneously.  
The indirect contact test (Figure 2.2B) allows for the interaction of any leachable byproducts to 
interact with the cell monolayer without direct contact of the material. The materials were placed into a 
transwell microplate membrane insert (3.0µm size exclusion) (Corning, Corning, NY) above the cell 
surface and submerged in the culture media. The treatment groups were incubated at 37°C and 5% CO2 
for 24 h prior to cytotoxic evaluation with XTT cell metabolic activity assay and fluorescence 
microscopy. 
The extract test (Figure 2.2C) evaluates the cytotoxicity of any leachable byproducts from the 
material by the simulation of clinical application. Cells were plated and grown to 80% confluency prior to 











Figure 2.2: A Schematic of the Cytotoxicity Tests. (A) Direct contact test where cells are seeded and the material is placed 
directly on top of cell sheet. (B) Indirect contact test where the material is placed into a transwell insert, which is cultured 
with cells seeded on the bottom of the well plate. (C) Extract test where the material is incubated in the appropriate culture 





initiating the assay. The materials (PPF and HDPE) were incubated with the appropriate culture media at 
a concentration of 3cm
2
/mL for 24 h. After 24 h, the cell culture media was removed and replaced with 
the extract media. Cells were then incubated at 37°C and 5% CO2 for 24 h prior to cytotoxic evaluation 
with XTT cell metabolic activity assay and fluorescence microscopy. For the cytotoxic control the culture 
media was removed and cells were incubated with 70% methanol for 30 minutes prior to evaluation of 
cytotoxicity.  
2.2.6 XTT Assay 
 The Cell Proliferation Kit II (XTT) (Roche, Mainheim, Germany) was used to quantitatively 
evaluate cell metabolic activity. XTT (2,3-bis-(2- methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-
carboxanilide) was used according to the manufacturer’s protocols. The electron coupling and XTT 
labeling reagents were thawed and immediately combined in a 1µl:50µL ratio. Then the XTT solution 
was added to the cell culture wells, 500µl or 1mL for a 24 well or a 12 well plate, respectively. 
Absorbance was measured after 4 hours of incubation at 37°C with a M5 SpectraMax plate reader 
(Molecular Devices, Sunnyvale, CA). Net absorbance was calculated (A450-A650) for each sample of the 
three biological replicates. Relative cell metabolic activity was normalized to the mean of the blank 
culture media. Samples were evaluated, the mean cell metabolic activity and standard deviations are 
reported (n=5). 
2.2.7 Osmolality 
 The osmolality of the cell culture media was measured using the Advanced
TM
 Micro Osmometer 
(Advanced Instruments, Inc, Norwood, MA) using freezing point depression. The osmolality of the cell 
culture media measured after 24 hours of direct contact with the material, per the direct contact test. A 
20µL sample was used to measure the total molar concentration of dissolved solids, three samples were 





2.2.8 Fluorescence Imaging 
Live/dead imaging was performed to qualitatively evaluate cell viability as described 
previously[233]. A live/dead solution was prepared with 4 µM of calcein AM (Invitrogen, Carlsbad, CA) 
and 2 µM of ethidium homodimer (Invitrogen, Carlsbad, CA) in PBS. Prior to the addition of the 
live/dead stain, cells were washed with PBS to remove any remaining culture media and FBS. Cells were 
incubated with the live/dead solution in dark conditions for 30 minutes prior to imaging. For the positive, 
or cytotoxic, control, cells were incubated with 70% methanol 30 minutes prior to the addition of the 
live/dead solution. Images were obtained with a fluorescence microscope (Axiovert 40CFL, filter set 23, 
Zeiss, Thornwood, NY) fitted with a digital camera (SPOT Insight 1120, or SPOT Idea 2920, Diagnostics 
Instruments, Sterling Heights, MI) and with an inverted TE2000-E microscope (Nikon, Melville, NY) 
outfitted with a CoolSnap HQ
2 
(Photometrics, Tucson, AZ) digital camera.  
2.2.9 Statistics 
 Statistical analysis was performed using ANOVA and Tukey’s multiple pairwise comparison 
(p<0.05). All tests were performed in triplicate (n=3) unless otherwise specified. Values provided are 
mean ± standard deviation. Please note that only relevant statistical relationships are denoted on figures. 
2.3 Experimental Section: Results 
 The objective of this work was to evaluate if there is a cytotoxic response to PPF. For each of the 
three cytotoxicity tests (direct, indirect, and extract) the cell metabolic activities of the cells exposed to 
180M PPF were found to be statistically different than those exposed to the cytotoxic control, ZCF, and 
not statistically different from the cells exposed to HDPE, and blank culture media. Additionally, no 
changes in cell viability, morphology, vacuolization or detachment were observed in the cells exposed to 
180M PPF, HDPE or blank culture media.  





cytotoxicity evaluation. For the 180M PPF films the sol fraction was found to be 3% ± 2% (n = 7) (Table 
5.1) and the crosslinking density was estimated to be 58  ± 25% (n = 7) (Table 5.2). The sol fraction for 
sterilized 180M PPF, 4 ± 3% (n=4), and pre-sterilized 180M PPF, 3  ±  0% (n = 3), were found to be 
statistically similar (Table 5.1). The sol fraction for 30M PPF films was found to be 53 ± 4% (n = 3) 
(Table 2.1) and the crosslinking density was calculated to be 10 ± 0% (n = 3) (Table 2.2). The 
crosslinking densities and the sol fractions of the 180M and 30M films were found to be statistically 
different (p<0.05).   
 
Table 2.1: Sol Fraction of PPF  
Sol Fraction of PPF 
180M PPF (n=7)   3% ± 2% 
    Pre-sterilization PPF (n=3) 3% ± 0% 
    Sterilized PPF (n=4) 4% ± 3% 
30M PPF (n=3) 53% ± 4% 
 
Table 2.1: Sol fraction was measured to calculate crosslinking density. The 180M PPF films were evaluated pre-sterilization 
and post sterilization to ensure that sterilization did not have an impact on the sol fraction. These groups were found to be 
statistically similar, and therefore it was determined that sterilization did not have an impact on the sol fraction. The 30M 
PPF films have a sol fraction significantly greater than the 180M PPF films (p<0.05) 
 




Table 2.2: Crosslinking Density of PPF. Crosslinking density was then calculated from the sol fraction using the Charlesby-
Pinner equation, crosslinking coefficient, the weight average degree of polymerization (Xw). as described previously
[230],27,28. 
The difference in crosslinking density between the 180M PPF and the 30M PPF films was found to be statistically significant 
(p<0.05) 
 
Crosslinking Density of PPF 
180M Crosslinked PPF  (n=7)      58% ± 25% 
















Figure 2.3 Cytotoxicity of 30M PPF. A): Cell Metabolic Activity: Cell metabolic activity for L929 cells cultured with 
180M PPF, 30M PPF,UN-30M PPF and those cultured with only the culture media (Blank) were found to be statistically 
different from those cultured with the cytotoxic control (p<0.05). The (*) symbol represent a statistical difference 
between ZCF and all other groups (p<0.05). B): Fluorescent images of L929 cells. Calcein AM (green) represents live 
cells, and ethidium homodimer (red) represents dead cells. Cells incubated with UN-30M PPF showed increased cell 





  The cytotoxicity of 30M, UN-30M, and 180M PPF films was investigated using the direct 
contact test. There was a statistical difference in the cell metabolic activities of L929 cells cultured with 
30M, 180M, and UN-30M PPF films, and the blank culture media when compared to the cell metabolic 
activity of the cells cultured with the cytotoxic control, ZCF (Figure 2.3A). The cell metabolic activities 
of the UN-30M PPF and the blank culture media were found to be statistically different (Figure 2.3A). 
The cell metabolic activities were 100.0 ± 8.6% (blank) 95.4 ± 8.7% (180M), 90.2 ± 17.6% (30M PPF), 
and 75.2 ± 24.7% (UN-30M PPF). Qualitative verification showed an increase in cell death with a large 
number of detached cells and dead cells in the UN-30M PPF treatment group (Figure 2.3B). 
 For the direct contact test, 180M PPF was shown to support a similar level of cell metabolic 
activity as HDPE, a material previously designated as non-toxic. Also, the cell metabolic activities of 
cells cultured with 180M PPF and to those cultured with blank culture media were found not to be 





when directly cultured with 180M PPF. The cell metabolic activities were found to be 96.1 ± 11.5% 
(MC3T3), 100.3± 10.1% (hMSC), and 77.1 ± 13.0% (cMSC). These results were statistically different 
(p<0.05) from the cells cultured with the cytotoxic control, ZCF.  
 
Figure 2.4: Cell Metabolic Activity (Direct Contact). 
Four different cell populations (MC3T3, L929, hMSC, 
and cMSC) were cultured in monolayer and in direct 
contact with HDPE, 180M PPF, ZCF, or nothing 
(Blank). Each cell type cultured in direct contact with 
180M PPF was found to have significantly higher 
metabolic activity when compared to those in 
contact with the positive, cytotoxic control, ZCF 
(p<0.05, * designated a statistical difference between 
groups). There were no statistical differences found 
between cells cultured with 180M PPF, HDPE or 




 Fluorescence imaging was used to confirm the XTT assay results. No changes in cell 
morphologies were seen in cells cultured directly with 180M PPF (Figures 2.5A – 2.5D). hMSCs that 
were directly exposed to 180M PPF were observed to have a spread, spindle-like morphology and 
appeared to be fully attached to the culture plate surface (Figure 2.5A). This spread, elongated 
morphology was consistent with cells that were directly exposed to HDPE (Figure 2.5E) and those that 
were incubated with blank culture media (Figure 2.5I). Imaging of L929 cells revealed that a normal, 
round morphology and confluent cell monolayer were maintained after direct incubation with 180M PPF 
(Figure 2.5C). The spread, confluent morphology that was observed per each cell type (Figures 2.5A - 
2.5L) was notably different than the robust amount of cell detachment and cell death that was observed 
for cells exposed to ZCF, the cytotoxic control. Cell detachment and morphological change was observed 





Figure 2.6: Cell Metabolic Activity (Indirect 
Contact). Four different cell populations 
(MC3T3, L929, hMSC, and cMSC) were cultured 
in monolayer under indirect contact with HDPE, 
180M PPF, ZCF, or nothing (Blank).  Each cell 
type cultured under indirect contact with 180M 
PPF was found to have significantly higher 
metabolic activity when compared to those 
cultured with the positive, cytotoxic control, ZCF 
(p<0.05, * designated a statistical difference 
between groups). There were no statistical 
differences found between cells cultured with 
180M PPF, HDPE or under blank culture media. 
 
Figure 2.5: Direct Contact Test. Fluorescent 
images of cells, where calcein AM (green) 
represents live cells, and ethidium 
homodimer (red) represents dead cells. A -
D: MC3T3 cells cultured with (A) 180M PPF 
(B) HDPE, (C) Blank media, (D) ZCF; 4E- 4H: 
hMSC cultured with (A) 180M PPF (B) 
HDPE, (C) Blank media, (D) ZCF; I -L: L929 
cells cultured with cultured with (A) 180M 
PPF (B) HDPE, (C) Blank media, (D) ZCF; M -
P: cMSC cells cultured with (A) 180M PPF 
(B) HDPE, (C) Blank media, (D) ZCF. Normal 
cell morphology was observed in the 
populations cultured with 180M PPF, HDPE 
and blank media.  
  
   
 
 Similar results were documented for the indirect contact test. Cell metabolic activity levels were 
found to be statistically similar compared to those cultured with either 180M PPF, HDPE or under blank 
culture media for each cell type. The highest levels of cell metabolic activity were seen in the MC3T3 
cells when cultured with 180M PPF with 106.5± 7.7%. The other cell metabolic activities, when cultured 
indirectly with 180M PPF, were 103.5 ± 10.8% (L929), 90.6 ± 9.8% (hMSC), and 86.6 ± 6.0% (cMSC) 
(Figure 2.6). The lack of cytotoxic response to indirect culturing with 180M PPF was visually confirmed, 






Figure 2.7: Indirect Contact Test. 
Fluorescent images of cells, calcein AM 
(green) represents live cells, and ethidium 
homodimer (red) represents dead cells. 6A 
-6D: MC3T3 cells cultured with (A) 180M 
PPF (B) HDPE, (C) Blank media, (D) ZCF; 6E- 
6H: hMSC cultured with (A) 180M PPF (B) 
HDPE, (C) blank media, (D) ZCF; 6I -6L: L929 
cells cultured with cultured with (A) 180M 
PPF (B) HDPE, (C) blank media, (D) ZCF; 6M 
-6P: cMSC cells cultured with (A) 180M PPF 
(B) HDPE, (C) blank media, (D) ZCF. Normal 
morphology was seen in the treatment 




culture media (Figures 2.7A-2.7E). Confluent, normal morphology was observed for cells exposed to 
180M PPF, HDPE and blank culture media for each cell type (Figures 2.7A – 2.7C, 2.7E-2.7G, 2.7I-2.7K, 
2.7M – 2.7O). A confluent monolayer was observed for each cell type indirectly exposed to 180M PPF. 
The hMSCs were elongated, spread, and maintained a characteristic spindle shape (Figure 2.7E). MC3T3s 
and L929s cultured with 180M PPF (Figures 2.7A and 2.7I) had similar confluency, morphology, 
viability, and had no noticeable cell detachment or abnormal morphology when compared to those 
cultured with HDPE or under blank culture media (Figures 2.7C, 2.7G, 2.7K and 2.7O). Cells exposed to 
the cytotoxic control, ZCF, were less spread compared to cells in the blank control. Detachment of the 
cell monolayer was also observed for the cells exposed to ZCF (Figures 2.7D, 2.7H, 2.7L and 2.7P). A 
significant change in morphology was observed in the MC3T3s exposed to the cytotoxic control (Figure 
2.7D), cells became spherical and detached from the monolayer surface as compared to MC3T3 cells 
exposed to 180M PPF. 
As with the indirect and direct contact tests, the extract test revealed that all cells cultured with 
HDPE extract or blank media had statistically similar cell metabolic activities compared to those cultured 





statistically different (p<0.05) to those of the cells cultured with the cytotoxic control, 70% methanol 
(Figure 2.8). When cultured with the 180M PPF extract the cell metabolic activity levels were found to be 
126.5 ± 16.2% (cMSC), 87.2 ± 8.2% (MC3T3), 100.1 ± 32.3% (L929), and 100.5 ± 12.2% (hMSCs).  
Figure 2.8: Cell Metabolic Activity (Extract) Four 
different cell populations (MC3T3, L929, hMSC, and 
cMSC) were cultured in monolayer with extract media of 
HDPE, 180M PPF, ZCF, or nothing (Blank). Each cell type 
cultured with 180M PPF extract media was found to 
have significantly higher metabolic activity when 
compared to those cultured with the positive, cytotoxic 
control, methanol (p<0.05, * designated a statistical 
difference between groups). There were no statistical 
differences found between cells exposed to extract 





Fluorescence imaging was used to qualitatively verify cell viability. For all four cell types, no 
significant morphological changes were observed in cell populations that were incubated with 180M PPF, 
HDPE and blank media (Figures 2.9A – 2.9C, 2.9E-2.9G, 2.9I-2.9K, 2.9M – 2.9O). All cells exposed to 
70% methanol appeared red indicating a significant decrease in viability of the entire population per cell 
type (Figures 2.9D, 2.9H, 2.9L, 2.9P). 
Figure 2.9: Extract Test. Fluorescent images 
of cells, calcein AM (green) represents live 
cells, and ethidium homodimer (red) 
represents dead cells. 8A -8D: MC3T3 cells 
cultured with (A) 180M PPF (B) HDPE, (C) 
blank media, (D) 70% methanol; 8E- 8H: 
hMSC cultured with (A) 180M PPF (B) HDPE, 
(C) blank media, (D) 70% methanol; 8I -8L: 
L929 cells cultured with cultured with (A) 
180M PPF (B) HDPE, (C) blank media, (D) 
70% methanol; 8M -8P: cMSC cells cultured 
with (A) 180M PPF (B) HDPE, (C) blank 
media, (D) 70% methanol. Normal 
morphology was seen in the treatment 
groups cultured with 180M PPF, HDPE and 






2.4 Experimental Section: Discussions 
 Cytotoxic effects can hinder the natural assimilation process that is required for successful in vivo 
integration of a biomaterial. The ideal in vitro test mimics the in vivo physiological environment. This 
study therefore chose cells to represent tissues that PPF will interact with in vivo in various bone tissue 
engineering therapies along with the cell line suggested per ISO 10993-5.[93, 95] The use of the ISO 
Standard 10993 allows for the comparison of the biocompatibility of PPF to other biomaterials. Other 
ISO Standard 10993-compliant cytotoxicity studies have evaluated implanted biomaterials such as 
electrospun collagen/chitosan nanofibers, poly (ε‐caprolactone)/calcium sulfate and hydroxyapatite–
ethylene vinyl acetate co-polymer.[234-236] Overall, our study demonstrated that 180M PPF has the 
same cytotoxic response as a known non-cytotoxic material when cultured with fibroblasts, preosteoblasts 
and mesenchymal stem cells. 
 Cellular response to a biomaterial can be impacted by both the crosslinked material and the 
soluble monomers that may leach out. For PPF, previous studies identified that uncrosslinked monomers 
of PPF based polymers have low cell viability.[227] We also determined that samples with a high sol 
fraction with leachable components remaining in the network impacted cell viability negatively. This was 
primarily seen when these films were not washed with acetone prior to evaluation (UN-30M). The 
acetone removes the soluble components of the polymer films, leaving only the fully crosslinked network. 
To evaluate the cytotoxicity of PPF films with high sol fractions, a direct contact test using L929 was 
performed to compare the 30M, UN-30M, and the 180M PPF films (Figure 2.3). The cell metabolic 
activities of the UN-30M PPF and the blank culture media were found to be statistically different (Figure 
2.3A). With increasing sol fraction and therefore decreasing crosslinking density, a trend of decreasing 
cell metabolic activity was observed (Figure 2.3A). Cell viability was qualitatively confirmed using 
live/dead fluorescent imaging. The UN-30M PPF treatment group showed some cell death (Figure 2.3B). 





the leachable components, the 180M PPF films were used for the remainder of the direct, indirect and 
extract tests.  
 The sol fraction of the 30M PPF films was determined to be 53% compared to the 180M PPF 
films that had a sol fraction of 3% (Table 2.1). Assuming that the Charlesby-Pinner equation is a 
representative model of the crosslinking during UV irradiation for PPF, the crosslinking densities were 
10% (30M) and 58% (180M). [230] Previous studies have shown that although photocrosslinking of PPF 
is initiated with BAPO, the crosslinking rate can be augmented with heat.[237] To ensure that 
sterilization, autoclaving at 121°C, had no impact on sol fraction, the sol fraction was measured pre and 
post-sterilization. Sterilization was found to have no impact, as the sol fraction for the sterilized and pre-
sterilized 180M PPF were found to be statistically similar (Table 2.1). 
 All three cytotoxicity tests demonstrated that the cell metabolic activity of cells exposed to 180M 
PPF directly (Figure 2.4), indirectly (Figure 2.6), or as an extract (Figure 2.8), were statistically different 
from cells exposed to the cytotoxic controls. Parallel tests using HDPE and blank culture media showed 
similar results as to the 180M PPF and were confirmed visually using fluorescence imaging. The greatest 
cell metabolic activity, a representative of cell viability, was seen in the extract tests; with values as large 
as 126.5 ± 16. 2% (Figure 2.8) for the cMSCs cultured with PPF extract. Cell metabolic activity levels 
were normalized using the blank culture media allowing for the possibility of metabolic levels greater 
than 100% to be achieved. The general trend of cell metabolic activities was lower in the indirect culture 
test (Figure 2.6) than in the extract test and lowest in the direct culture test (Figure 2.4). These results 
were as expected, as they followed a general trend of increasing interaction with the materials. The extract 
test and indirect culture tests provide for no physical interaction of the material with the cell monolayer, 
whereas the direct culture test allows for the material to be placed directly adjacent to the cell monolayer. 
The direct contact test also allows for the physical disruption of the cell monolayer, which may increase 
the cytotoxic impact. These results were acutely present for the tests using ZCF, the cytotoxic control.  





2.5D, 2.5H, 2.5L, 2.5P) compared to the indirect culture test with ZCF (Figure 2.7D, 2.7H, 2.7L, 2.7P). 
We suggest that this is due to the culture method. There may be some concern that degrading materials 
may impact cell viability through an increase osmotic pressure. To rule out increasing osmotic pressure as 
the reason for decreased cell viability during the tests, the osmolality of the direct culture test was 
measured. The blank media was found to have the highest osmolality (342 ± 5 mOSM) and was 
statistically different from all other medias. Since there was no documented increase in osmotic pressure 
after the direct contact test, we believe that the cytotoxicity of the ZCF is due to the direct contact with 
the material itself, and less the soluble factors released by the ZCF. During the direct contact test the most 
prominent sites of cell detachment were observed where the cytotoxic material was placed. However, cell 
morphological changes, detachment, and death were present throughout each cell culture for cells 
exposed to ZCF.  
Comparatively, the cellular response to indirect incubation with ZCF did not elicit massive cell 
sheet detachment as with the direct contact test. The greatest cytotoxic impact of ZCF was seen directly 
below the transwell insert. These results are consistent with the expected response due to the localized 
increased concentration of soluble factors. Direct contact would have a greater concentration of cytotoxic 
material when compared with indirect contact, where a smaller localized concentration is observed. In 
indirect contact experiments, the transwell inserts allow for ZCF to sit above the cell monolayer and not 
contiguous to the cell layer. These results are consistent with the fact that the direct contact test is cited as 
most sensitive of the three tests utilized.[89, 90, 92] 
Of particular interest were the differing responses to the cytotoxic control seen in the four cell 
types studied. The use of ZCF as cytotoxic control has been established previously for multiple cell types 
with varying cytotoxic responses.[89, 90, 92, 238] L929 cells had the greatest cytotoxic response to ZCF 
when compared to the MC3T3, hMSC and cMSC cells. Robust cell death, as well as lifting of the cell 
sheet, was seen most prominently in the L929 cells after incubation with ZCF. Previous studies have 





cells and astrocytes.[89, 90] We expected that both mesenchymal stem cell populations (hMSC, cMSC) 
would have similar responses to the ZCF as they both are MSC populations from mammals. For both tests 
using the ZCF the cMSC had a lower cell metabolic activity indicating a stronger cellular response than 
the hMSCs. Other similarities were expected between the MC3T3 and L929 cell lines, as previous studies 
established that both MC3T3 and L929 cells had similar cytotoxic responses.[239] However this was not 
the case for our study. The cytotoxic response during the direct contact test of the L929 cells was 
statistically different (p>0.05) than the MC3T3 cells. For both the indirect contact and extract tests the 
cell metabolic activities of L929 and MC3T3 are not statistically different. For the indirect culture and 
extract tests there were no distinctive variation by cell type in responses to the cytotoxic control. 
2.5 Conclusion 
Cytotoxicity testing, consisting of direct contact, indirect contact and extract testing on multiple 
cell types was performed to determine the cytotoxic response of cells exposed to PPF in bone tissue 
engineering applications. For all cell types and cytotoxicity tests, the cell metabolic activity of cells 
exposed to 180M PPF were found to be statistically different (p<0.05) from the cytotoxic control, ZCF, as 
well as not statistically different when compared to blank culture media and cells recommended by the 
ISO 10993-5 standard when exposed to the negative control, high-density polyethylene (HDPE). To 
confirm these results qualitatively, cell morphology, viability, vacuolization and detachment were 
evaluated. These results confirmed that there was little to no cytotoxic response of cells exposed to PPF. 
Therefore PPF appeared to not elicit a cytotoxic response under all of the experimental conditions for 
which it was evaluated. These results demonstrate that PPF has a similar cytotoxic profile to a known 
non-cytotoxic material (HDPE). Additionally, previous studies have demonstrated that PPF scaffolds can 
be used for the culture and osteoblastic differentiation of MSCs.[219, 229, 240] We suggest that PPF is a 
suitable material for bone tissue engineering as it showed a lack of cytotoxic response through its ability 





Chapter 3: Evaluating 3D Printed Biomaterials: A Novel Approach 
Using Poly(Propylene Fumarate) Scaffolds 
3.1 Introduction  
The development and use of three dimensional (3D) printed scaffolds represents a huge 
opportunity for the regenerative medicine community. However, once a design is created and fabricated, 
evaluation of what is a successful design for host integration remains a non-standardized process. There is 
an unmet need for a consistent set of tools to evaluate 3D printed regenerative medicine designs. This 
study proposes a combined set of methods, or a toolbox, that can be used to identify scaffold designs for 
enhanced host integration. Our toolbox consists of the following techniques: 1) modular design, 2) micro 
computed tomography, 3) biocompatibility and mechanical testing, and 4) in silico modeling. These 
methods evaluate scaffolds by first identifying the range of possible designs available for the scaffolds 
using a modular approach. Then a set of scaffold parameters from within the design space are chosen for 
fabrication and the 3D printed scaffolds are nondestructively compared to the design specifications. The 
scaffolds are evaluated for biocompatibility and mechanical attributes, according to well established ISO 
and ASTM standards. Lastly, they are evaluated for successful host integration by modeling angiogenesis. 
This approach can be applied to the broad scope of tissue engineered products from conception through 
development. We illustrate this methodology by applying our toolbox to the design and evaluation of 
porous 3D printed poly(propylene fumarate) scaffolds.  
3D printing represents an accurate (i.e., matches design) and precise (i.e., reproducible) method 
for the fabrication of porous scaffolds; however, we would like to know the exact limits of scaffold 
accuracy and the reproducibility of that accuracy. Currently, the most common methods for evaluating 
scaffold parameters, such as porosity and pore size, are destructive.[13] Therefore, we sought to 
implement a nondestructive method to evaluate the fabricated scaffold. This method can be used after the 





researcher to understand the impacts of small changes in pore size which may impact cell and tissue 
ingrowth.[241-244] These small changes in scaffold properties after implantation may also provide clues 
as to changes in mechanical properties.  
Suitable mechanical properties and biocompatibility are necessary characteristics for a successful 
tissue engineering scaffold. The critical role of mechanical properties over the lifetime of a scaffold is 
well understood as this is a requirement of many implanted materials. Similarly, guidelines for 
biocompatibility have been well established to ensure successful native tissue interaction after the 
material implanted. Since these characteristics are commonly required for many implanted materials, 
there has been significant research into developing consistent evaluation methods.[95, 245] For this study, 
we used poly(propylene fumarate) (PPF) as the main polymer resin component to print the scaffold 
designs. PPF has been thoroughly characterized for its mechanical and biocompatibility properties.[52, 
64, 219, 246, 247] Additionally, PPF is biodegradable and photocrosslinkable that has been has shown to 
exhibit minimal cytotoxicity.[81, 222, 226, 240, 247] Since the biocompatibility and mechanical 
properties have been well established for PPF we will discuss the other methods which comprise our 
toolbox to identify the necessary scaffold parameters for successful vessel ingrowth. 
Besides providing mechanical stability, successful regenerative medicine scaffolds provide 
architecture conducive to cell attachment, vascularization and tissue ingrowth.[248] One of the most 
important factors of successful host integration is the development of a vascular network within the 
scaffold after implantation.[249] Development of a vascular network has been shown to be successful 
with porous, degradable scaffold sleeve designs with a lumen.[250] Such a design, like our scaffold 
design (Figure 3.1), can provide the necessary mechanical support while allowing for proper nutrient and 
waste transport and vascularization. This hollow, cylindrical design is able to withstand compressive 
loads within a bone defect when fabricated using a high modulus material like PPF, as well as contain the 
biological treatment, acting as a delivery vehicle for the biologically active component. Ideally the 





compared to solid wall designs.  
 Research suggests that an ideal approach for obtaining precise mechanical and nutrient transport 
properties is through the use of modular scaffold designs.[251] Modular designs allow for tuning of the 
scaffold parameters such as pore size and porosity. Specifically, tuning porosity and pore size may be 
used to control degradation rate and mechanical properties which in turn may be optimized for cell 
differentiation and neotissue formation.[13] For example, in bone tissue engineering applications, the use 
of a modular design may allow for the optimization of porosity, while constraining other properties such 
as elastic strength. Previously, varying pore sizes and porosities within an individual modular design was 
difficult to achieve when using scaffold fabrication methods such as porogen leaching. This, in turn, made 
it difficult to decouple the effects of pore properties and mechanical properties. Fortunately, 3D printing 
has facilitated the fabrication of complex designs at very high resolution, e.g. 15- 60 µm.[1] Modeling the 
wide range of scaffold parameters available with modular designs allows us to identify the design space in 
which we can choose the optimal scaffold parameters to best elicit the desire physiological response. 
These parameters would include pore size, porosity and scaffold dimensions.  
The variables of porous designs, such as the pore size and porosity of cell-seeded scaffolds have 
demonstrated significant roles in successful tissue engineered constructs.[252] In examining bone as an 
example, we want to promote bone formation and vessel ingrowth, as these parameters greatly influence 
cell attachment, cell distribution, and cell migration, which in turn affect the cell signaling for osteogenic 
differentiation.[241] Additionally, pore size and porosity have been shown to impact vascularization and 
osteoconduction.[219, 242-244] For example, scaffolds with pore sizes of 2 - 6 μm and 33.5 % porosity 
yielded no bone ingrowth while scaffolds with 30-100 μm pore sizes and 46.9 % porosity yielded 50 μm 
of osteoid and fibrous tissue ingrowth.[253, 254] Factors such as degradation rate and mechanical 
stability are highly dependent on pore size and porosity, ultimately affecting bone formation.[241] 
Similarly, for vascularization, scaffolds with pores greater than 140 μm demonstrated increased functional 





vascularization increases with increasing pore sizes, and at a pore size of 270 μm the potential for scaffold 
interference in vascularization is removed.[256] Interconnected pores ranging from 300 - 500 μm are 
known to improve nutrient flow.[250] For some scaffold fabrication techniques, rendering sufficiently 
accurate pores to obtain specific porosities is difficult, requiring a new approach, such as 3D 
printing.[252] 3D printing allows for the fabrication of complicated designs with high precision and 
accuracy. For such designs, a variety of combinations of pore size and porosity can be obtained, allowing 
for tailoring of degradation rate, mechanical strength, and interconnectivity of the construct. After 
selecting a set of scaffold designs that are composed of biocompatible materials and have the 
physiologically appropriate mechanical properties the next step is to evaluate which design optimizes 
vascularization.  
Current methods to measure vascularization use animal models as the gold standard. In vivo 
studies are integral to evaluating the biological response; however, ideally, an in vivo study would be 
implemented at the last stage of development. Identifying the optimal combination of parameters for 
vascularization earlier in the design process would accelerate the process by reducing the number of 
designs investigated with each step in the toolbox. Moreover, refinement of the scaffold design prior to 
the in vivo stage is beneficial for implementing the 3Rs of replacement, reduction, and refinement of 
animal models.[257] Therefore to evaluate vessel ingrowth we suggest the use of an in silico model as an 
integral component of our toolbox. The in silico model we recommend has accurately replicated 
angiogenesis.[256] This in silico model allows for the investigation of a wide range of combined scaffold 
parameters that would be difficult and time consuming recreate the wide range of designs physically. 
Now that we have identified the steps in our toolbox necessary to examine the wide range of scaffold 





3.2 Experimental Section: Materials & Methods 
3.2.1 Poly(propylene fumarate) synthesis 
 Poly(propylene fumarate) was synthesized in a two-step process as described previously.[228] 
Gel permeation chromatography was used to calculate the number average molecular weight (Mn = 866) 
and polydispersity index (PDI =1.3) of the purified PPF.  
3.2.2 Scaffold Design  
Scaffolds were composed of repeating units of base rings connected by uniformly distributed 
c7ylindrical posts (Figure 6.1). These repeating units were stacked to form a porous cylinder (Figure 6.1). 
This modular design uses a wide range of scaffold parameters such as pore size, post number, post height, 
base height and wall thickness. From the set of possible designs, twelve were selected as representative 
scaffolds with three porosities, three pore sizes and two wall thicknesses. These scaffolds were designed 
using SolidWorks
®
 (Waltham, MA).  
3.2.3 Three Dimensional (3D) Fabrication 
Four of the twelve designs were 3D-printed using the EnvisionTEC Perfactory
®
 per previously 
described methods.[1] The resolution was 22.5 μm in the x-y directions and 50 μm in the z direction. 
Briefly, the polymer resin used to 3D-print the scaffolds was comprised of five components: PPF (38.46 
% w/w), diethyl fumarate (DEF) (38.46 %), bis(acyl)phosphine oxide (BAPO) (0.77 % w/w), TiO2 (0.77 
% w/w), and 2-hydroxy-4-methoxybenzophenone, (HMB) (21.54 % w/w). Scaffolds were built at an 
exposure of 350 mW/dm
2
 for 120 s (burn-in) or 60 s per layer. Uncured resin was removed with ethanol 
and compressed air. Scaffolds were post-cured in a 3D Systems UV-box (Rock Hill, SC) for 12 hours. 
3.2.4 Micro Computed Tomography 





scaffolds. Scanning was performed on a CT 100 (SCANCO Medical, Brüttisellen, Switzerland) operated 
at 70 kvP, 9 μm voxels and 200 mA. The resulting 3D data sets were segmented using thresholds (lower: 
35, upper: 188), and gauss sigma (0.8) and support (1) values to separate pores from polymer. Images 
were compiled and evaluated to calculate pore size, porosity, and wall thickness using Scanco’s Image 
Processing Language (IPL).  
3.2.5 Angiogenesis Modeling 
 Vascularization of scaffold designs was investigated using a previously developed agent-based 
model[258]. In this model, software agents, representing endothelial cells, are programmed to interact 
together and with the local environment based on a set of rules, leading to new capillary formation. The 
rules and specifics were detailed previously.[258] Scaffold structures serve as a steric hindrance to 
vascular ingrowth. 
MATLAB was used to convert scaffold designs into a triangulated mesh and then into a volume 
matrix. The scaffolds had a final resolution of 1 µm/pixel and were exported as individual volume slices 
into the model. A representative portion of the scaffold, including a layer of pores and scaffold, was used 
to reduce computational demands during simulation runs. The scaffolds are modeled as if they were 
implanted in vivo, in contact with skeletal muscle with a uniform distribution of host blood vessels 
surrounding the scaffold-tissue interface. Each simulation was performed for 400 time steps 
corresponding to four weeks and repeated 25 independent times for each case.  
Multiple parameters were calculated to assess vascularization. Total blood vessel length (TBVL) 
is the cumulative length of all blood vessels formed. Blood vessel length density (BVLD) is equal to 
TBVL divided by the number of initial sprouts from host vessels. Average invasion depth (AID) and 
maximum invasion depth (MID) measure sprout invasion into the scaffold. The ratio of successful sprouts 
(ROSS) denotes the percentage of initial sprouts which pass the walls into the inner core. Total number of 





The simulations were performed using 64-bit versions of Java JDK 1.6.0_10 with Java 3D 1.5.2 
and Eclipse Helios version 3.6.2 on a workstation running 64-bit Windows 7 Professional with an Intel 
Pentium i7 processor and 192GB of RAM. Repast version 2.0.1 was used with parameter sweep feature to 
perform batch simulation runs.[259, 260] The Java code outputs the 3D position of agents at pre-defined 
time steps. 3D renderings of scaffolds with blood vessels were produced using open source ImageJ 
(version 1.46o) visualization software package. 
3.2.5 In Vivo Study 
Animal experiments were performed at Chang Gung Memorial Hospital (Keelung City, Taiwan) 
with procedures approved by the Institutional Animal Care and Use Committee. A rodent subcutaneous 
implantation model was used to evaluate vascularization. Four scaffold conditions with 500 µm wall 
thickness were examined in vivo (400 µm and 38 % porosity, 400 µm and 25 % porosity, 800 µm and 50 
% porosity, 800 µm and 25 %). Scaffolds were steam sterilized at 121°C for 15 minutes and prepared 
under sterile conditions. Scaffolds were implanted into subcutaneous pockets created in Sprague-Dawley 
rats (n=2 per group per time point), under isoflurane anesthesia. Each rat received 4 implants with the 
implant location determined randomly. At 1 and 3 weeks after implantation the implants harvested with 
surrounding tissue and then formalin fixed. During implantation, one 800μm pore size, 50% porosity 
scaffold was damaged so n = 1 at week three. 
3.2.6 Histological Analysis 
The formalin fixed samples were paraffin embedded and sectioned (5 μm thickness). The tissue 
orientation resulted in a radial cross section of the scaffold allowing for clear identification of the 
biomaterial-tissue interface. Sections were stained for hematoxylin and eosin (H&E) and Masson’s 
trichrome for examination of tissue structure and inflammation. Immunostains for CD31 were performed 






 Statistical analysis was performed using ANOVA and Tukey’s multiple pairwise comparison (p < 
0.05). Values provided are mean ± standard deviation. Please note that only relevant statistical 
relationships are denoted on figures. 
3.3 Experimental Section: Results and Discussion 
We applied our toolbox to examine the wide range of scaffold parameters using a case study of 
porous PPF scaffolds. To utilize this set of tools, we designed, fabricated, characterized, and evaluated 
porous PPF scaffolds consisting of modular ring-shaped bases. The first step was to use modular design to 
identify the wide range of scaffold designs that are feasible with defined pore sizes, base heights and 
number of posts. Of the wide range of variables identified within the range of possible designs twelve 
scaffold designs were selected, with varying porosities, pore sizes, and wall thicknesses. Eight of the 
twelve theoretical designs are pictured in Figure 3.1b-3.1i with wall thicknesses of 100 µm (Figure 3.1b -
3.1e) and 500 µm (Figure 3.1f -3.1i). The designs include three different porosities (25 %, 38 %, 50 %), 
and two pore sizes (400 µm, 800 µm). Figure 1j shows that porosity is increased by varying the height of 
the posts connecting the modular ring structures. Conversely, modeling the effect of base height on 
porosities showed that increasing the base height to 500 μm (red), from 100 μm (blue), results in a smaller 
range of porosities (Figure 3.1j). Figure 3.1k highlights the trend that as the number of posts increases, the 
range of possible porosities decreases. Conversely, as post height increases, the range of possible 
porosities increases. A large range of possible porosities and pore sizes is necessary for the wide range of 
native tissues that regenerative medicine addresses. Of the twelve designs within the range of design 
specifications, four were chosen for the next steps in the toolbox.  





from PPF-based polymer resin. This absorbable polymer has been optimized in previous work for 3D 





designs µCT was implemented as the second step in our toolbox. First µCT was used to nondestructively 
image the fabricated scaffolds (Figure 3.2a - 3.2d). This µCT data was compared to the design 
specifications. For each design, the intended pore size, porosity, and wall thickness were compared to 
their corresponding physical construct parameter (Figure 3.2e). Similar values to the design specification 
for the porosity were achieved for three of the four scaffolds (Figure 3.2a - 3.2c); however, pore sizes 
were smaller than the designed values. For the scaffold designs with 400 μm pores, the printed scaffolds 
had an average pore size 63 % and 70 % of the intended pore sizes. The scaffold design with 38 % 
porosity, 400 μm pores and 500 μm wall thickness (Figure 3.2d) exhibited the largest deviation from the 
design, with the porosity at 53 %, pore size at 70 % and wall thickness at 78 % of the design 










Conversely, the two scaffolds that were most accurately fabricated had 800 μm pores; with 
porosities that were 88 % and 90 %, pore sizes at 80 % and 70 %, and wall thicknesses of 91 % and 79 % 
of the design specifications. In comparison with porogen leached scaffold fabrication, which creates pores 
based on the size distribution of the porogen, the 3D printed pores were printed with a tighter tolerance 
allowing for greater control of the scaffold parameters.[263, 264] The µCT 3D renderings and 
quantification of the printed scaffold parameters show promise for the fabrication of complex designs. 
The greatest design conformance was seen with the wall thickness and the overall porosity; however, the 
pore size was consistently found to the smaller than the design specification.  
 
Figure 3.1: Design of Standardized Modular Scaffolds. (a) Repeating Unit of Modular Scaffold Design. Base and post ring 
structure that is used as the repeating unit to create the scaffold designs. The modular design can be tuned by varying post 
number, base height and wall thickness to create a range of pore sizes and porosities. (b – e) 100 µm Wall Thickness 
Scaffolds. (b) 400 µm pore size, 50 % porosity, (c) 800 µm pore size, 25 % porosity, (d) 400 µm pore size, 25 % porosity, and 
(e) 800 µm pore size, 50 % porosity. (f - i) 500 µm Wall Thickness Scaffolds. (f) 400 μm pore size, 25 % porosity, (g)  800 μm 
pore size, 25 % porosity, (h) 400 μm pore size, 50 % porosity, and (i) 800 μm pore size, 50 % porosity. (j) Effect of Post height 
on Porosity. Increasing post height allows for a greater range of porosity. Smaller wall thickness (blue) modular designs allow 
for a greater range of porosities. (k) Effect of Number of Posts on Post Height and Porosity. As the number of posts increase, 


















Figure 3.2: μCT Characterization of 3D Printed Scaffolds. (a - d) μCT 3D Renderings of Scaffolds. 3D rendering of scaffold 
designs. (a) 800 μm pores, 25% porosity, (b) 800 μm pores, 50% porosity, (c) 400 μm pores. 25% porosity, (d) 800 μm pores, 
38% porosity. (e) Comparison of 3D Printed Scaffolds with Theoretical Scaffold Design Parameters. Nondestructive analysis 
of scaffold pore size, porosity and wall thickness was performed using Image Processing Language. Results are compared to 
the theoretical scaffold design parameters (Design). Printing efficacy was measured by calculating the percent difference 
between the fabricated scaffold parameters (Actual) compared to the scaffold design parameters (% of Design). 3D printing 
was most accurate for wall thickness with the closest accuracy at 91% of the design specifications for the 800 μm and 25% 
porosity scaffold design. Differences between design and fabricated scaffolds were greatest for pore size and porosity. (n = 4) 
Overall, the combination of the Perfactory
®
 device and the PPF resin were able to fulfill the 
desired ranges of porosities and wall thicknesses; however, the pore sizes ranged from 63 % to 80 % of 
the targeted values (Figure 3.2). The undesired infilling of designed pore spaces and subsequent rounding 
of the pores, is thought to be due to extraneous photocrosslinking caused by the light scattering effects of 
the dye, titanium dioxide (TiO2), and post-curing shrinkage of the polymer.[262] The rounding of the 
edges is best seen in the scaffold with 38 % porosity and 400 μm pore size (Figure 3.2d). This 
unintentional curing is referred to as “dark cure” or “over cure”.[262] Dark cure is polymerization of 





remain dark and uncured. Additionally, high viscosity polymer resins, like PPF, have been shown to 
negatively impact printing resolution with the undesired filling of pore spaces.[1] Over cure is observed 
with the crosslinking of the polymer resin beyond the dimensions in the design specification that are 
perpendicular to the build plate. This highlights some areas of future research for improving the accuracy 
and reproducibility of 3D printing. Now with the understanding of the dimensions of the fabricated 
scaffolds we were interested in the potential of angiogenesis of these different designs, or the last step in 
the toolbox.  
We evaluated the potential for vessel ingrowth into the scaffolds using a 3D agent-based model of 
angiogenesis.[258] This in silico model was used, as the last method in our toolbox, to investigate the 
effect of pore size, porosity, and wall thickness on the rate and depth of vascularization of the scaffolds. 
Variations of pore size, porosity, and wall thickness exhibited varying levels of vascularization (Figure 
3.3). Scaffolds with 200 μm, 400 μm, and 800 μm pore sizes, 25 % and 50 % porosities, and 100 μm and 
500 μm wall thicknesses were evaluated for their vascularization potential following implantation in vivo. 
Angiogenesis was assessed using six metrics as described in the methods below (Figure 3.3a). All 
angiogenesis metrics were found to increase with porosity when other properties (wall thickness, pore 






Figure 3.3: In Silico Angiogenesis Modeling Results. (a) Quantitative Results: Angiogenesis of twelve different 
scaffold designs with two different wall thicknesses and three different pore sizes was evaluated for six 
different parameters, total blood vessel length (TBVL), average invasion depth (AID), maximum invasion depth 
(MID), total number of anastomoses (NOA), ratio of successful sprouts (ROSS) and TBVL per initial sprout 
(TBVLS). Smaller wall thickness, 100 μm, was found to be preferable. At the smaller wall thickness increasing 
pore size had no impact on ROSS, TBVL or AID. Scaffolds with high porosity (50%), wall thickness of 100 μm 
and small/medium pore sizes (200 - 400 μm) had the best values for all six vascularization metrics. (b - f) 
Images of vascularization at 3 weeks. (b - c) Thinner walled scaffolds resulted in greater vascularization, as 
seen by greater number and length of vessels, correlating with all six parameters in (Figure 3a). Scaffolds 
shown have 200 µm pore size, 50% porosity, and (b) 100 µm and (c) 500 µm wall thickness. (d - f) As pore size 
increases vascularization decreases while porosity is held constant. Scaffolds shown have 25% porosity, 100 






We also observed that vascularization decreased with increasing wall thickness. This is clearly 
seen when comparing the growth of vessels in scaffolds with 100 µm wall thickness in comparison to 500 
µm (Figure 3.3b - 3.3c). A greater density and depth of vessels is observed in scaffolds with thinner walls. 
Interestingly, with 100 µm wall thickness, vascular parameters, such as the maximum invasion depth 
(MID), ratio of successful sprouts (ROSS), depth of invasion (AID), and total blood vessel length 
(TBVL), generally decrease with increasing pore size when porosity remains constant. This is highlighted 
in Figures 3.3d - 3.3f, where the thickness of the scaffold base increases as the pore size is increased to 
maintain a constant porosity.  
One interesting finding is that as pore size increases to 800 μm, wall thickness has less of a 
detrimental impact on vascularization. This is highlighted in the 800 μm pore size cases, the MID, ROSS, 
and total blood vessel length per initial sprout (TBVLS) metrics are seen to have similar results for the 
same size porosity. The effect of very small pore sizes is similar to the effect of very thick scaffolds. In 
both cases, large surfaces exist in the scaffold which hinder sprout invasion. As a result, when wall 
thickness is high, increasing the pore size improves the results. However, when wall thickness is low, 
increasing the pore size has either no effect or a modest negative effect on the ROSS, TBVL and AID 
(Figure 3.3). As expected, in all cases in this study, increasing porosity has a positive effect on depth and 
rate of scaffold vascularization. By controlling these scaffold parameters one can influence as well as 
improve nutrient and waste transport to and from the defect site. In general, agent-based predictions based 
on the smaller wall thickness of 100 μm showed increased angiogenesis compared to wall thickness of 
500 μm (Figure 3.3). In summary, the optimal scaffold designs for vascularization were found to have 
high overall scaffold porosity (50 %), low thickness (100 μm), and small or medium pore sizes (200 - 400 
μm). Along with wall thickness, porosity was shown to play an important role with all six measures of 
angiogenesis which increase with increasing porosity. These results may be impacted by the difference in 





is a complete cylinder with interconnected pores. These results only take into account the geometric 
factors influencing angiogenesis, and no biological characteristics so we looked to compare these results 
in vivo. 
 Vascularization was further investigated in vivo by implanting four scaffold designs in a 
subcutaneous implant model (Figure 3.4). At harvest, the explanted scaffolds appeared intact and were 
surrounded by a layer of fibrovascular tissue. Histologically, tissue invasion was observed within the 
scaffold for all conditions. The tissue exhibited a typical inflammatory response with a large density of 
vessels and significant collagen production. No signs of chronic inflammation, encapsulation, or 
multinucleated foreign body giant cells were observed. Vessels could be seen growing within the pores of 
the scaffolds (Figure 3.4c). As seen in Figures 4a and 4b the thin tissue sections include both 
contributions from the pores and the thick scaffold surfaces that block tissue ingrowth. Vessel density was 
analyzed quantitatively from CD31 immunostains and similar levels of vessel density were observed in all 
four scaffolds designs. Similar to the computational predictions vascular networks were observed growing 
in the pores in all scaffold conditions. However, quantitative analysis of vascular density did not show 
any differences between conditions (Figure 3.4d) as suggested by the in silico model. This suggests the 
challenges in relating histological findings to 3D structures. The computational model presents an 
evaluation of the 3D structure that cannot be determined from the essentially two dimensional (2D) 
tissues sections. Regardless, the results show that the scaffolds enable vascularized tissue ingrowth into 
the core as suggested by our methods in the toolbox. We suggest that to refine the toolbox to better match 
physiological outcomes a model of the fabricated scaffold could be evaluated in silico; therefore 
evaluating the scaffolds’ true pore size, porosity and wall thickness. Furthermore, the in silico data could 
be compared with in vivo results using µCT to better image three dimensionally the vessel penetration of 






Figure 3.4: In Vivo Angiogenesis. (a - c) Histological Analysis of Explanted Scaffolds. (a - b) Massons Trichrome staining 
showing tissue formation within 500 µm wall thickness scaffolds with (a) 400 µm pore size, 38 % porosity and (b) 800 µm 
pore size, 25 % porosity. Blood vessels and collagen can be seen between the scaffold posts and within the core of the 
scaffold. White arrows point to blood vessels. Yellow arrows point to a relatively mild and thin inflammatory response at the 
interface with the PPF. Blue staining is collagen and shows an overall standard fibrovascular response with collagen 
formation. Scale bar represents 500 µm. (c) Massons Trichrome staining for pore size of 800 µm, 25 % porosity scaffolds at 
week 3. Large vessels are seen in the tissue between the posts. Scale bar represents 100 µm. (d) Blood Vessel Density. Vessel 
density in the tissue growing within the pores of the scaffolds determined from immunohistochemical stains for CD31. There 
are no statistical differences in vessel density within the pores for these conditions. (n = 2, p < 0.05) 
3.4 Conclusion 
 Three dimensional printing allows for the development and use of many complex designs; 
however, no standard set of tools has been implemented for evaluating the design, fabrication, and 
implementation of 3D printed scaffolds. Here, we applied our toolbox to predict the best functioning 
porous scaffold designs for vascularization. Our toolbox was used to investigate the range of possible 
scaffold parameters using a modular design, to assess nondestructively the accuracy of the 3D printed 
scaffolds, and to model the potential for vascular tissue ingrowth using an in silico model. Since previous 
studies have investigated the mechanical and biocompatibility properties of porous PPF scaffolds these 





scaffold parameters such as pore size and overall porosity. After identifying a set of scaffold designs for 
further study, the scaffolds were printed. Printing efficacy of 3D printing fabrication methods was 
evaluated using nondestructive μCT imaging. The most accurate fabrication was seen in scaffolds with 
large pores and small porosities due to decreased incidence of inadvertent rounding in rectangular shaped 
pores. In silico modeling was used to investigate the impact of scaffold parameters on vascularization. An 
in vivo study was used to compare these results and found that all the porous scaffold designs allowed 
extensive vascularization through the pores and into the core of the scaffold. The use of the toolbox will 





Chapter 4: Structural and Cytotoxicity Evaluation of In Vitro Degraded 
3D Printed Porous PPF Scaffolds 
4.1 Introduction 
 Understanding changes in structural and mechanical properties, as well as biocompatibility, of 
absorbable polymer scaffolds during degradation is critical to designing a successful bone tissue repair 
product. Ideal repair of a bone defect allows for mechanical support while native bone replaces the void. 
To facilitate rapid repair bone tissue engineering suggests a combination approach of a biomaterial 
scaffold and a biologically active component. In this study we propose using 3D printed porous 
poly(propylene fumarate) (PPF) as the biomaterial for the scaffolds. Our scaffolds would provide 
mechanical stability during degradation while the bioactive material, housed in the lumen, would promote 
host tissue ingrowth and eventual repair of the bone defect. Another key property of a successful 
biomaterial is biocompatibility at the implantation site. As PPF is an absorbable polymer, the 
biocompatibility of PPF depends on both the polymer and its degradation by products. Therefore we 
investigated the potential for a cytotoxic response to the byproducts of degradation as PPF has already 
been determined to be noncytotoxic (Chapter 2).  
PPF is an aliphatic polyester consisting of a carbon-carbon double bond, flanked by two ester 
groups that has been determined to be well suited for bone tissue engineering. [52, 219] PPF degrades 
through the hydrolysis of the ester groups on the repeating unit (Figure 2.1). The byproducts of 
degradation are fumaric acid and propylene glycol.[226] PPF, and it’s degradation byproducts have been 
shown to be noncytotoxic.[247] Fumaric acid is produced during the citric acid cycle. Therefore in vivo it 
is expected that some of the fumaric acid would naturally be taken up by the cells in the immediate 
environment. It was established as “practically non-toxic” by the European Commission Report of the 
Scientific Committee on Animal Nutrition on the Safety of Fumaric Acid. Also, fumaric acid esters have 





glycol is a common food additive.  
 We hypothesized that the degradation extract of the 3D printed PPF scaffolds will have a low 
cytotoxic response as its degradation byproducts are nontoxic, and previous research has demonstrated 
biocompatibility. To test this we proposed a method to evaluate polymer degradation cytotoxicity using a 
series of extract assays based on the ISO Standard 10993-5, “Tests for In Vitro Cytotoxicity.” [95]  This 
is a novel method as the standards for evaluating the cytotoxicity of an absorbable polymer are not well 
defined for in vitro analysis. The scaffolds investigated were 3D printed with a resin containing PPF, 
diethyl fumarate, vitamin E, and ozybenzone (HMB). Previous studies have evaluated PPF for in vitro 
cytotoxicity and found that it elicits the same cellular response as known noncytotoxic materials (high 
density poly(ethylene) and blank culture media.[247] The remaining components have also been shown to 
be noncytotoxic; however, the cytotoxicity of the materials combination as well as during polymer 
absorption has not been evaluated.[49-51, 88-91, 265] To determine if our scaffolds would fulfill provide 
the necessary noncytotoxic mechanical support during degradation to treat bone defects, changes in mass, 
mechanical properties, pore size, porosity, and wall thickness were evaluated over 224 days of 
degradation. 
4.2 Experimental Section: Materials and methods 
4.2.1 Poly(propylene fumarate) synthesis  
 Poly(propylene fumarate) was synthesized in a two-step process as described previously.[228] 
Briefly, propylene glycol and diethyl fumarate were combined in a 3:1 molar ratio. Zinc chloride and 
hydroquinone were added in a 0.01:0.002 molar ratio to act as catalyst and radical inhibitor, respectively. 
The solution was reacted under a flow of nitrogen gas producing ethanol as a byproduct and 
bis(hydroxypropyl) as the intermediate. The second step is a transesterification of the intermediate, 





chromatography was used to calculate the number average molecular weight (Mn) and polydispersity 
index (PDI) of the purified PPF. For the solid wall and unaligned pore scaffolds PPF Mn = 1157 Da and 
PDI = 1.15; for the aligned pore scaffolds Mn = 1078 Da and PDI =1.67 
4.2.2 Scaffold Design 
Scaffolds were designed based on a modular design described previously (Chapter 6). Briefly, the 
design consists of a base ring with uniformly distributed posts, this unit is repeated and stacked upon the 
unit prior until the desired height of the scaffold is reached (Figure 4.2). This cylindrical structure is 
hollow, designed to house a biologically active (bioactive) component in the lumen. Two of the scaffold 
designs were porous, one with the pores from each modular unit aligned (aligned). The other porous 
scaffold was based on the same modular unit; however, each modular unit was rotated when stacked on 
previous unit. This created a structure where the pores are not stacked one on top of each other, or an 
unaligned structure (unaligned). The third design was a solid wall design (solid). These scaffolds were 
designed in SolidWorks® (Waltham, MA).  
4.2.3 Three Dimensional (3D) Fabrication and Post Curing  
The scaffold designs were 3D-printed using the EnvisionTEC Perfactory
®
 P4 per previously 
described methods.[1] The resolution was 25 μm in the x-y directions and 50 μm in the z direction. 
Briefly, the polymer resin used was comprised of: PPF and diethyl fumarate (DEF) in a 1:0.8 ratio along 
with dyes and initiator. Bis(acyl)phosphine oxide (BAPO) (1%) was used as the initiator and 2-hydroxy-
4-methoxybenzophenone, (HMB) (1%) and α-tocopherol (0.01%) were used as dyes. Scaffolds were built 
at an exposure of 275mW/dm
2
 for 120 s (burn-in) or 100 s per layer. Uncured resin was removed with 
ethanol and compressed air. Scaffolds were post-cured in a 3D Systems UV-box for 2000 flashes. After 
printing, scaffolds were first rinsed for 15 min in PBS (0.01M) to eliminate any extraneous debris. Then 





the scaffolds were rinsed 15 min in a PBS solution to remove all traces of acetone. Scaffolds were 
vacuum dried and their initial mass (Mi) was recorded. Scaffolds were sterilized 15min at 121°C prior to 
initiating the degradation study.  
4.2.4 Sol Fraction 
To assess the crosslinking density the sol fraction was measured per the previously described 
method[52]. Samples of the photocrosslinked film were weighed (Wi) prior to incubation in acetone, the 
solvent. The samples were then submerged in the solvent for 24 h. After incubation, samples were dried 
overnight and weighed again (Wd) (n = 3). Sol fraction was calculated using the formula: 
              Wi - Wd  
      Wi 
4.2.5 In Vitro Degradation 
 Scaffolds and 20mL of phosphate buffered saline (PBS) (0.01M, pH 7.4 ) and 0.01M asorbic acid 
were placed into vials. Ascorbic acid was added to stabilize the scaffold degradation byproducts. Vials 
were stored at 37°C on a shaker table (75RPM). At each timepoint (days 0, 1, 7, 14, 28, 56, 112, and 
224), pH was measured and PBS was replaced. At each timepoint scaffolds were removed from the vials 
and wet (Mw) weights were recorded. After vacuum drying and dry weight (Md) was recorded. At each 
timepoint mass loss, water absorption, pore size, porosity and wall thickness were evaluated (n = 3). Also 
at each timepoint wet scaffold mechanical properties evaluated using compressive testing (n = 5). Mass 
loss was calculated using the following formula:  
Mi - Md  
                    Mi 
 
Scaffold mean pore size, porosity and wall thickness was evaluated non-destructively using micro 
computed tomography (μCT) at each timepoint. 
Mass Loss =                  x 100% 





4.2.6 Micro Computed Tomography (μCT) 
  Micro computed tomography (µCT) was used to non-invasively image and characterize changes 
in scaffolds as previous described (Chapter 6.2.4). Scanning was performed on a CT 100 (SCANCO 
Medical, Brüttisellen, Switzerland) operated at 70 kvP, 9 μm voxels and 200 mA. The resulting 3D data 
sets were segmented using thresholds (lower: 35, upper: 188), and gauss sigma (0.8) and support (1) 
values to separate pores from polymer. Threshold segmentation values were determined using a peak 
histogram approach and confirmed visually. Images were compiled and evaluated to calculate pore size, 
porosity, and wall thickness using Scanco’s Image Processing Language (IPL).  
4.2.7 Compressive Mechanical Testing 
  Compressive mechanical testing was performed at each timepoint using an Instron 
mechanical testing system (33R/4465). At each timepoint scaffolds were removed from PBS and 
immediately used for wet mechanical testing with the exclusion of day 0 (n = 5). Day 0 testing was 
performed prior to exposure to PBS. Samples were placed into stainless steel fixtures, which ensured that 
compression was applied homogeneously. Each fixture had a radius of 7.5mm, an outer ring of 4mm, an 
inner post of 3mm, and a channel for the sample that was 2mm in width. All tests were performed using a 
high capacity load cell (5000N). Samples were compressed at a displacement rate of 10 mm/min. Prior to 
initiating compression, force and displacement were zeroed and then monitored throughout the 
experiment. Experimental values were recorded every 10 ms.  
During testing compression was maintained until a drop of at least 10% in force was measured. 
Engineering stress and strain were calculated based on cross sectional area and height, respectively, which 
were then used to compute compressive modulus, 1% offset yield stress, and ultimate, or maximum, 
compressive stress. Compressive modulus was calculated using Matlab to determine the slope of the 
linear region of the stress-strain curve. The program evaluated the slope after a preload of 2N. The linear 





continues to add data points in steps of 10 until the R
2 
> 0.97. The slope of this region is representative of 
the modulus of the sample. Yield stress was calculated as the intersection of the stress-strain curve with a 
line, drawn parallel to the initial slope, whose x-axis intercept is shifted 0.01 mm/mm strain.  
4.2.8 Cytotoxicity of Degradation Byproducts 
 PPF scaffolds were degraded in PBS (0.01M and pH=7.4), with 0.01M of ascorbic acid, in a ratio 
of 6:100 of scaffold to solution based on the ASTM F1635. Extract PBS was removed at days 1, 7, 14, 28, 
56, and 112 to evaluate the cytotoxicity of the degradation byproducts. The cellular response to the extract 
PBS was evaluated using a fibroblast cell line (L929) (ATCC, Manassas, VA) as recommended by the 
ISO standard 10933-5.[14] Cells were cultured per the manufacturer’s specifications with Minimum 
Essential Medium (MEM) (Life Technologies, Frederick, MD) and 10% horse serum (Life 
Technologies). Cells were plated and grown to ~80% confluency prior to initiating the assays.  
 The extract PBS was combined with L929 culture media in three ratios, 1:99, 10:90, and 50:50. 
The cell culture media was then removed and replaced with the extract and media solution (Figure 4.1). 
The extract and media solution was incubated at 37°C and 5% CO2 for 24 h after which the cytotoxicity 
was evaluated qualitatively with fluorescence microscopy and quantitatively with the XTT cell metabolic 
activity assay (Roche, Mainheim, Germany). For the cytotoxic control the culture media was removed 
and cells were incubated with 70% methanol for 30 minutes prior to evaluation of cytotoxicity. Blank 
culture media was used as a negative control.  
 
Figure 4.1: Diagram of cytotoxicity test for the degradation byproducts. Culture media was mixed with degradation extract in 





4.2.9 XTT Assay 
 The Cell Proliferation Kit II (XTT) (Roche, Mainheim, Germany) was used to quantitatively 
evaluate cell metabolic activity. XTT (2,3-bis-(2- methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-
carboxanilide) was used according to the manufacturer’s protocols. The electron coupling and XTT 
labeling reagents were thawed and immediately combined in a 1µl:50µL ratio. Then 250µl of the XTT 
solution was added to the cell culture wells. Absorbance was measured after 4 hours of incubation at 
37°C with a M5 SpectraMax plate reader (Molecular Devices, Sunnyvale, CA). Net absorbance was 
calculated (A492-A650) for each sample of the biological replicates. Relative cell metabolic activity was 
normalized to the mean of the blank culture media. Samples were evaluated, the mean cell metabolic 
activity and standard deviations are reported (n=3). 
4.2.10 Fluorescence Imaging 
Qualitative evaluation of cell viability was performed using live/dead imaging as described 
previously[233]. Live/dead solution was prepared (4µM of calcein AM and 2µM of ethidium homodimer 
in 0.01M PBS) (Invitrogen, Carlsbad, CA). Prior to the addition of the live/dead stain, cells were washed 
with PBS to remove any remaining culture media and FBS. Cells were incubated with the live/dead 
solution in dark conditions for 30 minutes prior to imaging. Images were obtained with a fluorescence 
microscope (Axiovert 40CFL, filter set 23, Zeiss, Thornwood, NY) fitted with a digital camera (SPOT 
Insight 1120, or SPOT Idea 2920, Diagnostics Instruments, Sterling Heights, MI).  
4.2.11 Statistics 
 Statistical analysis was performed using ANOVA and Tukey’s multiple pairwise comparison 
(p<0.05). All tests were performed in triplicate (n=3) unless otherwise specified. Values provided are 





4.3 Experimental Section: Results 
Three scaffold designs, aligned pore, unaligned pore and solid wall, were created and fabricated 
using 3D printing. Scaffolds were then degraded in 0.01M PBS with 0.01 ascorbic acid at 37°C on a 75 
RPM shaker table. Scaffold degradation was seen during the 224 day study through increasing mass loss, 
decreasing pH as well as changes in scaffold pore size, porosity and mechanical properties. Cytotoxicity 
of the degradation byproducts was evaluated and found to not elicit a negative cellular response.  
Scaffolds were 3D printed with a high degree of accuracy compared to the design specifications 
(Figure 4.2). The aligned and unaligned porous scaffolds had an effective average porosity of 52% and 
53%, respectively, close to the designed porosity of 50%. The scaffold mean wall thickness was 
fabricated at 532 μm and 558 μm for the aligned and unaligned scaffolds, respectively, compared to the 












Figure 4.2: μCT 3D rendering and evaluation of scaffold porosity, pore size and wall thickness. All three scaffold 
designs, solid wall, aligned pore and unaligned pore scaffolds were successfully fabricated using 3D printing. Most 
parameters of the porous scaffold, aligned and unaligned pore, were fabricated similar to the design specifications. 
However, the wall thickness of the solid wall scaffolds was found to be larger than the wall thickness of either of 






at 842 μm, much larger than the 500 μm design specification. The printed pores were unexpectedly 
slightly larger than the desired 500 μm size, with an average pore size of 619 μm, aligned, and 569 μm, 
unaligned, scaffolds. 
 Sol fraction was performed to determine if the different scaffold designs had any impact on the 
amount of crosslinked network (Table 4.2). The sol fraction for all three groups was found to be 
statistically similar.  
Table 4.1: Sol Fraction of Scaffolds 
Scaffold Design Sol Fraction 
Solid 12.6  ± 1.7% 
Aligned 13.3 ± 8.4% 
Unaligned 9.6 ± 3.3% 
 
 All three scaffold designs showed degradation during the 224 day study as seen through increases 
in mass loss and decreasing pH (Figure 4.3). Mass loss increased throughout the study, with the biggest 
increase in mass loss seen in the first 28 days. After 224 days, the solid wall scaffolds had lost 17 ± 7% of 
the mass compared to 12 ± 1% mass loss of the aligned scaffolds and 17 ± 2% of the unaligned scaffolds. 
At each timepoint the solid wall scaffolds had the same or greater percentage of mass loss compared to 
the porous scaffolds. As one of the degradation products of PPF is fumaric acid we expected to see a 
decrease in pH as the scaffolds degraded. The lowest pH was seen at day 224, with a range of values from 








 As degradation was shown to be occurring through increasing mass loss and decreasing pH, 
micro computed tomography (μCT) was used to elucidate how the scaffolds were degrading. μCT was 
used to evaluate the changes in scaffold pore size, porosity and wall thickness as previously 















Figure 4.3: Mass loss (A) and pH change (B).  Mass loss increases through the 224 day study, indicating that 
degradation is occurring. Also indicative of degradation is the change in pH, which decreases over the 
study. The decrease in pH is due to the formation of fumaric acid, one of the degradation byproducts of 
PPF. The mean and standard deviation are reported, some standard deviations are too small for the error 






approach. To understand the tolerance of these threshold values data from three threshold sets, [20, 188], 
[35, 188], and [35, 1000] were used to elucidate the potential impact of alternative threshold values 
(Table 4.2). 

















[20, 188] 588.6 4% 537.4 -6% 54% 4% 
[35, 188] 612.6 - 508.9 - 56% - 
[35, 1000] 620.8 -1% 511.1 0% 56% 1% 
 
Scaffold porosity was shown to slightly increase throughout the study, while the mean pore size 
remained statistically the same for the porous scaffolds (Figure 4.4). The average porosity increased from 
52 ± 9% and 53 ±3% at day 0 to 64 ± 2% and 57 ± 4% at day 224, for the aligned and unaligned 
scaffolds, respectively (Figure 4.4A). Average pore size was 619 ± 30 μm and 569 ± 45 μm at day 0 
compared to 634 ± 25 μm and 573 ± 13 μm at day 224 for the aligned and unaligned scaffolds, 
respectively (Figure 4.4B). A trend in wall thickness shows a decrease in size as the study progressed for 
the porous scaffolds (Figure 4.3C). The solid wall scaffolds also showed a decrease in wall thickness with 







To investigate how the porosity was increasing while average pore size remained constant a 
histogram of pore sizes was evaluated for each of the porous scaffolds. Figure 4.5 is an example of the 
Figure 4.4: Porosity (A), pore size (B) and wall thickness (C). µCT was used to calculate the porosity, pore 
size and wall thickness of the scaffolds during the study. Porosity (A) is seen to increase slightly from 
day 0 to day 224, while mean pore size remains constant (B). Similarly, there is no statistical difference 
in wall thickness for the aligned or unaligned scaffolds. The solid wall scaffolds wall thickness decreases 
over the study, with a statistically larger wall thickness on day 0 compared to all other timepoints.  The 
mean and standard deviation are reported, some standard deviations are too small for the error bars to 










histograms of pore sizes at four different times during the study, day 1, day 28, day 56 and day 224, for 
the aligned pore scaffolds. The green box highlights that as the scaffolds degrade we see the emergence of 
a population of small pores, less than 150 μm, which we refer to as surface pores and micropores.   
 
Figure 4.5: Histogram of aligned pore scaffold pore sizes during degradation.  (A) Day 1, histogram 
of pore sizes, there are very few pores < 150 µm (population highlighted in the green box). (B) Day 
28, a small population of pores <150 µm begin to emerge. (C) Day 56, the trend continues with 
additional small pores, along with some larger small pores, showing the propagation of surface 










 μCT was used to produce 3D renderings at each timepoint of the study to visualize the degrading 
scaffolds(Figure 4.6). Figures 4.6A – 4.6D are representative samples of the aligned scaffolds as it 
degraded, these scaffolds were also used to produce the histograms for Figure 4.5. As the scaffolds 
degrade we can see both the emergence of surface pores but also an increase in surface roughness. This is 
highlighted in the change in the surface of the solid wall scaffolds as they degrade (Figure 4.6C). In 



















Figure 4.6: µCT 3D Rendering of Scaffolds During Degradation. (A-D) Aligned scaffolds at day 1 
(A), 28 (B), 56 (C) and 224 (D). Surface pore formation can be seen with increasing number and 
length as the study progressed.  (E-H) Unaligned scaffolds at day 1 (E), 28 (F), 56 (G), and 224 
(H). Small number of surface pores and increase in surface roughening can be seen over the 
course of the study. (I-L) Solid wall scaffolds at day 1 (I), 28 (J), 56 (K) and 224 (L). Degradation 
can be seen with the formation of smaller surface pores as well as increased surface roughening 
at day 224 compared to the previous timepoints during the study.  

















Also seen during degradation was the emergence of a population of micropores which could be 
seen on the μCT pore map (Figure 4.7B, Figure 4.7D). As seen in the figure, the smallest pores, or 
micropores are seen in dark blue. Also seen in dark blue are the surface pores Figure 4.7B. Fewer surface 
pore formation was seen on the unaligned scaffolds compared to the aligned pores. The dark blue pixels 
represent the smallest pores on the pore map. As seen in Figure 4.7A and 4.7B the majority of dark blue 
pixels are formed by surface pores. Where as in the unaligned pore scaffolds, the majority of the dark blue 
pixels are in the form of micropores as seen in Figures 4.7C and 4.7D.  






C)     D) 
Figure 4.7: μCT 3D Renderings and Pore Maps. (A) Bottom section of aligned pore scaffold 3D rendering (B) 
Pore map of (A) used to visualize pores in scaffold. (C) Bottom section of unaligned pore scaffold 3D 
rendering. (D) Pore map of (D). Dark blue pores are present in the aligned scaffold mainly as surface pores 
where as in the unaligned pore scaffold the dark blue pores are seen as micro pores throughout the scaffold 





Figure 4.8: Wet Compressive Mechanical Testing Maximum Load (A) and Yield (B) during degradation. Porous 
scaffolds do not demonstrate any statistical differences in mechanical properties during the study. Solid wall 
scaffolds were seen to have a statistically higher yield at day 224 (p<0.05, n =5 per timepoint) and a statistically 

















To investigate the impact of scaffold degradation on mechanical properties compressive 
mechanical testing was performed (Figure 4.8). The maximum compressive load was found to not be 
statistically different from other another at any timepoint during the study for the porous scaffolds (Figure 
4.8A). Similarly, the yield for the porous scaffolds was found to be statistically the same over the 





differences in yield and maximum compressive during degradation. The yield was found to increase over 
the study with a statistically higher yield at day 224; whereas, the maximum compressive load was found 
to be statistically higher at day 0 compared to all other timepoints. Also evaluated was the wet 
compressive modulus. For both porous scaffolds the modulus at day 224 was not statistically different 
from the modulus at day 0. However at days 56 and 112, the aligned pore scaffolds had modulus 
statistically lower than the modulus at day 0 (Figure 4.9).   
Cytotoxicity of the degradation byproducts was performed for timepoints at day 1, 7, 28, 56 and 
112. Fibroblast cells (L929) were incubated with the extract PBS and cell culture media in three different 
ratios. The three ratios evaluated are C1 (1% PBS, 99% cell culture media), C2 (10% PBS, 90% culture 
media) and C3 (50% PBS, 50% cell culture media). Cell metabolic activity levels after 24 h of incubation 
was calculated using XTT. The three different concentrations of degradation PBS to cell culture media, 
C1, C2 and C3 were found to be statistically different from the positive control 70% methanol (Figure 
7.11). At day 14, C1 and C3 were found to be statistically different, as well as on day 56, the blank and 
C3 were found to be statistically different. In all timepoints but day 14 the cell metabolic activity levels 
Figure 4.9: Wet Compressive Mechanical Testing. Modulus of solid, aligned and unaligned scaffolds over the 224 
day study. For the aligned scaffolds day 56 and 112 had statistically lower moduli than the day 0 timepoint; 
however, by day 224 the moduli returned to statistically similar to day 0. For the unaligned scaffold there was no 





Figure 4.10: Cell Metabolic Activity Levels. Fibroblast cells (L929) were cultured with a mixture of degradation 
extract and cell culture media in one of three ratios of extract: media. C1: 1% extract: 99% media, C2 10% extract: 
90% media, or C3 50% extract: 50% media. Cell metabolic levels were compared with metabolic activities from cells 
cultured with blank media, or a toxic control, 70% methanol. * denotes statistical difference within the timepoint 




























Blank Media C1 C2 C3 Methanol
were statistically similar between all concentrations of extract and culture media (Figure 4.10). 
# 
*               *          *                   *
  







 Fluorescence imaging was used to qualitatively verify the cell viability. For all timepoints, no 
significant morphological changes were observed in cell populations that were incubated with the three 
different ratios of extract and culture media (Figure 4.11A-4.11F) compared to the cells incubated with 
blank culture media (Figure 4.11G). Cells exposed to 70% methanol appeared red indicating a significant 








4.4 Experimental Section: Discussions 
Three scaffold designs, aligned pore, unaligned pore and solid wall, were successfully fabricated 
using 3D printing. A 224 day, or 32 week, degradation experiment was then performed to evaluate how 
these scaffolds degrade and the impact on the scaffold’s mechanical properties. Also investigated was the 
potential cellular response to primarily the degradation byproducts, fumaric acid and propylene glycol. 
The motivation was to determine which scaffold design would provide long term mechanical stability 
Figure 4.11: Cytotoxicity of Degradation Byproducts. Fluorescent images of L929 fibroblast cells after 24 h of 
incubation with media and degradation extract, where calcein AM (green) represents live cells, and ethidium 
homodimer (red) represents dead cells. Images are of those cells cultured with 50% extract and 50% culture media 
(C3 concentration).  No significant changes in morphology are present when compared to the blank media control. 
Cells were incubated with 70% methanol as the toxic control. Scale bars represent 100 μm. 
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during degradation without eliciting a cytotoxic response. This long term mechanical stability would 
allow for the scaffold to function as a delivery vehicle for a bioactive material that is loaded into the 
lumen of the porous-walled scaffold. This scaffold would ideally provide the mechanical support to a 
bone defect while the bioactive material, such as stem cells encapsulated in a hydrogel, would facilitate 
new bone and vessel in growth into the defect.  
Previous studies have evaluated the use of PPF-based polymer networks to treat bone defects. 
PPF has been well characterized for bone tissue engineering as it’s mechanical properties fall within the 
range of bone.[226] Other modifications to PPF, such as additional co-polymers and additives have been 
investigated to enhance the mechanical properties of this already strong polymer.[52, 222] Our previous 
research investigated the use of a PPF, DEF based polymer resin.[266] The addition of DEF to PPF 
creates a stronger crosslinked polymer network with higher compressive yield and modulus.[52] 
However, this PPF and DEF based resin previously caused extraneous crosslinking when used in a 3D 
printing system so additional dyes and inhibitors were investigated to improve the accuracy of the 
fabricated scaffold to the design specifications (Chapter 3). The previous PPF based resins was modified 
with the replacement of TiO2 with HMB and vitamin E. This polymer resin provided a reduction in 
extraneous crosslinking (see Chapter 3.1) and improved the accuracy of the 3D printing (Figure 4.2). 
Previously the extraneous crosslinking led to smaller pore sizes and porosities compared to the design 
specifications; conversely our scaffolds had larger pores and greater porosities than the design (Figure 
4.2).  
Two of the designs were porous, with either aligned or unaligned pores, were formed using a 
modular design (Chapter 3.1, Figure 3.1). The modular design is based on a repeating unit comprised of a 
ring, or the base, with cylindrical posts extending from it. The pores are formed as squares and were 
designed to be 500 μm. 500 μm was chosen since previous fabrication had a reduction in pore size of 150 
– 250 μm from the design specifications. Therefore we wanted pores between 250 – 500 μm. Originally 





studies have shown that pore sizes of 100 – 350 μm promote greater cell migration and 
vascularization.[13, 267] Additionally, previous studies have shown that for scaffolds with pores larger 
than 270 μm, it is as if there is no scaffold to hinder the vascularization process.[256] Studies have also 
shown that interconnected pores ranging from 300 - 500 μm may improve nutrient flow.[250] Porous 
scaffold designs would allow for nutrient and mass transfer from the native tissue to the lumen of the 
scaffold; however, it was unknown how these scaffolds functioned during degradation, which design 
would be best  able to provide long term mechanical stability to allow for bone repair while degrading.  
Sol fraction was calculated to determine if scaffold design would impact degree of crosslinking. 
The scaffolds were found to have sol fractions of 12.6  ± 1.7% (solid), 13.3 ± 8.4% (aligned), and 9.6 ± 
3.3% (unaligned) (Table 4.1). Sol fraction was found to be statistically similar among the three groups 
demonstrating that the fabrication methods were consistent between the different designs.  
Degradation was observed through mass loss and change in extract pH (Figure 4.3). Previous 
studies have shown that porous PPF scaffolds see a mass loss of 18 – 30% over a 32 week period. [226] 
During the 224 day, or 32 week, study the scaffolds lost 12 ± 1 % (aligned), 17 ± 2 % (unaligned) or 17 ± 
7 % (solid wall) of their initial mass (Figure 4.3). These mass loss values are similar, although smaller, to 
those in previous in vitro PPF degradation studies.[226] The mass loss may have been smaller since these 
scaffolds had a hollow lumen and would have a reduced surface area exposed compared to a porous 
cylinder scaffold. These results were within the expected ranges of mass loss and indicated that 
degradation was occurring. 
To better understand how degradation was occurring, μCT was used to evaluate changes in 
scaffold wall thickness, porosity and pore size (Figure 4.4). Interestingly, there were no statistically 
significant changes in mean pore size or wall thickness; however, there was a significant increase in 
porosity from the initial printing (Day 0) to Day 224 (Figure 4.3). Visually, surface pore formation could 
be seen throughout the timepoints, with increasing number and length as the degradation study progressed 





(Figure 4.6A-4.6D) compared to the unaligned (Figure 4.6E- 4.6H). The unaligned pore scaffolds did 
have an increase in the <150um pore population as the study progressed but were mainly formed as micro 
pores (Figure 4.7). Other degradation could be seen in the increased surface roughening as seen in the 
solid wall scaffolds (Figure 4.6I – 4.6L). As these pores are smaller than the printed pores, the increase in 
number and frequency would be expected to impact the mean pore size, which is expected to lead to an 
average pore size that remains constant while the scaffolds are degrading.  To clarify the changes in pore 
size during degradation a histogram of pore sizes for the scaffolds at each timepoint was compiled (Figure 
4.5). A population of micropores and surface pores began to emerge along with the visual emergence of 
these changes of the scaffold during the degradation timepoints. The histograms are those for each of the 
aligned scaffolds in Figure 4.6A- 4.6D. Interestingly, neither the emergence of surface pores, nor the 
micropores were found to have an impact on the mechanical properties over the 224 day degradation 
study (Figure 4.8). These results for the maximum compressive load and the yield were found to be 
statistically the same throughout the study (Figure 4.9). Throughout the degradation study the porous 
scaffolds demonstrated compressive moduli larger than average trabecular bone.[226] This is a key 
finding, as in order to treat bone defects the scaffolds must provide long term mechanical support during 
degradation. This was confirmed; however, just as integral to successful defect repair is the cytotoxicity 
of the scaffold used to treat the defect. 
As changes in mechanical and structural properties are integral to understanding the incorporation 
of the scaffold in a bone defect, also integral for successful integration is scaffold and host tissue 
compatibility. To this end, it is critical to ensure that byproducts of scaffold degradation did not elicit a 
cytotoxic response. Currently few standards (ASTM F1635, ASTM F2902, ASTM F1983) evaluate 
cytotoxicity of absorbing polymers.[268-270] There are few standards that have set forth testing 
guidelines for in vitro analysis although it is pertinent to any implantable, absorbable material, such as the 
many that are used in tissue engineering. To address this lack, we developed a novel method to evaluate 





standards, the ISO standard 10993-5 for extract testing, and the ASTM standard F1635.  
As PPF hydrolytically degrades it produced propylene glycol and fumaric acid [271]. This is 
important as one indication of degradation of polyesters is a decrease in pH as seen in the study (Figure 
4.2).  However this decrease in pH did not impact cell viability even at the lowest pH ranges evaluated at 
day 112. Cell metabolic activity levels and live dead fluorescent imaging confirmed that as PPF degrades 
it does not elicit a cytotoxic response (Figure 4.10, Figure 4.11). The cell metabolic activity levels for all 
three concentrations of degradation extract and cell culture media were found to be statistically different 
from the dead control, 70% methanol. Additionally, in all timepoints but day 56, the three concentrations 
were statistically similar to the blank media control. On day 56, C3, the highest extract exposure 
condition was found to be statistically different from the blank media control; however, it still was 
statistically different from the positive control. In all timepoints, but day 14, the three concentrations had 
statistically similar cell metabolic activity levels. At day 14 the middle concentration (C2) had a 
statistically lower cell metabolic activity level than C3. All of the most concentrated exposure groups 
(C3) demonstrated cell metabolic activity levels similar to the blank culture media. These results were 
confirmed with fluorescent imaging, images of cell viability after 24 h of exposure to C3 are shown in 
Figure 4.11. No changes in cell morphology or number were seen after 24 h of exposure to the 
degradation extract and cell culture media solutions. Overall, our study demonstrated that the degradation 
byproducts did not elicit a cytotoxic response and had the same cytotoxic response as a known non-
cytotoxic solution, cell culture media, when cultured with fibroblasts. 
4.5 Conclusion 
 PPF porous scaffold degrade slowly and provide the necessary mechanical properties for the 
treatment of cancellous bone defects. This slow degradation and stable mechanical properties would allow 
for the delivery of a bioactive material, to enhance the treatment of bone defects. Degradation is seen 





micropores are best seen nondestructively with μCT evaluation. Increased surface roughing, caused by 
surface degradation, was also observed during the 224 degradation study. The degradation byproducts 
from the hydrolysis of the polymer network, and forming pores, were shown to not elicit a negative 
cellular response when cultured with fibroblasts. These results indicate that porous PPF scaffolds, 





Chapter 5: Hydroxyapatite Doped Alginate Beads as Scaffolds for the 
Osteoblastic Differentiation of Mesenchymal Stem Cells 
5.1 Introduction 
  Bone tissue engineering has developed a variety of promising approaches to improve the healing 
efficiency of bone defects and fractures. Numerous studies have used a cell-loaded scaffold approach in 
which a scaffold having similar mechanical properties of bone is implanted into a defect and carries a 
population of cells capable of differentiating into bone. Hydroxyapatite (HA), a form of calcium 
phosphate, is frequently used as a component in these cell-loaded scaffolds. Current research has 
identified the tubular perfusion system (TPS) bioreactor as enhancing late-stage osteoblastic 
differentiation of human mesenchymal stem cells (hMSCs) when encapsulated in alginate beads. This 
work investigates the formation of small alginate beads doped with hydroxyapatite, and their impact on 
osteoblastic differentiation of hMSCs that are encapsulated within the hydroxyapatite - alginate matrix 
under dynamic culture conditions using the tubular perfusion system (TPS) bioreactor.  
 The TPS bioreactor may be used to enhance osteoblastic differentiation prior to implanting a 
scaffold for bone tissue engineering. The TPS is a novel elegant bioreactor that provides for the long term 
culture of hMSCs when encapsulated in alginate beads.[78] Previous studies have identified the use of the 
TPS as a novel design that is easy to sterilize and assemble. The TPS bioreactor consists of growth 
chambers, where cell-laden polysaccharide alginate beads are cultured, a media reservoir, and a tubing 
circuit. The polysaccharide alginate used in the TPS bioreactor is crosslinked using calcium chloride. In 
vivo the alginate network is expected to slowly degrade due to the slow exchange of the calcium ions in 
the physiological environment.[272] Also, alginate beads have been shown to be biocompatible, facilitate 
three dimensional transfer of nutrients and signaling molecules, and serve as protection from the host 
immune response [50]. 





differentiation of hMSCs for the treatment of bone defects.[78-81]The TPS bioreactor has been shown to 
enhance late osteoblastic differentiation in vitro. Previous work with the TPS bioreactor identified the use 
of smaller diameter beads having an increased rate of proliferation (2.0mm) but a decreased rate of 
osteoblastic differentiation compared to larger diameter beads (4.0mm).[273] This work looks to fabricate 
small diameter alginate beads containing HA to enhance osteoblastic differentiation. One advantage of 
HA stems from its similarities in composition and structure to native bone.[40] HA is a commonly used 
material with degradable polymers as it provides desirable surface roughness and the ability to adhere 
directly to the bone.[46] The addition of HA has also been used to increase material stiffness, which in 
turn may improve osteoblastic differentiation.[83]  The objective of this work was to develop a method to 
reproducibly fabricate small diameter hydroxyapatite-doped alginate beads and demonstrate increased 
osteoblastic differentiation of hMSCs encapsulated in these beads during dynamic culture. 
5.2 Materials and Methods 
5.2.1 Human Mesenchymal Stem Cell Culture 
 Human mesenchymal stem cells (hMSCs) were used throughout the study. The hMSCs (passage 
< 6) from a single donor (Lonza, Walkersville, MD) were cultured, as previously described and per the 
manufacturer’s protocol, with hMSC media, consisting of Dulbecco’s Modified Eagle Medium (DMEM) 
(Life Technologies), supplemented with 10% fetal bovine serum (Life Technologies), 1.0% v/v 
penicillin/streptomycin (Life Technologies), 0.1 mM non-essential amino acids (Life Technologies).[231, 
232, 274] Cell culture took place on tissue culture polystyrene flasks (Corning) under 5% CO2 at 37°C, 
with media changes every four days. Upon the start of the cell-based studies, hMSC media was switched 
to osteogenic media, hMSC media supplemented with 100 nM dexamethasone (Sigma, St. Louis, MO), 
10 mM β-glycerophosphate, and 173 μM ascorbic acid. Dynamic culture was carried out in the TPS 





beads of different compositions was carried out over 7 days under static culture conditions. Comparison 
between dynamic and static cultures was carried out for 21 days.  
5.2.2 Preparation of Alginate Beads and hMSC Encapsulation 
 2.0% w/v solutions of alginate were prepared by dissolving alginic acid sodium salt from brown 
algae in 0.15M NaCl and 0.025M HEPES in deionized water. The alginate solution was then sterilized via 
autoclave under a 15-minute liquid sterilization cycle. Alginate solutions were then aseptically filtered 
through a 0.8μm syringe filter to ensure solution homogeneity. For non-cell containing beads, alginate 
solutions were dropped into a stirred solution of 0.1 M CaCl2 using a syringe pump (Harvard Apparatus) 
at a rate of 6.6 ml/minute using a 10 ml syringe and a 25 gauge needle (Becton Dickinson) suspended 
approximately 4.5 cm above the surface of the CaCl2 solution. Alginate beads immediately began cross-
linking in solution and were allowed to crosslink for 15 to 30 minutes to ensure full cross-linking. 
Hydroxyapatite beads were created using the above method by suspending HA microparticles (Berkeley 
Advanced Biomaterials) in the 2% w/v filtered alginate solution. HA was sterilized by ultraviolet light in 
a biosafety cabinet for at least 12 hours. HA ratios were determined based on %w/v with respect to the 
solution. For example: a 50:50 HA:alginate ratio solution would consist of 2 g alginic acid sodium salt 
dissolved in the above solution, followed by the addition of 2 g hydroxyapatite by vortexing. HA:alginate 
beads were prepared using the same method as pure alginate beads. 
 hMSCs were removed from culture using Trypsin/EDTA and pelleted at 500 x g for 5 minutes. 
The cell pellet was resuspended in alginate or HA:alginate solutions at a density of 1x106 cells/mL. After 
suspension of the pellet in alginate, beads were formed using the methods described above, washed in 
hMSC media for a minimum of 15 minutes before initiating culture conditions.  
5.2.3 TPS Bioreactor Setup 





attached to media reservoirs using a series of platinum cured silicone and Pharmed BPT tubing (Cole 
Parmer, Vernon Hills, NJ). Growth chambers were made from larger diameter platinum cured silicone 
tubing; 6.4 mm inner diameter and 11.2 mm outer diameter and approximately 13 cm in length. Platinum 
cured silicone tubing is steam sterilizable and allows for oxygen and carbon dioxide (CO2) gas exchange. 
Pharmed BPT tubing with high mechanical durability was used to interface with the pump head. The 
tubing circuit system was assembled outside of the biological safety cabinet (BSC) and was sterilized via 
autoclave for 30 minutes at 121°C. Once sterilized the system was assembled aseptically in the BSC. 
Alginate and HA:alginate beads were loaded in the growth chambers and pulsatile media was perfused 
using an L/S Multichannel Pump System (Cole Parmer) at 1mL/minute for the alginate dynamic group 
and one HA:alginate dynamic group. A second group of HA:alginate beads were cultured in a separate 
pump at a 2mL/minute pulsatile flow. Polyproplyene mesh #50 (Ted Pella, Redding, CA) was used to 
retain the alginate beads within the growth chamber. The TPS was housed in an incubator maintained at 
37°C and 5% CO2 for the duration of the study.  
5.2.4 hMSC Isolation from Alginate Beads 
 To isolate hMSCs from alginate beads, beads were incubated in 0.1M ethylenediaminetetraacetic 
acid (EDTA) for 15 minutes at 25°C. After 15 minutes hMSCs were centrifuged at 500 xg for 5 minutes 
to form a pellet and resuspended in PBS. Cells were then pelleted and washed once with PBS to remove 
any remaining EDTA and culture media. A final pelleting provided the cell pellets for assays. 
5.2.5 Mass Loss and Water Absorption 
 Non-cell containing beads at each HA:alginate ratio and an alginate control were massed after 48 
hours of suspension in hMSC media. Beads were massed immediately after removal from media then 
dried in a vacuum oven for 4 days prior to final massing. This difference in mass was used to calculate the 





determine mass loss. 
5.2.6 Swelling of Alginate and HA Alginate Beads and Microscopy 
 In order to determine how much beads will swell over time in media, a swelling study was 
conducted on the beads. The amount of swelling indicates the volume of space inside the beads available 
for cell proliferation. Beads at each ratio were placed in 6 well culture plates in media for 28 days. Media 
was added every 4 days to maintain the initial media volume. At each time point, bead diameter was 
measured in suspension using a light microscope at 2.5x objective. Diameter was measured using a 3 
point circle approximation via SPOT imaging software. Calibration was obtained using a hemocytometer 
and determined to be 278 pixels = 1 mm. A histogram frequency distribution of bead diameters was 
obtained for each ratio of HA:alginate beads (n = 25). Bin size = 43.95 μm.  
5.2.7 Scanning Electron Microscopy 
 Characteristics of hydroxyapatite microparticles were verified using a scanning electron 
microscope (SEM) (JEOL JSPM-4500A, courtesy Maryland MRSEC). UV sterilized and unsterile 
samples were mounted onto the specimen mounts. Samples were visualized at 3.0 kV under various 
magnifications. Imaging was performed at the UMD NISP center.  
5.2.8 Fluorescence Imaging 
Live/dead imaging was performed to qualitatively evaluate cytotoxicity as described 
previously.[276] A live/dead solution was prepared with 4 µM of calcein AM (Invitrogen, Carlsbad, CA) 
and 2 µM of ethidium homodimer (Invitrogen, Carlsbad, CA) in PBS. Prior to the addition of the 
live/dead stain, cells were washed with PBS to remove any remaining culture media or methanol. Cells 
were incubated with the live/dead solution in dark conditions for 45 minutes prior to imaging. For the 
cytotoxic control, cells were incubated with 70% methanol for 30 minutes prior to the addition of the 





40CFL, filter set 23, Zeiss, Thornwood, NY) fitted with a digital camera (SPOT Insight 1120, or SPOT 
Idea 2920, Diagnostics Instruments, Sterling Heights, MI) and with an inverted TE2000-E microscope 
(Nikon, Melville, NY) outfitted with a CoolSnap HQ2 (Photometrics, Tucson, AZ) digital camera.  
5.2.9 Alkaline Phosphatase Expression  
 The intracellular ALP protein level was assayed using a p-nitrophenyl phosphate liquid substrate 
system (pNPP) (Sigma-Aldrich, St. Louis, MO). Chromogenic substrate, p-nitrophenyl phosphate is then 
used to quantify phosphatase enzymes. ALP activity can be detected using a standard spectrophotometer 
by the distinct color shift from colorless to a yellow shade following reaction of NaOH with pNPP to 
form p-Nitrophenol. Cells were isolated from alginate beads as described above and Mammalian Protein 
Extraction Reagent (M-PER) (Thermo Fisher, Pittsburgh PA) was used to lyse cells. The lysate was then 
centrifuged at 14000 x g for 15 minutes and 75 μL of supernatant was diluted to a total volume of 310 μL 
with PBS. The solution was placed in a clear-bottom 96-well plate, mixed with pNPP, and incubated for 
30 minutes in the dark. After the reaction was stopped using 2 M NaOH the absorbance of the reacted 
substrate is detected at 405 nm using a microplate reader. A standard curve using 4-nitrophenol was used 
as a reference to quantify the concentration of the consumed pNPP substrate. The calculated alkaline 
phosphatase (ALP) protein levels were normalized with DNA content, measured using a PicoGreen
®
 kit. 
5.2.10 DNA Quantification for Proliferation 
 Cells were isolated from the alginate beads with the addition of 0.1 EDTA for 15 minutes. Cell 
pellets were then used for DNA isolation with DNeasy Tissue Kit (Qiagen, Valencia CA) following 
standard protocols. PicoGreen
®
, a fluorescent nucleic acid stain for quantitating double-stranded DNA, 
was used to quantify the amount of DNA present in each group. A serial dilution, negative control and the 
DNA from each of the treatment groups were plated on a 96-well black fluorescent plate and incubated at 





520nm using a microplate reader. DNA concentrations were calculated based on the standard curve of λ 
DNA provided in the PicoGreen
® 
kit.  
5.2.11 Quantitative Reverse Transcriptase Polymerase Chain Reaction (qRT-PCR) 
 A phenol-chloroform extraction technique was used to isolate RNA from the cell pellets. Briefly, 
Trizol reagent, solution of phenol and guanidine isothiocyanate, (Life Technologies) was used to 
resuspend the cell pellets and incubated at room temperature for 5 minutes. Chloroform (Sigma) was 





12000 x g for 18 minutes to separate the phases of extracted products. The clear upper aqueous phase 
contained the RNA. 200μL of the supernatant was vortexed with an equal volume of 70% ethanol, and the 
resulting solution was used in RNA extraction. RNA extraction was performed using RNeasy Mini Plus 
Kit (Qiagen, Germantown, MD) per manufacturer’s protocols. RNA was then translated into cDNA using 
cDNA Archive Kit (Applied Biosystems, Foster City, CA). cDNA was then combined with Universal 
Master Mix (Applied Biosystems) and oligonucleotide primers and Taqman Probes (Applied 
Biosystems). The table below (Table 5.1) shows the Taqman Applied Biosystems assay IDs for primers 
and probes for the genes of interest as the sequences are proprietary. The reaction was conducted on a 
7900HT Fast Real-Time PCR System Prism 7000 sequence detector (Applied Biosystems). The thermal 
profile was 2 min at 50 °C, 10 min at 95 °C, 15 s at 95 °C (40 cycles), and 1 min at 60 °C. Relative gene 
expression changes were calculated using the ΔΔCt method as previously described.[219] GAPDH was 
used as the endogenous control gene. Fold changes in gene expression are observed and reported as mean 













5.2.11 Histology  
 Alginate and HA:alginate beads were histologically stained for visual verification of matrix 
deposition. Beads were fixed in 4% paraformaldehyde for 2 – 4 h followed with an overnight soak in 
0.1M sodium cacodylate trihydrate and 10mM CaCl2 buffer. Beads were then dehydrated and prepared 
for paraffin embedding using a tissue processor, TP1000 (Leica Biosystems, Buffalo Grove, IL). The 
TP1000 prepared the samples using a series of ethanol washes to dehydrate the sample then the samples 
are washed with Citrisolv (Fisher Scientific) and then soaked in melted paraffin. Beads were then 
embedded in paraffin and sectioned to 5 μm. Sections were then placed on glass slides (SuperFrost, Fisher 
Scientific), air dried overnight, warmed on a slide warmer for 10 minutes until the paraffin became 
translucent, and oven dried for > 1 h at 37°C. Samples were deparaffinized using citrisolv and rehydrated 
in ethanol. Samples were then evaluated for calcium deposition using Von Kossa staining as described 
below.  
5.2.12 Von Kossa Staining  
 Von Kossa staining was used to visualize calcium deposition with nuclear fast red as a 
counterstain to identify cell nuclei. Sections were washed 3 times with distilled water, incubated with 5% 
silver nitrate solution under ultraviolet light for 20 minutes and then washed with distilled water. 
Unreacted silver was removed with a 5-minute soak in 5% sodium thiosulfate. Slides were placed in 0.1% 










nuclear fast red- 5% aluminum sulfate solution for 5 minutes and rinsed with distilled water. Samples 
were then dehydrated and cleared using citrasolv. Silver nitrate stains for calcium salts resulting in black 
or brownish-black deposits, and nuclear fast red stains cell nuclei red and the cell cytoplasm pink.  
5.2.14 Statistics 
Statistical analysis was performed using ANOVA and Tukey’s multiple pairwise comparison (p<0.05). 
All tests were performed in triplicate (n=3) unless otherwise specified. Values provided are mean ± 
standard deviation. Please note that only relevant statistical relationships are denoted on figures. 
 5.3 Experimental Section: Results  
5.3.1Characteristics of Hydroxyapatite Microparticles 
 Hydroxyapatite was visualized using SEM. There was no difference in morphology between the 
non-sterile and UV-sterilized group. Microparticle diameters ranged from 3.55μm to 46.7μm, with an 
average diameter of 20.6 ± 9.35 μm (n = 30). Figure 5.1 shows the nanoscale surface morphology of the 






Figure 5.1: Scanning Electron Micrograph of Hydroxyapatite Microparticles. Hydroxyapatite microparticles were visualized 
via SEM. (A) Close examination of the microparticle surface shows a rough, porous environment. (B) Microparticle of 
approximately 7μm, porous environment. (C) microparticle sizes and morphologies 
5.3.2 Characteristics of Alginate and HA/Alginate Beads  
Different ratios of HA:alginate beads were characterized by light microscopy.  Ratios of 05:95, 











types had similar spherical morphologies. 50:50 beads had an average diameter of 2366.4 ± 32.8 μm. 
25:75 beads had an average diameter of 2440.04 ± 62.2 μm. 05:95 beads had an average diameter of 
2450.0 ± 82.4 μm. Figure 5 shows representative light microscope images of the different bead ratios. 
Qualitatively, hydroxyapatite particles appear to be evenly distributed throughout the alginate beads.  
Figure 5.2: Light Microscope Images of HA:alginate Beads. Beads were visualized with a light microscope at 2.5x. (A) Image of 
05:95 beads, (B) 25:75 beads, and (C) 50:50 beads. Scale bar represents 500 μm. 
  Alginate beads of each ratio were evaluated for swelling of the beads over a 28 day timeframe. 
Diameters of the beads were measured every 7 days for 28 days. A distribution of bead diameters was 
obtained on day 21 of the swelling study. Figure 5.3 shows a histogram of the results. Diameter of 
alginate beads decreased with increasing ratios of hydroxyapatite to alginate. The 50:50 ratio had an 
average diameter, which was significantly smaller than the both of the other HA doped beads (p < 0.05). 
The average diameter increase of the beads was 0.29 ± 0.031 mm, indicating a volume increase of 2.61 
μL. There was no significant difference in the amount each group of beads swelled.    




























Figure 5.3: Histogram of HA:Alginate Beads After 
Swelling. Bead diameter were measured after 21 
days of swelling  using a 3-point circle on imaging 
software with a light microscope and digital camera 
attachment. Bin size was chosen based upon the 
average maximum and minimum bead sizes across 
the three groups. Histogram shows frequency 
versus bin number. Frequency was based on the 
number of samples less than the bin number. For 
example there were no beads with diameters less 





Figure 5.4: Normalized ALP Expression in HA Alginate Beads ALP expression of hMSCs was measured using the 
PNPP assay and normalized to DNA quantification using PicoGreen®. 
5.3.4 Osteoblastic Differentiation for HA:Alginate Ratios 
 A 7 day cell culture study was carried out to determine the optimal HA:alginate ratio for 
osteoblastic differentiation. HMSCs were encapsulated in each ratio of HA:alginate beads and cultured 
under static osteogenic conditions for 7 days. Groups were assayed for ALP expression, DNA 
concentration, and gene expression at days 1, 4, and 7. The 50:50 ratio had the highest normalized ALP 
protein expression. Normalized ALP results are shown in Figure 5.4. Average DNA content was lowest 
for the 50:50 ratio at every time point. ALP protein expression and DNA quantification assays were not 













Gene expression levels of osteoblastic genes were obtained using qRT-PCR. The 50:50 ratio showed the 
largest fold change for ALP and BMP-2 expression at day 7. Figure 5.5 shows the gene expression fold 































Figure 5.5: Osteoblastic Gene Expression of Various HA:Alginate Ratios. Gene expression of hMSCs in HA:alginate beads at 
three different ratios at days 1, 4, and 7. There was a significant difference (indicated by *) between the 50:50 alginate group 
and both of the other HA ratios at day 7 only for ALP fold change (A). There was also a significant difference between the 
50:50 ratio and the other two ratios for BMP-2 at day 7 (B) (p <0.05).  
5.3.5 HA:Alginate Beads and Alginate Beads in Static and Dynamic Culture 
 A 21 day cell culture study was carried out to study the effects of HA doping on hMSC 
differentiation in alginate beads. HA doped beads at the 50:50 HA:alginate ratio and pure alginate beads 
were cultured at 1mL/minute. A second bioreactor was set up to culture HA doped beads at 2mL/minute 
to evaluate the effects of increased shear on HA doped beads. Static alginate beads were used as a control. 
Von Kossa and live/dead fluorescent imaging was evaluated for each group. Live/Dead qualitative 
fluorescent imaging was performed at days 1 and 20. Figure 5.6 shows the Live/Dead images for each 
group. All groups showed similar morphology and similar brightness representing live cells. On day 20, 
some staining was prevented due to the mineralization of the beads. Figure 5.7 shows an example of the 
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Figure 5.6: Fluorescence Imaging of HA Doped Beads. Live/Dead stain was used to stain each group. On Day 1 the 
(A) Static control and (B) alginate dynamic beads were visibly bright green and qualitatively alive compared to the 
(C) plain alginate dead control. (D) 1mL/minute and (E) 2mL/minute HA doped beads showed similar brightness 
and were qualitatively alive compared to the (F) HA doped dead. On Day 20, all beads showed significant 
mineralization, which may have prevented complete staining. (G) Day 20 alginate dynamic beads were qualitatively 
alive and staining was visible because the bead was broken prior to staining. (H) Shows the HA doped 1 ml/minute 
dynamic group and (I) shows the HA doped 2 ml/minute dynamic group. Both groups show green fluorescence and 
the stain-blocking effect of the mineralized shell (J) shows the static control, which had the most uniform 
mineralization and no breaks in the bead, therefore, little stain was taken up. (I) shows the dead control, which 







 Von Kossa staining was carried was used to evaluate the osteoblastic differentiation of hMSCs, 
visualized as the production of mineralization within the ECM of the cells as shown in Figure 5.8. The 
HA doped beads showed the greatest production of mineralization. Both HA groups seemed to induce 
osteoblastic differentiation quicker than the either of the alginate groups. There did not seem to be a 
significant difference in mineralization production between the HA groups. However, all of the dynamic 
groups seemed to induce differentiation quicker than the static group. The morphology of the beads was 
most consistent across the time points for the static group, while the dynamic groups seemed to break 
apart over time in the bioreactor, losing their spherical morphology. Day 1 of the HA doped groups 
showed more staining than the alginate groups, however this is most likely staining from the HA particles 
within the bead. Interestingly, as shown in the 40x objective image of the HA 2mL/minute group, there 
does seem to be cellular interaction with the HA (Figure 5.7). At day 7, both HA groups showed much 
more mineralization than either of the alginate groups. At day 20, mineralization in the HA doped beads 
was much denser, as characterized by the black stain, than the static control.  
 
Figure 5.7: Mineralization of HA-Doped Alginate Beads. Mineralization of HA:alginate beads at day 20 of 2 ml/min dynamic 
culture conditions is extensive.  (A, B) show the mineralization seen with light microscopy at 2.5x objective. Scale bar 
represents 1000 µm (C) Von Kossa staining shows mineralization (black) surrounding cell (pink), as well as some potential 
cell-HA interaction where the black dots are adjacent to the cell bodies. Scale bar represents 100 µm. 
























Figure 5.8: Mineralization of HA Doped Alginate Beads. Von Kossa staining showed increase mineralization in the 
HA-doped alginate beads. Mineralization increased from day 1 to day 20 in all groups, with the most increase 
shown in the HA doped beads. There was evident mineralization at day 7 in all groups as shown by the black 






5.4 Experimental Section: Discussion 
 This study showed that the surface of the hydroxyapatite microspheres was rough and porous 
(Figure 5.1). Dispersion of HA particles within alginate beads at various ratios was uniform, and beads 
were formed within a narrow distribution at each ratio, with the 50:50 ratio being significantly smaller 
than both of the other ratios. After 4 weeks of swelling, each swelled by an average of 2.61 μL. Each 
HA:alginate ratio contained 5.67 ± 0.16 μL of water. In a 7-day static culture comparison of each 
HA:alginate ratio, the 50:50 ratio showed the highest levels of normalized ALP expression. The fold 
changes for ALP and BMP-2 expression were significantly higher for the 50:50 ratio than either of the 
other ratios. Based upon these results, the 50:50 ratio was chosen for the 21-day dynamic study for 
comparison with alginate groups. By characterizing the HA doped alginate beads, this study demonstrated 
the feasibility and reliability of the fabrication methods for the creation of HA doped alginate beads as 
scaffolds for osteoblastic cell delivery. 
 Characterization of the hydroxyapatite microparticles showed the surface roughness of the 
spheres and the porosity of the HA. These characteristics may provide for a cell attachment site. 
Additionally, the nanoenvironment of the HA particles may provide interaction sites for cell excreted 
proteins and may act in a signaling manner to the hMSCs. There did not seem to be a significant 
difference in the free space of each bead. This is contrary to the expectation that, given the reduced size 
and increased density of the 50:50 ratio, there would not be similar amount of available space for cell 
proliferation.  
 The 7 day static comparison of HA doping ratios allowed for the selection of an optimal doping 
ratio and suggested that HA induces osteoblastic protein and gene expression in a dose dependent manner. 
However, the 50:50 also had the lowest DNA amount, this may indicate that cellular proliferation stops 
earlier in the higher HA ratio. DNA content stayed constant at day 7 and went down for the 25:75 and 





differentiation markers was greatest for the highest HA:alginate ratio. Both ALP and BMP-2 expression 
increased significantly in the 50:50 ratio at day 7. ALP expression increased over 25 fold in the 50:50 
beads, and BMP-2 expression increased approximately 12 fold. The static culture condition allowed for 
the selection of the 50:50 ratio as the optimal ratio for increasing the rate of osteoblastic differentiation.  
Therefore this ratio was chosen to investigate as to the impact of HA under 21 day dynamic culture 
conditions. 
 The 21 day study showed that the HA doped groups outperform the alginate only groups when it 
comes to osteoblastic differentiation. Live/dead fluorescence imaging showed no significant reduction in 
viability in any group, although interpretation of the live/dead results was difficult due to the 
mineralization of the beads. All bead groups seemed to allow for cell viability at day 1, and at day 20 it 
was difficult to evaluate the viability of each group due to the mineralization of the beads, however, there 
was apparent viability in every group except for the static group, which may indicate that the 
mineralization of the static bead was more uniform than the dynamic beads, and that the outer layer of the 
alginate bead was intact. Light microscopy of the HA 2ml/minute beads showed a dense layer of 
mineralization surrounding the bead. Von Kossa staining showed that the HA doped groups produced 
mineralization at a quicker rate than the alginate groups at day 7 and at day 20 as well. 
 The von Kossa staining showed that the HA doped groups produce mineralization more rapidly 
than either of the alginate groups. There does not seem to be a large difference between the two HA 
groups which may indicate that the impact of HA doping is greater than the impact of shear on the 
differentiation of osteoblasts. However, this lack of difference may stem from too small of a difference in 
flow rates or too short of a comparison. Consistent with previous studies, the alginate 1mL/minute group 
outperformed the static control in terms of mineralization. From day 7 forward, it is evident that HA 
doping leads to increased mineralization and much denser mineralization, as evidenced by comparison of 
the staining. This density difference is especially apparent at 40x objective. Interestingly, in each case, the 





mineralization localizes at the edge of the beads, although mass transport of nutrients, minerals, and 
oxygen at closer to the surface of the bead may allow for enhanced production of mineralization. 
This study has shown that HA doping of alginate beads promotes osteoblastic differentiation in 
both static and dynamic culture. Although previous studies have demonstrated both the in vivo and in 
vitro osteoinductive properties of HA as both a scaffold and a dopant, they have not shown the effects of 
HA doping in alginate beads within a perfusion bioreactor. These findings are consistent with previous 
findings demonstrating the improved differentiation of hMSCs into osteoblasts in the presence of HA. 
The 50:50 ratio of HA to alginate exhibited the best osteogenic properties of the three ratios. Despite 
lower water content and lower DNA content, hMSCs within the 50:50 ratio produced the greatest amount 
of ALP in the 7-day static comparison study. Consistently, the 50:50 ratio also showed the greatest fold 
changes in both ALP and BMP-2 at day 7 compared to the other ratios. This suggests that HA doping 
may have a dose dependent effect on osteoblastic differentiation, although this would most likely be 
limited by the available space for cell proliferation within any scaffold. The finding that the 50:50 ratio 
performed better is supported by previous findings suggesting that HA improves cell adhesion.[52] Better 
cell anchoring within the alginate scaffolds could lead to more rapid osteoblastic differentiation and 
signaling. This study also demonstrates that HA can be easily incorporated into alginate based constructs 
as a dopant in readily controllable manner.  Also results from the 7 and 21 day studies indicate that the 
HA doped alginate beads promote quicker differentiation of hMSCs into osteoblasts.  
5.5 Conclusion 
 This study found that HA doping of alginate beads promotes osteoblastic differentiation in vitro 
in a dynamic TPS culture system. This induction improves the rate of differentiation further over that of 
dynamic culture of alginate beads. Further, an optimal differentiation-inducing ratio was determined. This 
approach may serve to shorten the culturing time of bone tissue engineering scaffolds, and ultimately 
reduce the time and cost required to create implantable, cell-loaded, bone tissue engineering scaffolds for 





Chapter 6: Summary & Future Directions 
6.1 Summary 
 The overall goal of this work was to develop functional biodegradable bone tissue engineering 
strategy. This work demonstrated that porous PPF scaffolds could be designed and fabricated to function 
as a carrier of precultured hMSC encapsulated in HA-doped alginate beads. Previous research has 
investigated the interaction of cells and PPF, in vivo and in vitro; however, no study looked specifically at 
the cytotoxicity of PPF through the three different exposure methods provided by the ISO standard 
10993-5 as described in chapter 1.  Therefore we show in chapter 2 that highly crosslinked PPF, with the 
soluble components removed, is noncytotoxic. Specifically, we demonstrate that highly crosslinked PPF 
elicits the same cellular response as a known noncytotoxic material (HDPE). We also showed that PPF 
films that are not highly crosslinked, may elicit a cellular response that is similar to other cytotoxic 
materials. This is important as it highlights the need to ensure that when utilizing PPF as a biomaterial, it 
is fully crosslinked and washed thoroughly to remove all soluble components before interacting with 
cells. Therefore, if PPF is highly crosslinked and the soluble components are removed we believe that it is 
suitable for use in tissue engineering applications. After establishing that PPF is suitable for use as a 
component in vivo we then investigated the design and fabrication of PPF-based scaffolds as described in 
Chapter 3. 
 Once we established that PPF did not elicit a cellular response, we looked to use it as the base of 
our resin to fabricate porous scaffolds. In chapter 3 we outline the design, fabrication and characterization 
of porous 3D printed PPF scaffolds. We developed a toolbox that could be used to evaluate 3D printed 
scaffolds. This toolbox may be used to identify scaffold designs for enhanced host integration. First 
modular design was used to investigate the wide range of scaffold parameters feasible with 3D printing. 
Then twelve scaffold designs were used to evaluate for their potential for vascularization when implanted 





qualitatively with a nude rat study. These results provided a case study for a novel method to evaluate 3D 
printed scaffolds for tissue engineering. We proposed the application of this set of methods, or toolbox, to 
help design scaffolds to identify scaffold parameters that would be promising for improved 
vascularization when implanted in vivo.  
 Once we designed the scaffolds, we needed to ensure that they would function in the desired 
manner when implanted in vivo. To accomplish this we performed a degradation study of porous PPF 
scaffolds. This work is described in Chapter 4. We needed to determine if these 3D printed scaffolds 
would degrade as expected, allowing for the long term, noncytotoxic, mechanical stability of the defect 
site during degradation. As the PPF-based polymer scaffold degrades it produces byproducts. We 
investigated both the cellular response to the degradation byproducts as well as the structural and 
mechanical changes in the scaffold during degradation. We found that porous PPF scaffolds did not elicit 
a cytotoxic response during degradation. This is an important finding, as the degradation of PPF was 
found to lower the local pH by the release of fumaric acid. However, we believe that our results represent 
the greatest exposure of the degradation products since the body would be expected to remove these 
components faster than the timepoints evaluated. For example, all of the degradation that occurs between 
days 56 and 112 would not be exposed to the cellular environment all at one time but spread throughout 
the degradation process. Therefore these byproducts could be consumed over the 56 day period. Also in 
chapter 4 we show that our porous scaffold designs do not lose mechanical stability while degrading. This 
is critical for the delivery of our bioactive component of the graft, as it alone does not have the 
mechanical strength for direct implantation.  
 With chapters 2, 3, and 4 identifying that PPF scaffolds could be fabricated and degrade while 
providing long term mechanical support we were able to investigate the size and composition of the cell-
laden alginate beads that would be the bioactive component housed in the lumen of the PPF scaffolds. 
This work is described in chapter 5. The objective of this work was twofold, one to produce small 





of HA to the alginate hydrogel could improve osteoblastic differentiation of hMSCs when cultured in the 
TPS bioreactor. These two goals were accomplished and we demonstrated that small diameter, 
hydroxyapatite (HA)-doped, alginate beads which encapsulated hMSCs could be reproducibly created. 
We also demonstrated that the addition of HA to these beads enhanced osteoblastic differentiation when 
cultured in the TPS bioreactor.  
6.2 Proposed Future Work 
 This project focused on developing a bone tissue engineering solution using a porous 3D printed 
PPF scaffold to deliver hMSCs encapsulated in hydroxyapatite-doped alginate beads. Our goal was to 
provide long term mechanical stability while delivering a bioactive component to the bone defect site. 
However, one additional main objective for successful repair of bone defects would be to ensure 
vascularization of the defect site. Successful vascularization is understood to be at the heart of 
maintaining a viable cell population after implantation. Vascularization and the delivery of oxygen and 
nutrients has been identified as one of the major hurdles for successful cell implantation.[249] Other  
factors for successful repair of bone defects would focus on native tissue integration and subsequent in 
vivo evaluation. 
6.2.1 Enhancing Rapid Vascularization  
  One area of interest for future work would be to enhance the ability of the scaffold for rapid 
vascularization once implanted into the bone defect. This could be investigated in a number of different 
studies including using PPF to delivery exogenous growth factors. Previous studies have used PPF for the 
controlled release of growth factors, corticoid steroids and even antibiotics.[277-279] In this same 
manner, PPF could be used to deliver vascular endothelial growth factor A (VEGFA), Fibroblastic 
Growth Factor 2 (FGF-2) and Platelet-Derived Growth Factor (PDGF) when acting as the carrier scaffold 





hMSCs with endothelial progenitor cells in the TPS bioreactor. Additionally the exogenous delivery of 
angiogenic growth factor, such as VEGFA, FGF-2 or PDGF, during TPS coculture could be investigated.  
 To follow up to the vascularization in silico modeling performed in chapter 6, we could perform 
an in vivo study that uses the suggested scaffold designs in a bone defect model to see if vascularization 
would occur as predicted. This would also be informative as it would help to understand if the small 
changes between groups as seen during in silico modeling have as significant of an impact when 
implanted in vivo. 
6.2.2 Native Tissue Integration  
 Along with the release of growth factors to promote rapid vascularization, additional studies to 
investigate improved host tissue integration would be enlightening. Improved host tissue integration could 
be accomplished through improving the potential for cell adhesion to the scaffold surface and reducing 
the time to differentiation into osteoblasts. Changes such as increasing surface roughness, through acid 
washing or the addition of HA, could reduce the time to osteoblastic differentiation of hMSCs.[46, 280, 
281] Enhanced surface roughness has also been linked to increased cell adhesion and osteoblast 
differentiation. [282, 283] To allow for native tissue integration and eventual replacement, we would also 
want to determine the point during degradation at which scaffolds would mechanically fail at 
physiological loads. This would tell us at which point the native tissue would have to be completely 
integrated with the scaffold.  
6.2.3 Preclinical Studies 
 Some future work that could allow this project to be applied clinically would be for an in vivo 
study to evaluate the combined strategy of the bioactive HA-doped alginate beads encapsulating hMSCs 
housed in porous 3D printed PPF scaffold. These studies would be modeled after previous in vivo studies 





285] Additionally, 3D printing could be utilized to custom print scaffold to fit shape specific defects.[286] 
These unique scaffolds could be then filled with the bioactive HA-doped alginate beads for defect repair.  
6.3 Closing Remarks 
 In closing, this dissertation outlines the work completed in the creation of a novel treatment for 
bone defects. We accomplished this through the combined approach of an absorbable porous hollow 
cylindrical scaffold that will provide mechanical support to the bioactive material housed in the lumen. 
We first demonstrated the biomaterial to be used for the porous scaffolds was noncytotoxic. Then we 
designed, fabricated and characterized the scaffolds using 3D printing, nondestructive characterization 
methods and an in vivo study. After fabrication and characterization, we performed a 224 day degradation 
study to investigate changes in scaffold mechanical and structural properties. In addition, we examined 
the potential of cytotoxicity from the degradation byproducts of the absorbable scaffold. Concurrently we 
developed the bioactive material that would be housed in the lumen of the porous scaffolds. The 
composition and size of bioactive material was studied for enhanced osteoblastic differentiation and 
reduced size to allow for ease of implantation within the porous scaffolds. Finally, future research was 
proposed for areas of additional investigation for improving the integration of the treatment method into 
the bone defect through rapid vascularization, enhanced native tissue integration, and preclinical studies. 
With further refinement and optimization our combined tissue engineering approach could provide for 
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